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Abbreviations: 
 
Ab Antibody 
BSA bovine serum albumin 
CA 19-9 carbohydrate antigen 19-9 
CEA carcinoembryonic antigen 
Con. (or C) concentration of analyte in solution 
C (in the additive assay) Accumulated concentration 
Da Dalton 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EDAC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
FIA flow injection analysis 
hA human albumin 
hCG human chorionic gonadotropin 
hHBV human hepatitis B virus 
HRP horse radish peroxidase 
IA biosensor immunoaffinity biosensor 
IA layer immunoaffinity layer 
IgG immunoglobulin 
K (in the additive assay) the accumulated concentration at the half of Rmax 
ka the association rate constant 
KA the associatioin constant 
KD the dissociatioin constant 
LB  Langmuir-Blodgett 
LLD lower limit of detection 
m  the mean signal  
millio  milli degree 
MEMS micro electro mechanical system 
min minute 
M.W. molecular weight 
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N number 
Neu-ProA NeutrAvidin-protein A comlex layer 
NHS N-hydroxysuccinimide 
NSB nonspecific binding 
OD optical density 
PAP  peroxidase-anti-peroxidase 
POC point-of-care 
r2  the square of the correlation coefficient (r) 
R the sensor signal 
R (in the additive assay) the accumulated signal 
Rt  the sensor response at time t 
Rmax  the maximal sensor response 
Rmax (in the additive assay) the maximal accumulated signal 
RI refractive index 
RIA radioisotope immunoassay 
RU response unit (Biacore) 
s  second 
SAM self assembled monolayer 
S-Chimeric NeutrAvidin-protein A chimeric complex 
immobilized on the biotinylated SAM layer 
sd the standard deviation of the signal 
SIA sequential injection analysis 
S-Neu-ProA NeutrAvidin-protein A complex layer on the 
biotinylated SAM layer  
SPR  surface plasmon resonance 
TMB tetramethybenzidine 
TSH thyroid stimulating hormone  
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Abstract 
 
(A) Zusammenfassung (German version) 
 
Biosensoren werden häufig verwendet um bestimmte Analyten aus komplexen Gemischen 
mittels ihrer hohen Selektivität zu anderen Biomolekülen zu detektieren. Üblicherweise sind 
Biosensoren aus zwei verschiedenen Komponenten aufgebaut: erstens einer aus 
Biomaterialien bestehenden Oberfläche, die in der Lage ist, selektiv mit den Zielmolekülen 
in einer Testlösung zu reagieren und zweitens aus einer Signalverstärkungseinheit, die die 
beobachtete biologische Wechselwirkung in ein elektrisches Signal konvertiert. 
Immunoaffinitäts (IA) Biosensoren machen sich die Eigenschaften von Antikörpern, hoch 
selektiv spezifische Antigene zu erkennen, zu Nutze. Eine solche IA-Oberfläche wurde in 
dieser Arbeit an einen Signalverstärker unter Verwendung von sich selbst generierenden 
Einzelschichten gekoppelt. Anschließend wurde ein Surface Plasmon Resonance (SPR) 
Sensorsystem (SpreetaTM) zur Echtzeit-Detektion von Molekül-Molekül-Wechselwirkugen 
verwendet. Das Hauptziel der vorliegenden Arbeit war es, eine kostengünstiges SPR 
Biosensor Diagnostik-Verfahren zu entwickeln, das eine geringe Analysezeit in Anspruch 
nimmt, eine simultane Detektion verschiedener Interaktionen erlaubt und darüber hinaus 
über eine hohe Sensitivität aufweist. 
 
1) Der erste Teil der Arbeit befasst sich mit der Entwicklung eines „Additiven Assays“. Ziel 
dieses Tests ist es, Sensorchips mit IA-Oberflächen ohne ein Austauschen des Chips oder 
den Einsatz von Regnerierungs-Chemikalien wiederverwenden zu können. Üblicherweise 
werden IA-Oberflächen, die mehrfach verwendet werden sollen, unter Entfernung des 
bereits gebundenen Analyts regeneriert. Diese Methode ist sehr zeitaufwendig und kann 
darüber hinaus zur teilweise oder gar vollständigen Denaturierung der Antikörper und/oder 
Antigene auf der Sensorchip-Oberfläche führen. Beim „Additiven Assay“ wird die Probe 
mehrfach über den Sensor gegeben, ohne dass bereits gebundene Analyten durch chemische 
Substanzen entfernt werden. Die Konzentration eines Analyts in der Probe wird ermittelt, 
indem das nach mehrmaliger Injektion der Probe aufgezeichnete akkumulierte SPR- Signal 
mit einer  Eichkurve verglichen wird, die aus der Wechselwirkung zwischen 
immobilisierten BSA und Anti-BSA gewonnen wurde. Die Anwendbarkeit dieser Methode 
in der medizinischen Diagnostik wurde anhand der Detektion des Tumor-Markers CA 19-9 
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gezeigt. Die ermittelte Detektiongrenze für diesen Marker lag bei 410,9 U/ml. Dieser Wert 
liegt zwar über dem angestrebten Wert von 37 U/ml, ist jedoch ausreichend, um Proben von 
Patienten, die möglicherweise an Pankreas-Krebs erkrankt sind, zu analysieren (zwischen 
400 – 192000 U/ml CA 19-9). Die Konzentrationsbestimmung von vier verschiedenen CA 
19-9 Proben bekannter Konzentration unter Verwendung der Eichkurve lieferte eine geringe 
Standardabweichung von 5.3 %. Dieses Ergebnis zeigt eindeutig, dass der „Additive 
Assay“ für die Analyse des Tumor-Markers CA 19-9 verwendet werden kann, ohne dass ein 
Chip-Austausch oder eine Regenerierung mit Chemikalien notwendig ist. 
 
2) Der zweite Schwerpunkt dieser Arbeit bestand in der Entwicklung eines Biosensors, mit 
dem verschiedene Analyten simultan aus einer einzelnen Probe detektiert werden können. In 
der simultanen Detektionsmethode werden mehrere Analyten durch die jeweiligen 
spezifischen Antikörper, die auf derselben Sensor-Oberfläche immobilisiert sind, detektiert. 
Dabei werden zur Unterscheidung zwischen den jeweiligen spezifischen Antikörper-
Antigen-Wechselwirkungen die Analyten nachträglich mit einem Massemarker versehen. 
Somit lassen sich ebenfalls spezifische Konzentrations-Eichkurven erzeugen, die 
anschließend unter Verwendung des ermittelten SPR-Signals zur Bestimmung der 
jeweiligen Analyt-Konzentration in den Proben verwendet werden können. In dieser Arbeit 
wurden zwei verschiedene Methoden zur simultanen Detektion angewendet. Modell 1: 
Verwendung einer Probe, die sowohl einen Analyt enthält, der aufgrund seiner 
Konzentration und Molekülgröße direkt mittels SPR detektiert werden kann als auch einen 
Analyt, der nachträglich mit einem Massemarker detektiert werden muss. Modell 2: beide 
Analyten müssen nachträglich und nacheinander mit verschiedenen Massemarkern 
detektiert werden. Die Anwendbarkeit dieser Modelle wurde anhand eines Testsystems 
bestehend aus einer IA-Oberfläche mit BSA und Anti-HRP sowie Proben, die Anti-BSA und 
HRP enthielten, untersucht. Die Ergebnisse zeigen, dass beide Modelle für die simultane 
Detektion von Analyten einsetzbar sind. Die klinische Relevanz von Modell 2 wurde für die 
Diagnose möglicher Frühgeburten von Diabetes-Patientinnen getestet, indem Urin-Proben 
auf das Vorhandensein von humanen Chorion-Gonadotropin (hCG) und humanen Albumin 
(hA) untersucht wurden. hCG ist ein Schwangerschaftsindikator, währenddessen hA für die 
Diagnose von Mikroalbuminurie (MA) verwendet wird. MA ist dabei ein Alarmsignal für 
schwangere Patientinnen mit Typ1 Diabetes, dass eine Frühgeburt bevorstehen könnte. Die 
hier ermittelten Detektionsgrenzen für hCG und hA betrugen 464 miU/ml bzw. 25 µg/ml mit 
einer Standardabweichung von 6,5% bzw. 5,9%. Diese Konzentrationen stellen die 
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minimale Detektionsgrenze da, um MA in der 4ten Schwangerschaftswoche zu bestimmen. 
Die gewonnenen Ergebnisse zeigen, dass Methode 2 für die simultane Detektion von 
verschiedenen Analyten erfolgreich eingesetzt worden ist. 
 
3) Der dritte Teil der Arbeit hatte als Zielsetzung die Verbesserung der Sensitivität und der 
Detektionsgrenze des Biosensors. Dies sollte zum einen durch die Verwendung von 
bestimmten Massenmarkern und zum anderen durch das Generieren von orientierten IA-
Oberflächen erreicht werden. Durch Massemarker wird die Molekülmasse des gebundenen 
Analyts vergrößert, was zu einer Verstärkung des SPR-Signals führt. Von den in dieser 
Arbeit getesteten Massemarkern gegen die jeweiligen Analyten wie z.B. sekundäre 
Antikörper, Avidin-biotinylierte-Antikörper und einen Peroxidase-anti-Peroxidase (PAP) 
Komplex war die Signalverstärkung durch den PAP-Komplex am effektivsten. Die 
Anwendbarkeit dieses Markers für diagnostische Verfahren wurde durch Analyse von 
humanen Antikörpern gegen Hepatitis B Viren (hHBV) getestet. Die Detektionsgrenzen für 
hHBV-Antikörper, die ohne Signalverstärker, unter Verwendung eines sekundären 
Antikörpers oder mittels des PAP-Komplexes ermittelt wurden, betrugen 9,2 nM, 4,39 nM 
bzw. 0,64 nM. Der mittels des PAP-Komplexes bestimmte Wert liegt nahe dem 
Detektionslimit des derzeit verwendeten kommerziell erhältlichen hHBV-Antikörper ELISA 
Tests (0,24 nM). 
Es ist bekannt, dass die Sensitivität von Immunosensoren durch die Kontrolle der 
Orientierung und Dichte des Rezeptors auf der IA-Oberfläche erhöht werden kann. An eine 
gerichtete IA-Oberfläche können mehr Analyten binden, was zu einer Signalverstärkung 
verglichen mit anderen ungerichteten IAs führt. In dieser Arbeit wurde der Einfluss der 
Rezeptor-Molekül-Dichte auf die Detektionseffizienz unter Verwendung verschiedener 
Oberflächen getestet (anti-hIgG-Antikörper-, Avidin-, NeutrAvidin-, Protein A-, 
NeutrAvidin-Protein A-Komplex- und blanke Gold-Oberfläche). Die NeutrAvidin-Protein 
A-Komplex-Oberfläche wies dabei die höchste Rezeptor-Dichte sowie die höchste Menge 
an gebundenen Analyten verglichen mit der unbehandelten Gold-Oberfläche auf (1,9 bzw. 
3,6 fach erhöht). Darüber hinaus führte die Generierung des NeutrAvidin-Protein A-
Komplexes auf einer biotinylierten Oberfläche zu einer 1,3fach erhöhten Analyten-
Bindungsrate verglichen mit der Bindungsrate an eine Oberfläche, an die der jeweilige 
Rezeptor direkt chemisch gekoppelt wurde. Die Anwendbarkeit des Systems auf 
medizinische Fragestellungen wurde untersucht, indem eine NeutrAvidin-Protein A-
Komplex-IA für die Bindung von Carcinoembryonales Antigen (CEA) Antikörpern 
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verwendet wurde. Der diagnostisch relevante Detektionsbereich für dieses Antigen muss 
dabei zwischen 0-100 ng/ml liegen. Mit der hier getesteten NeutrAvidin-Protein A-
Komplex-IA konnte die Bindungsrate verglichen mit der blanken Gold-Oberfläche 1,5fach 
erhöht werden. Die Detektionsgrenze lag bei  30 ng/ml CEA. Dieses Ergebnis zeigt, dass 
eine mittels des NeutrAvidin-Protein A-Komplex generierte gerichtete IA-Oberfläche zu 
einer Verbesserung der Sensitivität durch Erniedringung des Detektionslimits führt. 
 
Zusammenfassend konnte in dieser Arbeit mit dem „Additiven Assay“ ein kostengünstiger 
Biosensortest etabliert werden. Unter Verwendung einer simultanen Detektionsmethode 
wurde die Analysezeit für unterschiedliche Analyten entscheidend verringert und mit der 
angewendeten Signalamplifikationssmethode konnte die Sensitivität der Assays gesteigert 
werden. Die in dieser Arbeit gezeigten Methoden werden entscheidend zu der Entwicklung 
von SPR-basierten Biosensoren für medizinisch relevante Fragestellungen und Diagnosen 
beitragen. 
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(B) English version 
 
A biosensor is an analytical device to detect target analyte in a complex mixture by using 
high selectivity of biomolecules as the molecular recognition tool. Usually, the biosensor 
consists of two major parts; 1) molecular recognition layer of biomaterials which reacts 
selectively with the target analyte from other substances in a sample, and 2) transducer 
which converts the biological event occurred in the molecular recognition layer into 
quantitative electrical signal. Especially, the immunoaffinity (IA) biosensor exploits the 
highly specific and selective interaction between antigen and antibody for the detection of a 
target analyte. Such an IA layer was connected to the transducer surface by using the self 
assembled monolayers (SAMs) as a linker layer. The surface plasmon resonance (SPR) 
sensor was used for label-free detection and real-time monitoring, and SpreetaTM was used 
for this work. The major objective of this work is the development of SPR biosensor for 
medical diagnosis with the features of a cost-effective test by ‘additive assay’, short 
analysis time through ‘simultaneous detection’ and high sensitivity by ‘signal amplification’.  
 
[1] First topic is a reuse method of IA biosensor called ‘additive assay’ which enables the 
reuse of the IA layer without chip exchange and chemical treatment between measurements. 
For the reuse of IA biosensors, ‘regeneration’ method has been most frequently used for 
repeated measurements, which removes the already bound analyte from the IA layer. 
However, the regeneration method by chemical treatment usually requires additional 
analysis time and the regeneration procedures were reported to partially or completely 
denature the antigens or the antibodies on the IA layer. In the ‘addtive assay’ method, the 
sample is repeatedly injected to the IA layer without removing the already bound analytes 
by chemical treatment and then the concentration of sample is calculated from the actually 
measured signal by using previously prepared correlation curve between the accumulated 
concentration of additively injected sample and accumulated signal which represents the 
number of occupied binding sites. The application of additive assay for real medical 
diagnosis was demonstrated by using tumor marker (CA 19-9) as a target analyte. Though 
the detection limit by direct assay of SPR biosensor (410.9 U/ml) was higher than cut-off 
value (37 U/ml), however, it was enough for the general concentration range of CA 19-9 for 
most patient samples of pancreatic cancer (400 – 192,000 U/ml). When the concentrations 
of four samples were analyzed by using the correlation curve of CA 19-9, the average 
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deviation of the calculated concentrations from the real concentrations was estimated to be 
5.3 %. This result shows that the additive assay can be applicated for the repeated 
measurement of CA 19-9 without chip exchange and chemical treatment. 
 
[2] The second topic is the ‘simultaneous detection’ which enables the detection of multiple 
analytes on the single sensor element with single sample treatment. In the ‘simultaneous 
detection’, a sample with several analytes is treated to the single sensing region which has 
multiple receptors for each target analyte and then the concentrations of each analyte is 
analyzed sequentially with label antibodies by using the respective standard curves for the 
correlation between the concentration and signal. In this work, two simultaneous detection 
models (Model 1 and Model 2) were devised for the samples with the following 
composition: (1) one target analyte resulting in a sensor response without any label and the 
other analyte with only additional label (Model 1), (2) both target analytes requiring 
additional labels for detetion (Model 2). The feasibility of Model 1 and Model 2 was tested 
with two model antigen-antibody systems: IA layer with BSA and anti-HRP antibodies, 
Sample with anti-BSA antibodies and HRP. The result showed that the Model 1 and Model 
2 were acceptable for application. The real medical diagnosis based simultaneous detection 
(Model 2) was demonstrated by analysis of human chorionic gonadotropin (hCG) and 
human albumin (hA) in human urine for the diagnosis of preterm delivery of patients with 
diabetes. The hCG has been used for the qualitative pregnancy test. The hA can be used for 
diagnosis of microalbuminurea and this diagnosis can be used as an alarm for women with 
type I diabetes, who have the steeply increased prevalence of preterm delivery. The 
detection limits for hCG and hA were estimated as 464 mIU/ml and 25 µg/ml, respectively, 
which were the minimum detection range for the diagnosis at the 4th week of pregnancy and 
microalbuminuria. The average errors of analysis based on Model 2 were 6.5 and 5.9 % for 
hCG and hA, respectively. This result shows that Model 2 was suitable for the simultaneous 
detection of both analytes. 
 
[3] The third topic is the improvement of sensitivity and detection limit through two ‘signal 
amplification’ methods by using mass label (A) and by the orientation control of IA layer 
(B):  
(A) The mass label attached to the already bound target analyte increases the total mass 
attached to the sensor surface and then it induces the increase of SPR signal. In this work, 
the efficiencies of several labels were compared with direct assay to select most efficient 
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label for signal amplification. Among several labels such as secondary antibodies, avidin-
biotynylated antibodies and peroxidase-anti-peroxidase (PAP) complex, the amplification 
using the PAP complex was selected as the most efficient method. The feasibility of this 
signal amplification method was demonstrated by analysis of infectious disease marker, 
human hepatitis B virus (hHBV) antibody. The detection limits of SPR measurements by 
direct assay, sandwich assay and PAP complex method were calculated to be 9.20, 4.39 and 
0.64 nM, respectively. This result from PAP method shows that the detection limit of SPR 
biosensor (0.64 nM) approached closely to cut-off value for medical diagnosis (0.24 nM) 
by using the commercial ELISA kit.  
(B) The sensitivities of immunosensors are known to be improved by the control of IA layer 
(orientation & density). As more target analytes can be attached to this controlled IA layer, 
the signal at the same concentration of target analyte can be increased. In this work, among 
several controlled IA layers such as the layer of avidin, NeutrAvidin, protein A, 
NeutrAvidin-protein A complex, the NeutrAvidin-protein A complex on gold surface of 
SPR biosensor showed the highest surface density of receptor and ligand antibody, which 
were 1.9- and 3.6- fold higher than the bare gold surface, respectively. And the binding ratio 
of ligand per unit receptor antibody was also one of the highest values (1.9- fold higher 
than the bare gold surface). When the NeutrAvidin-protein A complex was prepared on 
biotin-labelled SAM, the binding ratio of ligand per unit receptor was found to be 
significantly improved (2.1- fold higher than the bare gold surface) in comparison to the IA 
layer prepared by chemical coupling of receptor antibody to the SAM layer (0.8- fold 
higher than the bare gold surface). For the feasibility test of orientation control, the 
NeutrAvidin-protein A complex was applied for the detection of a tumor marker, 
carcinoembryonic antigen (CEA), which has the detection range for diagnosis to be 
between 0 and 100 ng/ml. By using NeutrAvidin-protein A complex, sensitivity was 
improved to be 1.5-fold higher than bare gold surface and the detection limit of 30 ng/ml 
was achieved. This result shows that the control of IA layer (orientation & density) 
improved the sensitivity as well as the detection limit of IA biosensor. 
 
These results demonstrated the ‘additive assay’ for cost-effective test, ‘simultaneous 
detection’ for short analysis time and ‘signal amplification’ for high sensitivity. The 
presented three methods in this study will be applied for the development of a practical SPR 
biosensor for the various medical diagnosis. 
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1. Introduction    
 
A biosensor is an analytical device to detect a specific target analyte in a complex mixture 
by using the high selectivity of biomolecules for the molecular recognition. Usually, the 
biosensor consists of two major parts; 1) molecular recognition layer of biomaterials (e.q. 
enzyme, receptor-ligand, and antibody-antigen) which reacts selectively with the target 
analyte from other substances in a sample, and 2) transducer (e.q. optical, amperometic, 
potentiometric and acoustic) which converts the biological event occurring in the molecular 
recognition layer into quantitative electrical signal. 
The immunoaffinity (IA) biosensor exploits the highly specific and selective interaction 
between antigen and antibody for the detection of the target analyte. The detection of the 
target analyte by the IA biosensor is based on the selective binding of the target analyte by 
the molecular recognition layer called immunoaffinity (IA) layer produced by immobilizing 
antigens or antibodies to the transducer surface. The IA biosensor has been applied for 
clinical diagnosis, microbiological and environmental applications. Despite the progress of 
the IA biosensor in recent years, further improvement in technical specifications is still 
required for the medical diagnosis, such as sensitivity, detection limit, analysis time and 
instrumentation (Ekin, 1999; Luppa et al., 2001). 
 
1.1. Objective 
 
This work aims to develop an IA biosensor based on an SPR-transducer for the practical 
application to medical diagnosis. Three technical topics were investigated for the realization 
of the aimed biosensor.  
 
[1] The first topic is a reuse method of IA biosensor called ‘additive assay’ which enables 
the reuse of the IA layer without any chemical treatment. In this method, the sample is 
repeatedly injected to the IA layer without removing the already bound analytes by 
chemical treatment. The concentration of the sample is calculated from the actually 
measured signal by using the correlation curve between the accumulated concentration of 
additively injected sample and accumulated signal which represents the number of occupied 
binding sites (section 3.1). 
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[2] The second topic is the ‘simultaneous detection method’ which enables the detection of 
multiple analytes on the single sensor element with single sample treatment. In the 
‘simultaneous detection method’, a sample with multiple analytes is injected to the IA layer 
which has multiple receptors for each target analyte. The concentrations of each analyte are 
then analyzed sequentially by using the respective standard curves for the correlation 
between the concentration and signal. Two simultaneous detection models were defined by 
the response ratio of the target analytes in a sample (section 3.2). 
 
[3] The third topic is the improvement of sensitivity and detection limit through signal 
amplification by using mass label (A) and by the orientation control of the IA layer (B): A. 
The mass label was attached to the already bound target analyte and then the total mass 
attached to the sensor surface induced the increase of the SPR signal (section 3.3.1). B. The 
orientation of antibodies on the IA layer was controlled so that the surface density of 
receptor antibody and the binding amount of the ligand (analyte) to the IA layer could be 
increased (section 3.3.2).  
 
1.2 State of the art of IA biosensor development 
 
The IA biosensor uses immunoaffinity (IA) layer as the molecular recognition part for the 
selective binding of the target analyte, which is produced by immobilizing antigens or 
antibodies to the transducer surface. For the application of IA biosensor to the medical 
diagnosis, three core topics were selected: (1) reuse of IA biosensor, (2) simultaneous 
detection of more than two analytes in a sample, (3) signal amplification to improve the 
sensitivity of IA biosensors. In this section, the state of the art of the selected topics will be 
presented and the requirements for new technologies will be clearly specified. 
 
1.2.1 Regeneration method for repeated measurements 
 
The ‘regeneration’ method has been most frequently used for repeated measurements of IA 
biosensors, which removes the already bound analyte from the IA layer (see Figure 1-1). 
The interaction between antibody and antigen is known to be the combination of 
electrostatic force (E), polar force (L), van der Waals force and hydrogen bonding. Several 
reagents have been selected and optimized for rapid dissociation of antigen-antibody 
complexes as well as the stability of the IA layer with transducer. (Wijesuriya et al., 1994; 
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Anderson et al., 1999). 
O O O O O OO O O O O O
O: IA layer
Measurement 
Regeneration
by acid, base and competitor
Y
Y : analyte
Y Y
Sample
Injection
 
Figure 1-1: Conventional regeneration method for successive measurements using an 
IA biosensor. For the next measurement, the already bound analyte is removed by chemical 
reagents, such as acid, base and competitor. 
 
(1) High or low pH 
Acid (high pH) and base (low pH) solution can break the electrostatic bond between 
antibody and antigen. As a regeneration agent, the acidic solutions such as glycine-HCl (pH 
1.7-2.2, 10-100 mM) and HCl (10-100 mM) and the basic solutions such as 
thriethanolamine (TEA) buffer (pH 11.0, 50 mM) and NaOH have been used for IA 
biosensors (Wijesuriya et al., 1994; Anderson et al., 1999). For example, a flow cell of a 
SPR biosensor (BIACORE 1000) was regenerated by glycine-HCl (pH 2.0) in the real-time 
immunoassay of ferritin, and the regeneration could be repeated more than 50 cycles (Cui et 
al., 2003). The SPR biosensor (BIACORE 3000) for the analysis of morphine-3-
glucuronide was reported to be regenerated by base (10 mM NaOH) solution at least 30 
cycles (Dillon et al., 2003). In the purification procedure of antibodies with the protein A 
column, IgG was eluted by using the glycine-HCl (50 mM, pH 2.5) as an elution buffer 
(Nakanishi et al., 1996). 
 
(2) Ions at high concentration / Chaotropic agent 
An ion is an atom or a group of atoms with a net electric charge by gaining or losing one or 
more electrons. The electrostatic interaction is mainly composed by charged groups of 
antigen and antibodies and the effect of charged groups can be dispersed by adding ions at 
high concentration. A highly concentrated salt solution such as 2-4 M MgCl2 or 1M NaCl 
can decrease the electrostatic interaction between antigen and antibody through a high ionic 
strength. Therefore, such a salt solution has been used with chaotropic agents for 
regeneration of IA biosensors (Anderson et al., 1999).  
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Chaotropic agents such as urea or guanidine-HCl are denaturing salts which bind strongly 
to proteins and they decrease hydration. These agents can cause the disrupture of the 
molecular structure by weakening nonbonding forces such as hydrogen bonding, van der 
Waals interactions and the hydrophobic effect (Anderson et al., 1999). For example, 
trichloroacetic acid was reported to be very effective chaotropic agent in releasing cortisol 
from binding proteins in the use of a time-resolved fluoroimmunoassay (Eskola et al., 1985). 
The chaotropic agent can be used at acidic pH to improve the effect of regeneration. In the 
analysis of multiple mycotoxins such as DON, fumonisin B1, zearalenone and aflatoxin B1, 
chaotropic agent (6.0 M glycine chloride) at acidic pH (50 mM glycine, pH 2.0) was used 
to regenerate the SPR biosensor (BIACORE 2000) (van der Gaag et al., 2003). 
 
(3) Detergent 
Detergents have a general structure R-SO4-Na+, where R is a long-chain alkyl group. 
Various detergents have been used for the regeneration of IA biosensors such as 0.3% 
Tween 20, 0.3% Tween 80, 0.3% Triton X-100 and 0.3% CHAPS (Anderson et al., 1999). 
Tween 20 and sodium dodecyl sulfate (SDS) have been reported to achieve rapid 
regeneration time and high numbers of reusable regenerations for the fiber-optic-based 
immunosensor (Betts et al., 1991).  
 
Nonpolar solvents or chelating agents have been also reported for the application of 
regeneration. The nonpolar solvent is a solvent which has no positive or negative electric 
charge, such as dimethyl sulfoxide (DMSO), formamide, ethanol and acetonitrile. DMSO at 
high or low pH is reported to break the antibody-antigen bonds (Anderson et al., 1999). 
Chelation is the process of reversible binding of a ligand to a metal ion, forming a metal 
complex. The capacitive biosensor based on synthetic proteins for sensitive detection of 
heavy metals such as Hg2+, Cd2+, Pb2+, Cu2+, and Zn2+ ions was regenerated with 10 mM 
ethylenediaminetetraacetic acid (EDTA) by removing the bound heavy metal ions 
(Bontidean et al., 2003). In the detection of herbicides with the SPR biosensor (BIACORE 
X), herbicides were injected onto the heavy-subunit-histidine-tagged Reaction Centers 
(HHisRCs)-immobilized chip. The HHisRCs were immobilized on the chip via nickel-
histidine chelation chemistries and EDTA was used as regeneration buffer to remove the 
nickel ions (Nakamura et al., 2003). 
 
As previously mentioned, several research groups have reported success in regenerating IA 
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layers for reuse in many cycles by treatment with acidic or basic solutions or competitor 
solutions. 
As the regeneration efficiency depends mainly on the stability of antigen or antibody in the 
IA layer, however, the optimization process should be selected case by case. For example, 
in the competitive assay for the detection of the pesticide 2,4-dichlorophenoxyacetic (2,4-
D) preincubated with antibody, the chip can not be regenerated by excess of 2,4-D and 
other attempts, e.g. using 0.1 M glycine of pH 2.5 were unsuccessful as well (Svitel et al., 
2000). Even more drastic strategies recommended for Biacore chip regeneration, such as 
using pH less than 2 or pH greater than 10 cleaved the chip surface only partially. 
Furthermore, such procedures were reported to partially or completely denature the antigens 
or the antibodies on the IA layer (Bright et al., 1990; Betts et al., 1991). For each IA layer, 
between 60% and 90% of the antigen binding activity remained after 10 cycles of 
regenerations, and the activity continued to decrease in a nearly linear fashion (Betts et al., 
1991). In most instances, after 10-20 regeneration cycles the sensor activity is significantly 
lowered. In the regeneration method, additional analysis time by the step of chemical 
treatment also make a disadvantage. 
 
1.2.2 Detection of multiple analytes 
 
To overcome the limitations of single analyte detection, simultaneous detection of multiple 
analytes have been reported, including flow injection analysis (FIA), sequential injection 
analysis (SIA), microsensor array and methods which uses different labels.  
 
(1) Flow injection analysis (FIA) system 
In the FIA type immunoassays, the sample passes through the sensing element by using a 
flowing carrier system. When several sensing elements are combined in the flow channel of 
the analysis system, multi-analyte detection can be done with one sample treatment. For 
example, glucose and L-lactic acid were simultaneously monitored during a fermentation 
process by on-line FIA with dual amperometric biosensors (Min et al., 1998). Four 
amperometric electrode biosensors were also simultaneously used to detect the insecticides 
paraoxon and carbofuran by using the FIA system (Bachmann et al., 1999).  
 
(2) Sequential injection analysis (SIA) system  
SIA is a variation of FIA. A selection valve is used to carry a stack of the sample to the 
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sensing zones sequentially and then to the detector. The SIA has enabled automated sample 
handling. When the sample is sequentially distributed to several sensing zones for different 
analytes, multi-analyte detection can be done. The SIA systems have been used for various 
analysis: the detection of 2,4,6-trinitrotoluene (TNT) and hexahydro-1,3,5-trinitro-1,3,5-
triazine (RDX) by a capillary-based flow immunosensor (Narang et al., 1998), the 
determination of S- and R-captopril by amperometric biosensors (Stefan et al., 2000) and 
the continuous monitoring of glucose and lactate by a dual electrochemical assay system 
(Jones et al., 2002).  
 
(3) Microsensor array 
The microsensor arrays based on Micro-Electro-Mechanical System (MEMS) technique 
have been applied for multi-analyte detection by fabricating an array of sensing areas into a 
single chip. 
A planar array immunosensor with a charge-coupled device (CCD) has been used for the 
simultaneous detection of several target analytes, such as 3 toxic analytes (staphylococcal 
enterotoxin B (SEB), ricin and Yersinia pestis) (Wadkins et al., 1998), six biohazardous 
agents (ricin, cholera toxin, F.tularensis LVS, B.abortus (killed), B.anthracis Sterne, SEB) 
(Rowe-Taitt et al., 2000) and both the tumor suppressor gene and protein (fragile histidine 
triad (FHIT) gene and protein) (Askari et al., 2002). The Bead Array Counter (BARC) 
biosensor containing a 64-element sensor array can be used to detect biological warfare 
agents such as Bacillus anthracis, Yersinia pestis, Brucella suis, Francisella tularensis, 
Vibrio cholerae, Clostridium botulinum, Campylobacter jejuni and Vaccinia virus by using 
DNA hybridization, magnetic microbeads and giant magnetroresistive (Edelstein et al., 
2000). However, these array type methods require the same number of independent sensing 
areas as the target analytes. 
 
(4) Different labels in the same assay zone 
The multi-analytes analysis method using a single sensing element was first reported 
involving the use of radioisotopes such as 125I and 131I (Morgan, 1966). This radioisotope 
immunoassay (RIA) was applied for the diagnostics of insulin and growth hormone in 
human serum. The immunoassay for dual analytes was also reported, involving 125I and 
57Co (Gutcho et al., 1977). However, the application of RIA is restricted by difficulties in 
handling and the waste treatment of radioisotopes.  
ELISA kits for the detection of more than two target analytes at a single well of microplate 
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were also reported using different reporting enzymes and substrates (Blake et al., 1982). 
However, there are also several problems in multi-analytes detection by ELISA. In the case 
of sequential enzyme reaction for each analyte, the first color signal by one label can 
interfere with the second color signal by the other label, and the distinguishment of signals 
from different labels is often not clear.  
 
Other types of assays have been also reported to use different fluorescent labels for the 
analysis of lutropin and follitropin in serum (Hemmilae et al., 1987), mixture of 
radioisotope labels and enzyme labels for the analysis of total and IgA-conjugated α1-
microglobulin (DeMars et al., 1989), different metal ion labels for the analysis of HSA and 
IgG (Hayes et al., 1994), particles of different sizes for the analysis of AFP and hCG 
(Frengen et al., 1995) and colored latex particles (Hadfield et al., 1987). 
 
1.2.3 Signal amplification to improve sensitivity and detection limit 
 
The SPR biosensor is reported to have a detection range affected by the detection method 
(for example, direct assay or sandwich assay) and molecular weight of the target analyte. In 
the case of single step assay, the detection ranges for the analytes at M.W. > 1000 Da are 
reported to be nM ~ µM (Lundstroem, 1994). In comparison to the conventional 
immunoassay such as ELISA, the sensitivity of the SPR biosensor should be improved for 
medical diagnosis. Signal amplifications by the attachment of mass label and the control of 
the IA layer (orientation & density) have been reported for the improvement of the 
sensitivity and detection limit. 
 
1.2.3.1 Signal amplification by mass label 
  
The multi-step (sandwich) assay, where various label proteins are added to the already 
bound analyte on the sensor surface for the signal amplification, has been applied for the 
signal amplification of IA biosensors. Especially in the SPR system, signal amplification by 
the following mass labels have improved the detection ranges of analytes to be pM ~ nM 
(Lundstroem, 1994; Mullett et al., 2000).   
 
(1) Secondary antibody  
The simplest label for the sandwich assay is an analyte-specific ‘secondary antibody’, 
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which is attached to the target analyte on the IA layer. However, the amplification effect is 
confined by molecular weight of antibodies (150 kDa) and usually the degree of 
amplification is not high. For example, the amplification ratio of ferritin detection was 
estimated to be only as much as 1.7-fold (Cui et al., 2003). Compared with the direct assay, 
the detection limit of thyroid stimulating hormone (TSH) detection in the sandwich assay 
was improved only from 12 ng/ml to 7 ng/ml (Kubitschko et al., 1997). 
 
(2) Latex particle  
Nanoparticles with heavy weight such as latex particle have been used for signal 
amplification of SPR IA biosensors. This latex particles can be coated with counterparts of 
the analyte by using EDAC/NHS technique (see Figure 1-6), and the effect of signal 
amplification is affected by the particle size, particle coating conditions and particle 
concentration. With hCG-coated latex (diameter 238 nm), the sensitivity for hCG detection 
was improved by a factor of 30 ~ 50 (Severs and Schasfoort, 1993). In the case of thyroid-
stimulating hormone (TSH) detection, anti-TSH IgG-coated latex enhanced the detection 
limit from 12 ng/ml to 3 pg/ml (Kubitschko et al., 1997). Because of the large size of latex 
particles, the possible number of binding to the analyte on the IA layer is not so high and 
the enhancement effect is rapidly reduced at high analyte concentration.  
 
(3) Gold colloid 
Other nanoparticles with high refractive index such as colloidal gold can be used for 
sensitivity enhancement of SPR biosensors (Leung et al., 1994). Colloidal gold can be 
coated with various proteins by charge adsorption (Lyon et al., 1998). For the detection of 
human complement factor 4 (C4), the analyte was conjugated with colloidal gold conjugate 
and the detection limit could be improved to be 10-fold lower than the direct assay (Liu et 
al., 2004). Moreover, when the secondary antibody was conjugated with the colloidal gold, 
the detection limit was improved by 40-fold compared with the direct assay. However, the 
enhancement effect was also similar to be sandwich assay (1.25-fold) at high analyte 
concentration. 
 
(4) Liposomes 
Liposomes are an artificial microscopic vesicles consisting of an aqueous core enclosed by 
one or more phospholipid layers. The liposome immunosorbent assay (LISA) has been 
developed for improving the detection limit and sensitivity of SPR. In this assay, liposomes 
 
Introduction                                                                            9 
 
and the secondary antibodies are biotinylated to be used as a label. After injection of the 
analyte, a biotinylated second antibody is added, and then avidin is used as the bridging 
molecule between the biotinylated antibody and the biotinylated liposome. The liposome 
strategy was used for the detection of interferon-γ (IFN- γ) and both sensitivity and 
detection limit were improved by ~ 104 times. However, because liposomes are very large 
vesicles (100~1000 nm) (Wink et al., 1998), the possible number of binding events to the 
analyte on the IA layer is also small and the enhancement effect is decreased at high analyte 
concentration. 
 
1.2.3.2 Signal amplification by orientation & density control of IA layer 
 
The orientation control and the density control of the antibody on the IA layer were 
conceived for the signal amplification of IA biosensors. As shown in the Figure 1-2A, the 
orientation control of IA layer means that variable regions of receptors in the IA layer are 
arranged to face the sample fluid. In this case, more target analytes can bind to the oriented 
IA layer (the orientation control) (Lu et al., 1996; Muramatsu et al., 1989). As shown in the 
Figure 1-2B, the density control of IA layer aims to bind as many receptors as possible to 
the IA layer. Hence, more target analytes can be attached to the IA layer and the sensitivity 
of the IA biosensor can be improved (the density control). Several techniques have been 
used to achieve the signal amplification by the control of those properties of the IA layer. 
A 
Y
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Figure 1-2: Signal amplification by the control of the IA layer. (A) Control of the 
orientation of receptor antibodies of the IA layer. (B) Control of the density of receptor antibodies 
on the IA layer. 
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(1) Protein A method 
The most frequently used technique for the orientation control of the IA layer has been to 
apply protein A. Protein A is a cell wall protein deriving from Staphylococcus aureus which 
exhibits unique binding properties for IgG from a variety of mammalian species and for 
some IgM and IgA as well. As protein A binds to polysaccharides at the Fc region of the 
antibody, it has been applied to immunosensors for the orientation control of the antibody in 
the IA layer (Owaku and Goto, 1995; Kanno et al., 2000; Bae et al., 2005). For example, the 
effectiveness of protein A has been proved in the detection of Yersinia pestis Fraction 1 (F1) 
antigen by a fiber optic biosensor (Anderson et al., 1997) or red tide-causing plankton 
Chattonella marina by a piezoelectric immunosensor (Nakanishi et al., 1996).  
 
(2) Avidin - biotinylated protein interaction 
Avidin is a glycoprotein with a strong affinity for biotin (affinity constant > 1015 M-1). For 
the control of antibody orientation, the avidin is usually immobilized on the sensor surface, 
and then the biotin-labelled antibody against a target analyte is bound. As the biotin is 
known to be labelled at the Fc region of antibodies, the F(ab’) region is exposed to the 
analyte after binding to the immobilized avidin. The avidin bridging method, however, 
proved relatively inefficient in the enzyme immunoassay (ELISA) of prolactin showing 
three fold improvement of the non-specific binding (Ahluwalia et al., 1991). 
 
(3) The Langmuir-Blodgett (LB) film technique 
The Langmuir-Blodgett (LB) film means a film of organic material (often surfactant 
molecules) assembled at the liquid-gas interface and it can be transferred onto a solid 
substrate. The LB technique has been used to make a closely packed and highly oriented 
protein layer and it was used for many commercial sensors for glucose detection (Davis and 
Higson, 2005). However, this protein layer produced by LB technique is not stable. As the 
protein layer immobilized using the LB technique is easily denatured and desorbed from the 
substrate, the fabrication of an immunosensor using this method seems to be impractical 
(Preininger et al., 2000; Bae et al., 2005).  
 
(4) Self-assembly technique 
Well-oriented immunosurfaces can be prepared by the direct immobilization of F(ab’) 
fragments of IgG onto gold (Au) surfaces via the formation of a Au-thiolate bond (Brogan 
et al., 2003). The F(ab’) fragment can be made by using pepsin and 2-mercaptoethylamine 
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(2-MEA) (see Figure 1-3). Enzymatic fragmentation of IgG produces F(ab’) 2 fragment by 
pepsin and this fragment is further fragmented into two F(ab’) by 2-MEA by reduction of S-
S bonding. Each F(ab’) has one binding site and one thiol (-SH) group. This F(ab’) 
fragment can bind spontaneously to the gold surface of immunosensors through the specific 
interaction between thiol (-SH) group and the gold surface. Such a self-assembly technique 
was applied to detect insulin by using SPR sensor (Lee et al., 2005). 
 
Binding
site
IgG
Pepsin
Fc
2-MEA
SH HS
F(ab’)
 
Figure 1-3: Scheme of the strategies used to prepare F(ab’) of whole molecule IgG. 
Enzymatic fragmentation of IgG produces F(ab’) 2 fragment by pepsin and this fragment is further 
cleaved into two F(ab’) by 2-mercaptoethylamine (2-MEA). 
 
(5) Charged substrate technique 
Charged substrates have been used for the orientation control of IA layer on the self 
assembled monolayer (SAM). The orientation of anti-hCG antibody was found to be better 
oriented on the primary amine–terminated SAM (positively charged) than on the 
carbohydrate-terminated SAM (negatively charged) (Chen et al., 2003). Because the 
immobilization of an antibody on the negatively charged or positively charged surfaces is 
based on a physical adsorption, this strategy has a limitation in stability.  
 
1.3 Principal elements for the construction of an immunoaffinity SPR biosensor 
 
Usually an IA biosensor system (see Figure 1-4) is composed of four functional parts: (1) 
sampling, (2) molecular recognition, (3) transducer and (4) data processing.  
(1) In the sampling part, a sample with the target analyte is prepared into a suitable format 
for the analysis by using the biosensor. For example, serum has many interrupting proteins 
for the specific detection of the target analyte and it is diluted for the effective detection. 
Sometimes, microfluidic sample handling system is used for the sample with restricted 
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volume, such as neonatal blood sample. 
(2) The molecular recognition part of the IA biosensor detects the target analyte in the 
sample by the highly specific interactions between antibody and antigen. Such an 
interaction changes the physical properties of the molecular recognition part, such as 
refractive index, mass or density.  
(3) The transducer converts these physical property changes into the electrical signal. For 
the detection of antigen-antibody interaction, several types of transducers have been applied 
for IA biosensors, such as electrochemical (potentiometric, amperometric or 
conductometric/capacitative), microgravimetric, optical, and thermometric. In this work, 
the surface plasmon resonance (SPR) sensor was used as transducer.  
(4) The data processing part calculates the concentration of the target analyte from the 
electrical signal obtained from the transducer part. 
 
Adsorption layer Electrical
Signal
A
Transducer [A]
(A: Analyte)
: IA layer
: SPR sensor
B
C
Molecular recognition
part Electrical
Signal
Transducer
[ ]
Immunosensor
 
Figure 1-4: General structure of an IA biosensor. The target analyte (A) in a mixture is 
selectively bound to the molecular recognition part and the quantitative electrical signal 
corresponding to the amount of bound analyte is generated by the transducer. The IA biosensor 
displays the concentration of the target analyte in the sample. 
 
1.3.1 Properties of IA layer 
 
When the sample is applied onto the IA biosensor, the sensor response is produced by the 
occupancy of the free binding site of the IA layer by the analyte. As correlation between the 
concentration and signal is used for the calculation of analyte concentration, the 
reproducible preparation of the IA layer is very important for the precise calculation of the 
analyte concentration.  
Various techniques have been reported for the immobilization of antibodies (or antigens) to 
the metallic surface of the transducer. Such techniques can be classified into two categories: 
(1) physical adsorption to the metallic surface of the transducer, and (2) covalent coupling 
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of antibodies (or antigens) to the transducer, which is reported to have good reproducibility 
and coverage. Although the physical adsorption is simple to use, this technique is known to 
induce denaturation or conformational changes of the adsorption layer, poor reproducibility, 
elution by the detergent of the washing solution and so on (Bae et al., 2005). 
Usually, the IA layer is composed of the adsorption layer and linker layer as shown in the 
Figure 1-5. The adsorption layer specifically binds the target analytes and the linker layer 
connects the adsorption layer to the surface of the transducer. The linker layer is prepared 
by modifying the surface of the transducer to bind the antibodies (or the antigens) of the 
adsorption layer and it also influences the orientation of the antibodies (or the antigens). 
 
 
 
Figure 1-5: The functional structure of the IA layer. The layer is composed of an adsorption 
layer for the selective binding of target analyte and the linker layer for the stable binding of the 
adsorption layer to the transducer surface. 
 
The self assembled monolayers (SAMs) have been frequently used as the linker layers. The 
strong adsorptions of thiol (R-SH), disulfide (R-S-S-R) and sulfides (R-S-R) to gold surface 
have been used to make well-ordered SAM on the SPR biosensor surface (Wink et al., 
1997). The SAM can be easily prepared by immersion of the substrate into a solution 
containing an appropriate amphiphile (Ulman et al., 1996). The SAM has been reported to 
have many advantages for the application of IA biosensors. First of all, the non-specific 
binding can be reduced three to five times compared with conventional linker layers (Su et 
al., 1999). By using this well-ordered SAM, well-oriented immobilization of proteins could 
be prepared without altering the biological activities and the improvement of detection 
limits, reproducibility of the assay could be achieved.  
In this work, 11-mercaptoundecanoic acid was used to prepare an SAM on the gold surface 
of the SPR transducer (see Figure 1-6A). The inside chemistry of SAM formation on the 
gold surface is known to be a two-step mechanism: (1) First step is the oxidative addition of 
(A: Analyte)
IA layer
A
B
C
Adsorption layer
Linker layer
Transducer
Electrical
Signal
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the S-H bond and reductive elimination of the hydrogen (chemisorb): R-S-H + Au Æ R-S-
Au+•Au + 1/2H2. (2) After the fast formation of an S-Au bonding, the hydrocarbon chains 
are known to assemble together to form the well-ordered monolayer by Van-der-Waals 
forces between the hydrocarbon chains (Ulman et al., 1996; Davis and Higson, 2005). In 
the case of long alkyl chains such as 11-mercaptoundecanoic acid, strong intermolecular 
bonds can be formed to make well-ordered structures with amines, which are similar to the 
internal packing energies of crystalline hydrocarbon (Allara et al., 1995). After the 
preparation of SAM (linker layer) on the gold surface, the protein (adsorption layer) was 
covalently coupled to the SAM by the well-known chemistry, which uses 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC) and N-hydroxysuccinimide (NHS) as 
coupling reagents (see Figure 1-6B). In this reaction, the carboxylic groups of SAM are 
activated by a mixture of EDAC and NHS, and then amine groups of ligand are covalently 
bonded to the carboxylic groups of SAM. The remaining esters are deactivated by addition 
of ethanolamine (Johnsson et al., 1991). 
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Figure 1-6: Self assembled monolayer (SAM) and it’s coupling chemistry.  
(A) Schematic view of the SAM on the gold surface. (B) The reaction of EDAC/NHS for coupling 
of protein to the carboxylate group of SAM. 
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1.3.2 Properties of SPR transducer 
 
In principle, the SPR biosensor can detect all kinds of analyte binding to the IA layer 
without any additional labels such as fluorescent, radioactive or scattering labels (Homola, 
2004). The surface plasmon resonance (SPR) effect occurs in the very close vicinity of a 
thin metal film surface at the interface of two transparent media of different refractive index 
(RI) (see Figure 1-7) (Kretschmann and Raether, 1968; Otto, 1968).  
When incident light goes from optically dense media (higher RI) to less dense media (lower 
RI), it is partly reflected and partly refracted. Above a special angle of incident light, all 
light is reflected back into the dense media (total internal reflection) and a component of 
this light (the evanescent wave) can propagate into the less dense media to a distance of one 
wavelength (Faegerstam et al., 1992). If a thin metal film is positioned at the interface 
between two media, the evanescent wave of incident light is able to interact with free 
electrons (plasmons) in the metal film at a narrow angle range of incident light (SPR angle). 
When this surface plasmon is resonantly excited, a longitudinal charge density wave 
propagates along the interface between two different media. In this situation, light energy is 
lost to the metal film and the intensity of reflected light decreases. As the refractive index of 
the media changes, the SPR angle is also shifted. This shift of the SPR angle is a signal for 
the SPR sensor. This phenomenon is usually observed with noble metals such as gold and 
silver (De Bruijn et al., 1992).  
Optically dense media
(higher RI)
Metal film
(gold, silver..)
Prism
Optically less dense media
(lower RI)
Detector                                                        Light source
α
(Reflected light)                                               (Incident light)
Evanescent wave
 
Figure 1-7: Structure of the surface plasmon resonance (SPR) transducer. A thin metal 
film is positioned at the interface between two media, and the evanescent wave of incident light is 
able to interact with free electrons (plasmons) in the metal film at a special angle (α) of incident 
light (SPR angle). As the binding of analyte to the sensor surface changes the SPR angle, the analyte 
concentration related to the amount of bound analyte can be measured by using the SPR transducer. 
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As the analyte binds to the the sensor surface, the refractive index and SPR angle changes 
according to the increase of the mass at the sensor surface (Sjoelander and Urbaniczky, 
1991). When the interaction between analyte and the immobilized receptor occurs at the 
sensor surface, a sensorgram can be obtained in real time by plotting the signal against time, 
as shown in the Figure 1-8 (Liedberg et al., 1983; Lundstroem, 1994). 
 
 
Figure 1-8: A typical sensorgram for the monitoring of analyte binding to the SPR 
biosensor. In the association step, analyte solution is injected to the biosensor for attachment. In 
the dissociation step, buffer solution replaces analyte solution and some analytes on the biosensor 
detached. For next experiment, all analytes on the biosensor are removed in the regeneration step. 
 
In this work, the SpreetaTM from Texas Instrument Inc. (TI) was used as a SPR transducer. 
SpreetaTM sensor contains whole optical components necessary to implement SPR sensing, 
such as an infrared LED (830 nm peak wavelength), a 128-pixel linear diode array detector 
and a non-volatile memory chip for recording identification and calibration information 
(see Figure 1-9A). SpreetaTM has the size of 4.1 cm ⅹ 2.9 cm ⅹ 1.3 cm and the active 
sensing region is located on the middle of the gold surface with the size of 0.45 mm ⅹ 0.1 
mm (see Figure 1-9B). The sensor surface is prepared on a glass chip by sputtering a 50 nm 
gold layer and it was fastend to the plastic prism with epoxy. The SPR effect occurs on the 
thin gold layer: at a certain angles of incidence, part of the energy of the transverse-
magnetic polarized incident light will be coupled into a surface plasmon wave traveling 
along the interface between the gold layer and the analyte. This device has the limit of 
detection of 1 pg/mm2. As the evanescent field decays exponentially from the surface, SPR 
technique is sensitive to refractive index variation within 300 nm from the surface 
(Chinowsky et al., 2003). 
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Figure 1-9: The SpreetaTM SPR sensor from Texas instrument Co. LTD. (A) Inside 
structure of the SpreetaTM. The light from the LED is reflected at the surface plasmon layer, and then 
it reflected to the photodiode array. (B) The SpreetaTM chip with the size of 4.1 ⅹ 2.9 ⅹ 1.3 (cm). 
 
In a view of medical diagnosis, the SPR sensor has several advantages, such as label-free 
detection, real-time monitoring and one-shot analysis. Especially, SpreetaTM requires 
relatively small instrumentation and it is suitable for point-of-care testing (POCT) (Homola, 
2004). As the POCT can supply laboratory test result without central laboratory, POC 
system has been developed for medical diagnosis in a small clinics as well as home-health 
care (Soper et al., 2006). Such a POCT have been used to detect several analytes such as 
glucose, hemoglobin, urine dipsticks, pregnancy and drug testing (Nichols, 2001). The 
development of POC technologies will be used for better screening of at-risk patients, 
tighter surveillance of disease recurrence and better monitoring of treatment. 
 
1.4 Biomarkers for medical diagnosis 
 
The biomarker is defined as a change in biological response ranging from molecular 
through cellular and physiological responses to behavioural changes (Allan et al., 2006), 
which includes several indicators of a biologic state, such as nucleic acids, proteins and 
low-molecular-weight metabolites. Especially, a biomarker can be used to examine organ 
function or other aspects of health in medicine. In the medical point of view, this biomarker 
must not only signal the presence of a disease such as cancer, but should also predict the 
state of disease such as the stage of tumorigenesis (Soper et al., 2006). However, this 
disease-indicating analyte is mixed with a lot of other materials in serum or urine. The 
BA
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biosensor can selectively detect biomarker as a target analyte to inform the presence of a 
disease and quantify the amount of biomarker to know the state of disease through the high 
“selectivity” and “sensitivity” of biosensor. 
In this work, the application of the SPR biosensor technology for medical diagnosis was 
demonstrated by using several biomarkers for medical diagnosis, such as tumor markers 
(CA 19-9, CEA), an infectious disease marker (hHBV Ab), a hormone (hCG) and a plasma 
protein (hA).  
 
(1) Tumor markers (CA 19-9, CEA) 
Tumor markers are substances developed in tumor cells and secreted into body fluids. As 
the concentration and the kind of tumor markers are related with the active tumor mass and 
site, the tumor markers can be used for the medical diagnosis of cancer.  
 
Carbohydrate antigen 19-9 (CA 19-9) used in the additive assay is one of the most widely 
used carbohydrate tumor markers for gastrointestinal malignancies. CA 19-9 has a subunit 
of 210 kDa glycoprotein and it’s aggregate has a molecular weight between 600 and 2,000 
kDa. Especially, it is reported to be found in patients of pancreatic cancer with a high score 
of over 79 % (Del Villano et al., 1983; Suresh, 2001). Conventionally, various kinds of 
immunoassays such as enzyme immunosorbent assay (Ohkura et al., 1985), 
Chemiluminescence immunoassay (Nishizono et al., 1991; Lin et al., 2004), 
electrochemical immunoassay (Du et al., 2003) and fluorescence immunoassay (Song et al., 
2004) have been applied for the medical diagnosis of CA 19-9. 
 
Carcinoembryonic antigen (CEA) is another widely used tumor marker in oncology, which 
is a glycoprotein with the molecular weight of 180 kDa. CEA is considered to be a broad 
spectrum cancer marker because various malignancies at the colorectal, lung, breast, 
stomach, ovary, pancreas and other organs can cause the elevated CEA concentrations. CEA 
assay is mainly used for the monitoring of the recurrence of cancer and it is most frequently 
used for recurrence tests of colorectal cancer (Suresh, 2001). Conventionally, various kinds 
of immunoassays such as enzyme immunoassay (Hurley et al., 1986), Chemiluminescence 
immunoassay (Nishizono et al., 1991) and so on have been applied for the medical 
diagnosis of CEA. 
 
(2) Infectious disease marker (hHBV Ab) 
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Human hepatitis B virus (hHBV) is a widespread cause of liver disease. There are several 
markers for this disease and the appearance of each marker has a characteristic sequence. 
As hHBV antibody appears several months after the disappearance of hHBV antigen, 
hHBV antibody tests can be used to confirm recovery and immunity in patients with acute 
hepatitis. And it is also used to check that vaccination has been effective (Mushahwar, 
2001). The conventional method of hHBV diagnosis has been ELISA. Several kinds of 
biosensors were reported using electrochemical (Erden et al., 1999), piezoelectric (Zhou et 
al., 2002) and optical (Ivanov et al., 2003) principles.  
 
(3) Hormone (hCG) and plasma protein (hA)  
The human chorionic gonadotropin (hCG) and plasma protein (hA) can be used for 
preliminary diagnosis for the abortion and the preterm delivery during early pregnancy.  
 
The concentration of human chorionic gonadotropin (hCG) in urine has been measured for 
the qualitative pregnancy determination (Wehmann et al., 1981). Usually, the doubling time 
of hCG in early pregnancy has been reported to be two days and the failure to increase over 
a period of four days or more is an unfavourable sign to threaten abortion (Chard, 2001). 
Thesedays, lateral-flow immunoassay called rapid test is widely used for the pregnancy test 
to measure the concentration of hCG (Wheeler, 2001). Several kinds of biosensors were 
also reported using electrochemical immunoassay (Lu et al., 2005), fluoroimmunometric 
assay (Neto et al., 2005) and radioimmunoassay (Vaitukaitis et al., 1972). 
 
In diabetes mellitus, the concentration of glucose in the blood is abnormally high. There are 
two main types of diabetes mellitus. Type I diabetes patients have a significantly reduced 
secretion of insulin and type II diabetes is associated with insulin resistance and obesity. 
The ‘microalbuminuria’ means the presence of low concentration of human albumin (hA) in 
urine and it is known to be related with the diabetes (Clark, 2001). Especially for women 
with type I diabetes, the prevalence of preterm delivery has been reported to increase 
steeply for those with microalbuminuria and diabetic nephropathy (Ekbom et al., 2001). To 
detect albumin concentration of microalbuminuria, sensitive immunoassay methods have 
been developed including RIA, immunoturbidometric assay, nephelometric assay and 
ELISA (Clark, 2001). 
 
1.5 Concept for the development of an improved biosensor 
 
Introduction                                                                            20 
 
The overall goal of this work is the application of the SPR immuno-biosensor for medical 
diagnosis. Because the SPR biosensor still needs improvement in technical specifications 
for the medical diagnosis (such as sensitivity, detection limit, analysis time and 
instrumentation), three topics have been targeted to improve this type of biosensor. 
 
[1] The first topic is a reuse method for the IA biosensor called ‘additive assay’ which 
enables the reuse of the IA layer without chip exchange and chemical treatment between 
measurements. In this work, the binding of anti-BSA antibodies to the BSA layer will be 
used as a model of immunoaffinity interaction to prepare a correlation curve and 
demonstrate the additive assay. Before making the correlation curve, three requirements for 
the realization of the additive assay should be satisfied: (1) Reproducible preparation of IA 
layers to use the same correlation curve. (2) Stable IA layer. (3) Stable antigen-antibody 
interaction. The correlation curve will be made by relation between the accumulated 
concentration of additively injected sample and accumulated signal which represents the 
number of occupied binding sites. After making the correlation curve, the feasibility of 
additive assay will be tested by injection of samples at mixed concentrations. After defining 
the valid uncertainty of accumulated concentration as the detection limit, the valid range of 
accumulated concentration will be determined. In this valid range, several analytes with 
different concentration will be injected in arbitary sequence and the respective 
concentrations will be calculated from each signal by using the correlation curve. After 
comparing the calculated concentrations with those of real values, the average error of the 
additive assay will be evaluated to determine whether the additive assay is feasible for the 
immunosensors. The additive assay will be also demonstrated by using another SPR 
biosensor called Biacore 3000, which will be performed by cooperation with the group of 
Prof. Bernhardt at Saarland University (Germany). And then the result will be compared 
with that of SpreetaTM. The application of the additive assay for real medical diagnosis will 
be demonstrated by using the tumor marker (CA 19-9) as a target analyte.  
 
[2] The second topic is the ‘simultaneous detection’ which enables the detection of multiple 
analytes on a single sensor element with single sample treatment. In this work, two 
simultaneous detection models (Model 1 and Model 2) will be devised for the sample with 
the following composition: (1) one target analyte resulting in a sensor response without any 
label and the other analyte with additional label (Model 1), (2) both target analytes 
requiring additional labels for detetion (Model 2). The IA layer was prepared by 
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immobilizing BSA and anti-HRP antibodies together. And the sample was composed of 
anti-BSA antibodies and HRP. After making the respective standard curves for the 
correlation between the concentration and signal, the average errors of simultaneous 
detection based on Model 1 and Model 2 will be calculated for anti-BSA antibodies and 
HRP to determine whether each Model is acceptable for application. As requirements for 
the realization of the simultaneous detection, (1) cross-reaction arising from non-specific 
binding among the participating antigens and antibodies will be tested and (2) the binding 
capacity of the IA layer for each target analyte will be optimized by adjusting of the 
concentration ratio of the molecular recognition element at the immobilization step. The 
real medical diagnosis based simultaneous detection will be demonstrated by analysis of 
human chorionic gonadotropin (hCG) and human albumin (hA) in human urine for the 
diagnosis of preterm delivery of patients with diabetes.  
 
[3] The third topic is the improvement of the sensitivity and detection limit through two 
‘signal amplification’ methods by using mass label (A) and by the orientation control of the 
IA layer (B): (A) In comparison with the direct assay, the amplification ratio by using 
secondary antibodies, avidin-biotynylated antibodies and peroxidase-anti-peroxidase (PAP) 
complex will be estimated to select the most efficient label for signal amplification by 
considering the non-specific binding of label protein. The feasibility of this signal 
amplification method will be demonstrated by analysis of an infectious disease marker, 
human hepatitis B virus (hHBV) antibody. The detection limit of the SPR biosensor by 
using the selected method will be compared with the cut-off value for medical diagnosis 
(0.24 nM) by using the commercial ELISA kit. (B) In this work, the surface density of 
receptor antibody (anti-hIgG) will be compared by attachment of receptor antibody to the 
layer of avidin, NeutrAvidin, protein A, NeutrAvidin-protein A complex and bare gold 
surface of SPR biosensor. The ligand antibody (hIgG) will be injected to each IA layer and 
the binding ratio of ligand antibody per unit receptor will be estimated as a parameter of 
orientation control. By considering the surface density of (1) receptor and (2) ligand 
antibody and (3) the binding ratio of ligand per receptor antibody, the most efficient layer 
will be selected. With the selected layer, test will be also done on biotin-labelled SAM in 
comparison to the IA layer prepared by chemical coupling of receptor antibody to the SAM 
layer. For the feasibility test of orientation control, the selected layer will be applied to 
detect a cancer marker, carcinoembryonic antigen (CEA). 
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2. Materials and Methods 
 
2.1 Materials 
 
•  Chemicals 
11-mercaptoundecanoic acid, N-(3-dimethylamino-propyl)-N’-ethylcarbodiimide (EDAC), 
N-hydrosuccinimide (NHS), p-nitrophenyl phosphate, tetramethylbenzidine were purchased 
from Sigma-Aldrich Chemical Co. (Deisenhofen, Germany). All reagents for the Biacore 
3000 instrument such as amine coupling kit and HBS running buffer were purchased from 
Biacore International SA (Freiburg, Germany). EZ-LinkTM Biotin Hydrazide was bought 
from Pierce Biotechnology, Inc. (Rockford, IL, USA).  
 
•  Antigen - Antibodies 
Bovine serum albumin (BSA), rabbit anti-BSA antibody (polyclonal), human Chorionic 
Gonadotropin (hCG), human albumin (hA) and goat anti-human albumin antibody 
(polyclonal) were purchased from Sigma-Aldrich Chemical Co. (Deisenhofen, Germany). 
Carbohydrate antigen 19-9 (CA 19-9), mouse anti-CA 19-9 (monoclonal), rabbit anti-hHBV 
(polyclonal), carcinoembryonic antigen (CEA), mouse anti-CEA antibody (monoclonal) 
and goat anti-CEA antibody (polyclonal) were purchased from Fitzgerald Inc. (Concord 
MA, USA). Human hepatitis B virus (hHBV) antigen was purchased from Yashraj 
Biotechnology, Ltd. (Mumbai, India). Goat anti-hCG antibody (polyclonal) was obtained 
from Affinity BioReagent, Inc. (Hamburg, Germany). Goat anti-horseradish peroxidase, 
donkey anti-rabbit IgG, donkey alkaline phosphatase conjugated anti-rabbit IgG, human IgG, 
(hIgG) donkey anti-hIgG, rabbit Peroxidase-Anti-Peroxidase (PAP), and donkey biotin 
conjugated anti-rabbit IgG were purchased from Jackson immunochemical research 
laboratories, Inc. (West Grove, PA, USA).  
 
•  Others 
Newborn calf serum was bought from Biochrom AG (Berlin, Germany). The commercial 
ELISA kit for the diagnosis of hHBV (Monorisa® Anti-HBs 3.0, Ver. 3.0) and non-fat milk 
were purchased from BioRad Laboratories GmbH (Muenchen, Germany). Biotin labeled 
protein A, protein A and avidin were purchased from Calbiochem-Novabiochem GmbH 
(Schwalbach, Germany). NeutrAvidinTM was bought from Pierce Biotechnology, Inc. 
 
Materials and Methods                                                                  23 
 
 
(Rockford, IL, USA). Casein was bought from Merck, Inc. (Darmstadt, Germany). Water 
was purified by Milli-Q system (Millipore Co., MA, USA). 
 
2.2 Methods 
 
2.2.1 Preparation of IA layer 
 
The IA layer was prepared on the gold surface of the Spreeta™ chip at 37°C. First, the self-
assembled monolayer (SAM) was prepared on the gold surface by incubating 5 mM 11-
mercaptoundecanoic acid in ethanol for 2 hrs. For the coupling of biomolecules, the sensor 
surface was rinsed with ethanol and then with 10 mM PBS buffer (pH 4.5). The PBS buffer 
was prepared by mixing 10 mM di-sodium hydrogen phosphate (Na2HPO4) with 0.15 M 
KCl and 10 mM sodium dihydrogen phosphate (NaH2PO4) with 0.15 M KCl. Biomolecules 
were coupled to SAM by using the coupling reagents of EDAC (50mM) and NHS (50 mM) 
in 10 mM PBS (pH 4.5). The SAM was first treated with EDAC and NHS for 10 min and 
then the solution of biomolecules in 10 mM PBS (pH 4.5) was incubated. The concentration 
of the biomolecules and incubation time are summarized in Table 2-1. After immobilizing 
recognition parts, the other reactive sites of SAM were blocked by 1 M ethanolamine 
(Naimushin et al., 2002; Kim et al., 2005; Lee et al., 2005). 
 
Table 2-1. The concentration of biomolecule and incubation time for making IA layer. 
 The concentration of 
biomolecules 
Incubation time 
BSA (10 mg/ml) 10 min Additive assay  
(section 3.1) CA 19-9 (500 µg/ml) 1 hr 
BSA (0.1 mg/ml) and  
anti-HRP (2mg/ml)  
1 hr  
Simultaneous detection 
(section 3.2) Anti-hCG (500 µg/ml) and  
anti-hA (100 µg/ml) 
1 hr 
Signal amplification by using mass label 
(section 3.3.1) 
hHBV antigen (75 µg/ml) 2 hr 
Signal amplification by the orientation 
control of IA layer (section 3.3.2) 
Anti-CEA (0.5 mg/ml) 
 
1.5 hr 
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In the signal amplification with the control of IA layer, several modified surfaces were 
prepared on the bare gold surface or the SAM surface. After modification of sensor surface, 
the anti-hIgG solution at the concentration of 1 mg/ml in the 10 mM PBS (pH 7.4) was 
incubated as a receptor protein for 90 min. In order to prevent the non-specific binding, the 
protein bound sensor surface was treated with highly concentrated BSA solution (10 mg/ml). 
 
For the preparation of modified surfaces on the bare gold surface, several proteins such as 
avidin, protein A and NeutrAvidin were prepared on the bare gold surface by incubating the 
protein solution for 90 min. The concentration of protein was adjusted to be 1 mg/ml in 10 
mM PBS (pH 7.4).  
 
The NeutrAvidin-protein A complex layer on the bare gold surface was prepared by 
sequential treatment of NeutrAvidin (1 mg/ml) and biotin-labelled protein A (1 mg/ml) for 
90 min, respectively (see Figure 2-1A).  
 
For the preparation of NeutrAvidin-protein A complex layer on the SAM surface, 
NeutrAvidin (1 mg/ml for 90 min) was attached to the SAM surface by using EDAC/NHS 
and then biotin-labelled protein A (1 mg/ml for 90 min) was attached to the NeutrAvidin 
layer (see Figure 2-1B).  
 
For the preparation of NeutrAvidin-protein A complex layer on the biotin-labelled SAM 
surface, biotin hydrazide at the concentration of 1 mg/ml was attached to the SAM surface 
by using EDAC/NHS for 60 min, and then NeutrAvidin (1 mg/ml for 90 min) and biotin-
labelled protein A (1 mg/ml for 90 min) were also sequentially treated to prepare 
NeutrAvidin-protein A complex layer (see Figure 2-1C).  
 
The chimeric complex which was made by mixing equimolar biotin-labelled protein A and 
NeutrAvidin was incubated for 60 min after treatment of biotin hydrazide at 1 mg/ml on the 
SAM layer for 60 min (see Figure 2-1D).  
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Figure 2-1: Schematic of description for the preparation of modified surfaces. (A) 
NeutrAvidin-protein A complex layer on the bare gold surface. (B) NeutrAvidin-protein A complex 
layer on the SAM surface. (C) NeutrAvidin-protein A complex layer on the biotin-SAM surface. (D) 
Chimeric complex layer on the biotin-SAM surface. 
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2.2.2 Signal measurement of SPR biosensor. 
 
The typical sensorgram by SPR biosensor is shown in Figure 2-2. The signal detection was 
composed of three steps; washing step before sample injection, sample incubation step, 
washing step after sample injection. For the washing step, 0.5 % Tween 20 was flowed at 
the point of ‘1’ and incubated for 4 min at washing step, and then 20 µl of sample was 
flowed at the point of ‘2’ and incubated for 10 min in the sample injection step. In this work, 
we used stopped-flow measurement system which is similar to the cuvette based SPR 
systems. The measurement was performed at the stopped-flow condition after washing step 
to avoid wrong measurement of refractive index by the sample with high protein 
concentration, such as serum. As shown in Figure 2-2, the ‘Signal’ is calculated to be the 
difference between SPR angles at the washing step before sample injection and after sample 
injection.  
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Figure 2-2: A typical sensorgram of the SPR biosensor.  
The point ‘1’ indicates injection of washing buffer which flows for 2 min as indicated by ‘3’. The 
point ‘2’ indicates the sample injection. The ‘Signal’ is calculated to be the difference between SPR 
angles at the washing step before sample injection and after sample injection.  
 
(1) Sensor response at the equilibrium 
 
The sensor response of analyte binding was calculated by the following equation based on 
the binding kinetics of one-to-one interaction (O’Shannessy et al., 1993): 
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RCR  where Rt is the sensor response at time t, C is the 
concentration of analyte in solution, Rmax is the maximal sensor response, KD is the 
dissociation constant, ka is the association rate constant. The response of SPR sensor 
reaches a signal plateau after a certain incubation time. The equation can be simplified as 
follows: [ ]Ktt eMR ⋅−−⋅= 1  where M and K are independent parameters to the sample 
concentration. For the calculation of parameters of M and K, the sample at the 
concentration C was injected and the sensor response had been recorded for enough 
incubation time (2 hour). The obtained sensorgram was fitted by using the non-linear fitting 
of Origin software (Microcal Software, MA) based on the above equation (see Figure 2-3A).  
 
A      B 
 
Figure 2-3: The sensor response at the equilibrium.  
The SPR sensor response of the reaction between anti-BSA antibody (analyte) and BSA (IA layer). 
(A) The SPR sensorgrams with several concentrations of analyte (anti-BSA antibody). After proper 
incubation time, the maximum signal value for each concentration (M) can be calculated as the 
signal at the equilibrium by using the non-linear fitting: [ ]Ktt eMR ⋅−−⋅= 1  where M and K are 
independent parameters to the sample concentration. (B) The does-response curve at the equilibrium. 
To make does-response curve, the concentration and the signal at the equilibrium (M) for each 
concentration were plotted as X-axis and Y axis and the maximum signal value for all concentration 
(Rmax) and KD were calculated by using the non-linear fitting of ⎥⎦
⎤⎢⎣
⎡
+
⋅=
)(
max
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RCM . 
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The calculated M value was the maximum signal value for each concentration such as the 
signal at the equilibrium. When the calculated M values were plotted to the respective 
concentration, the maximum M value (Rmax) and KD were calculated by using the non-
linear fitting of ⎥⎦
⎤⎢⎣
⎡
+
⋅=
)(
max
DKC
RCM  (the Langmuir isotherm model), and then this equation 
could be used for the sensor response at the equilibrium (see Figure 2-3B). For this 
calculation, more than five concentrations were selected for each analyte within the 
concentration range used in this work. 
 
(2) Optimization of incubation time. 
 
Generally, the sensor response reaches the equilibrium after a long incubation time and it is 
not efficient for real application. For more efficient application, the incubation time should 
be shortened. In this case, the standard curve which is obtained by short incubation time has 
less similar physical meaning with Langmuir isotherm model. In this work, the optimum 
incubation time was selected to get a high enough fitting result (r2) to the fitting model, 
where “r2” is the the square of the correlation coefficient (r). Compared with the does-
response curve at the equilibrium of Figure 2-3B (r2=0.995), the “r2” value after the 
incubation time of 10 min was slightly changed from 0.995 to 0.993 (see Figure 2-4). From 
this result, the incubation for 10 min could be applied in this experiment. 
 
 
 
 
 
 
 
 
 
 
Figure 2-4: The sensor responses with different incubation times. Compared with the 
does-response curve at the equilibrium of Figure 2-3B (r2=0.995), the “r2” value with the incubation 
time of 10 min was slightly changed from 0.995 (▲) to 0.993 (■). From this result, the standard 
curve following incubation for 10 min was also observed to fit well to the same model. 
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The other factors were also considered for the selection of an optimum incubation time. For 
example, the incubation time is related to the sensitivity of the measurement, the baseline 
drift and the detection limit. For suitable measurements in this work, the optimum 
incubation time should be determined by considering these parameters along with the 
square of the correlation coefficient (r2). 
 
(3) Calculation of lower limit of detection (LLD) by using baseline drift.  
 
The sensitivity of an assay has been defined as the lower limit of detection (LLD), and it 
has been estimated from the slope of the dose-response curve. The LLD is the lowest 
analyte concentration that makes a positive signal significantly different from the negative 
signal in the absence of antigen. In a noncompetitive assay, the LLD is usually defined as 
three standard deviations from the mean of the zero analyte control. Accordingly, signal for 
LLD is m + 3sd, where “m” is the mean signal obtained in absence of antigen, “sd” is the 
standard deviation of the signal in absence of antigen. LLD is the concentration where 
signal of m + 3sd is positioned in the dose-response curve (Ezan and Grassi, 2000). The 
baseline drift was measured in absence of antigen by repeated injection of 10 mM PBS (pH 
7.4) which is used as a sample buffer and 0.5 % Tween 20 (see Figure 2-5).  
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Figure 2-5: SPR sensorgram by repeated injections of 0.5% Tween 20 and PBS by 
turns. The baseline drift was calculated by the repeated injection of 10 mM PBS (pH 7.4). The 
baseline drift was estimated to be 0.9 (m) ± 0.4 (sd) milli° (n = 50) and signal for LLD (m + 3sd) 
was calculated to be 2.1 milli° in this system. 
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The baseline drift was calculated by the difference of SPR angles by 0.5 % Tween 20 
solution measured before and after the injection of 10 mM PBS. The baseline drift was 
estimated to be 0.9 (m) ± 0.4 (sd) milli° (n = 50). From this result, signal for LLD (m + 3sd) 
was calculated to be 2.1 milli° in this system. 
 
As the baseline drift decreased to be stabilized, signal was kept less than ± 1 milli° for 30 
min and then the concentration of LLD was also decreased. As the refractive index is 
sensitive to temperature, the change of temperature is related to the baseline drift (Roos et 
al., 1998). The influence of the temperature on the responses of the transducer was 
investigated by variation of the temperature of the water bath, which was slowly cooled 
down in the ice box from 42 oC to 22 oC. As the temperature change of 1 oC caused a 
baseline drift of 8.7 milli o (see Figure 2-6), the temperature of SPR sensor system should 
be set to be ±0.5 oC for the drift of less than 5 milli o. 
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Figure 2.6: Influence of the temperature on the SPR signal.  
 
2.2.3 Instruments 
 
(1) Spreeta™ system 
 
The Spreeta™ chip from Texas Instrument Co. (Dallas, TX, USA) was used for SPR 
measurement. The response of SPR chip was transferred on-line to a PC by a 12-bit analog-
to-digital converter. Before the preparation of an IA layer, the SPR chip was first calibrated 
with the air and then with deionized water of refractive index (RI) of 1.33. The SPR chip 
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was equipped with an integrated flow cell with a capacity of 5 µl. The sample and the 
washing solution were injected to the flow cell of the SPR chip using an autosampler and an 
integrated peristaltic pump from EKF diagnostik GmbH (Magdeburg, Germany) (see Figure 
2-7). The pumping rate was set to be 1.0 ml/min. The peristaltic pump and the autosampler 
were controlled using a programmable microprocessor board. The flow of solution was 
programmed to stop during the incubation step and the measurement step. In the 
preparation of IA layer, the injection of reagents was performed by a peristaltic pump from 
Amersham-Pharmacia Biotech AB (Uppsala, Sweden). The whole instrument was kept in 
an incubator and the temperature was set to be 37 °C. 
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Figure 2-7: SPR system in KIST-Europe. 
The SPR chip was equipped with an integrated flow cell with a capacity of 5 µl. The sample and the 
washing solution were injected to the flow cell of the SPR chip using an autosampler and an 
integrated peristaltic pump which were controlled using a programmable microprocessor board. The 
whole instrument was kept in an incubator and the temperature was set to be 37 °C. 
 
(2) BiacoreTM system 
 
The additive assay was also demonstrated using another SPR biosensor called Biacore 3000. 
In previous work, the IA layer was prepared by immobilization of BSA to the SAM layer of 
SpreetaTM chip. In the Biacore system, modified cellulose layer (CM5 chip) was used for 
the preparation of the IA layer. Therefore, the number of binding sites on the CM5 chip was 
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expected to be different from SpreetaTM chip. The gold surface of the CM5 chip is 
covalently covered with a matrix of carboxymethylated dextran, a flexible unbranched 
carbohydrate polymer forming a thin surface layer approximately 100 nm thick. Coupling 
of protein to the CM5 chip was performed by activating the carboxyl groups on the chip 
with a solution containing 50 mM EDAC and 50 mM NHS. The pumping rate was set to be 
5 µl/min. After coupling of protein, remaining free ester groups were blocked by 1 M 
ethanolamine. All protein-containing solutions were prepared in Biacore HBS-EP buffer 
(0.01 M HEPES buffer pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% Surfactant P20). 
Analysis of the data was accomplished by using the Biacore evaluation software 3.1. 
 
(3) ELISA 
 
Enzyme-linked immunosorbent assay (ELISA) is widely used for a selective and sensitive 
analysis of biological samples. Typically, horseradish peroxidase (HRP) with high turnover 
rate is most commonly utilized in an ELISA protocol (Vo-Dinh et al., 2004). The 
immobilization of receptor antibody was performed in a 96-well microplate for 2 hr at 
37 °C, and then it was blocked by using 10 mg/ml BSA. After washing with 0.5 % Tween 
20, test sample (100 µl) was incubated for 1 hr. For the measurement of target analyte, HRP 
conjugated label was treated and the colorimetry was performed by treating 
tetramethybenzidine (TMB) (0.02 mg/ml in 0.2 M citrate buffer) with hydrogen peroxide. 
The concentration of the test sample was calculated using a standard curve for each analyte. 
The optical density was measured at 450 nm using a SPECTRA Rainbow Thermo (TECAN 
DEUTSCHLAND GmbH).
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3. Results 
 
The major objective of this work is the development of a SPR biosensor for medical 
diagnosis with the features of a cost-effective test by ‘additive assay’, short analysis time 
through ‘simultaneous detection’ and high sensitivity by ‘signal amplification’. For the 
realization of this major objective, the three topics were investigated as follows:  
 
•  Additive assay for the repeated measurements without regeneration step 
‘Additive assay’ enables reuse of the IA layer without chip exchange and chemical 
treatment between measurements. The concentration of each measurement is calculated by 
using a previously prepared correlation curve. This method was demonstrated to be feasible 
by measuring a cancer marker (CA 19-9). The result showed that the ‘additive assay’ could 
be applicated for the repeated measurement of CA 19-9 without chip exchange and 
chemical treatment (see Section 3.1). 
 
•  The simultaneous detection of multiple analytes  
‘Simultaneous detection’ enables the analysis of multiple analytes in the same sample. The 
molecular recognition part of SPR IA-biosensor was prepared by immobilizing two kinds 
of receptor antibodies. Each concentration of analyte was measured by treatment of labelled 
antibodies and by using standard curves. The feasibility of this method was demonstrated 
by the analysis of hCG and hA in urine for the diagnosis of preterm delivery. The result 
showed that ‘simultaneous detectioin’ of both analytes with single sample treatment could 
be applicated for the short analysis time (see Section 3.2). 
 
•  Signal amplification of SPR biosensor 
Two ‘Signal amplification’ methods were developed to improve the sensitivity and 
detection limit of SPR IA-biosensor. 
(1) The mass label attached to the already bound target analyte increases the total mass 
attached to the sensor surface and then it induces the increase of SPR signal. Among several 
kinds of mass labels, PAP method was selected for the efficient signal amplification. With 
this mass label, the feasibility of this signal amplification method was demonstrated by the 
detection of hHBV antibody. The result showed that the detection limit of SPR biosensor 
approached closely to cut-off value for medical diagnosis by using the commercial ELISA 
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kit (see Section 3.3.1). 
(2) The control of IA layer (orientation & density) could improve the sensitivity and 
detection limit of IA biosensor. For this work, several kinds of proteins were tested. As an 
efficient controlled IA layer, NeutrAvidin-protein A complex layer was selected. With this 
layer, the feasibility of this signal amplification method was demonstrated by analysis of a 
cancer marker (CEA). The result showed that control of IA layer (orientation & density) 
improved the sensitivity and detection limit of IA biosensor (see Section 3.3.2). 
 
These results demonstrated the ‘additive assay’ for cost-effective test, ‘simultaneous 
detection’ for short analysis time and ‘signal amplification’ for high sensitivity. The 
presented three methods in this study will be applied to develop a practical SPR biosensor 
for the various medical diagnoses. 
 
3.1 Additive assay for the repeated measurements without regeneration step 
 
The ‘additive assay’ aims to use SPR immunosensor for repeated analysis without chemical 
treatment between measurements. In the additive assay, the concentration of sample is 
calculated from the actually measured signal by using a correlation curve. In this work, the 
accumulated concentration of additively injected sample was correlated to the accumulated 
signal. By using a this way prepared correlation curve, the feasibility of the additive assay 
was tested by injection of samples at mixed concentrations and the real medical diagnosis 
was demonstrated by using the tumor marker (CA 19-9) as a target analyte. 
 
3.1.1 The comparison of the conventional methods   
 
The ‘regeneration’ method has been conventionally used for the repeated measurements by 
immunosensors. In this method, the already bound analytes are removed from the IA layer 
by chemical treatment such as high or low pH agents for each measurement. As shown in 
Figure 3.1, the IA layer is regenerated by removing the already bound analytes before each 
measurement. In this case, the signal (S1) is expected to have constant relation to the 
concentration (C1) of the analyte. After several times of regeneration steps, the damage of 
the IA layer is known to occurr so that the relation between signal and concentration is 
changed. In this case, new calibration of the IA biosensor is required. For example, when 
the anti-BSA antibody (327 nM) was injected to the BSA layer on the CM5 chip and NaOH 
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was repeatedly treated for regeneration, the SPR signal at 1st injection was measured to be 
794 RU and the SPR signal at 7th injection was changed to be 619.6 RU. This result shows 
that there was a 22 % reduction of binding activity after only six regeneration treatments. 
As the regeneration is repeated, the signal to the same concentration is expected to be 
decreased gradually. In the additive assay, measurements are performed without the 
regeneration step. The analytes are additively injected to the IA layer without removing the 
already bound analytes as shown in Figure 3-1. As the number of binding sites is confined 
in the IA layer, the number of free binding sites is reduced as the analytes are additively 
bound to the IA layer. After a certain amount of binding sites are occupied by repeated 
treatment of samples, the IA layer becomes saturated and the sensor no longer responds to 
the injection of sample. 
 
 
 
Figure 3-1: The schematic diagram of the additive assay in comparison to the 
conventional regeneration method. 
 
3.1.2 Requirements for additive assay 
 
The additive assay is based on the correlation between the accumulated concentration of 
additively injected sample and accumulated signal. For the realization of the additive assay, 
the following requirements should be satisfied: (1) The layer-to-layer homogeneity should 
be achieved to use the same correlation curve. (2) The IA layer on the sensor surface should 
be stable enough during the whole measurement steps. (3) The binding of analytes should 
be maintained during the whole measurement steps.  
 
(1) Reproducible preparation of IA layers 
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The IA layer of a SPR biosensor has a constant number of binding sites for analytes. 
Usually, the signal of the IA biosensor is generated by the occupancy of the free binding 
sites of the IA layer. If the number of the free binding sites is different, the biosensor signals 
from the sample at the same concentration are also different. Therefore, the IA layer to IA 
layer homogeneity should be achieved for the realization of an additive assay to use the 
same correlation curve. The reproducibility of IA layers can be investigated by comparing 
the number of free binding sites. Four IA layers were prepared and each IA layer was 
treated with a standard sample (108.7 nM) and then five samples were sequentially injected 
(54.7 Æ 65.3 Æ 108.7 Æ 163.3 Æ 326.7 nM) (see Table 3.1). As the biosensor signal is 
proportional to the number of free binding sites in each IA layer, the signal from standard 
sample and the accumulated signal by sequentially injected samples can be used to compare 
the number of free binding sites of different IA layers. The standard signal and accumulated 
signal from four IA layers was estimated to be 28.9 ± 0.5 milli° and 215.9 ± 6.2 milli°, 
respectively. The deviation was calculated to be 1.7 % and 2.9 %, respectively. These 
deviations were used for the calculation of measurement errors and the limit of detection. 
 
Table 3.1: Reproducibility of the response of IA layers (chip-to-chip difference)  
No. of Chips Standard Signal2 (milli°) Accumulated Signal3 (milli°) 
1 29.5 212.6 
2 28.4 221.7 
3 29.1 220.5 
4 28.8 208.8 
Mean ± sd 28.9 ± 0.5 (1.7%)1 215.9 ± 6.2 (2.9%)1 
1: Deviation is defined as (100ⅹstandard deviation (sd) / mean).  
2: A standard signal was measured by injecting standard sample at the concentration of 108.7 nM. 
3: Accumulated signal is the sum of signals which were made by five sequentially injected samples. 
 
(2) Stability of the IA layer 
 
The IA layer should be stable enough to be maintained during the whole additive assay 
steps. If the IA layer is not stable, a part of IA layer can be detached from the sensor surface 
during washing steps required for signal measusrement. In this case, the total number of 
free binding sites is changed and the standard correlation curve can not be used for the 
additive assay as mentioned previously.  
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The stability of the IA layer was estimated by measuring the baseline drift by repeated 
injection of blank sample (10mM PBS) as shown in Figure 3-2. The sensor signal from the 
BSA binding to SAM layer was 151 ± 11.1 milli°. If this BSA-layer (IA layer) is detached 
from the sensor surface, the signal would be decreased from this value after blank sample 
treatment. Baseline drift after repeated blank sample injection was estimated to be -0.1 ± 
0.9 milli° (n = 16). This value is also similar to the baseline drift on the bare gold sensor 
surface without IA layer (0.9 ± 0.4 mili°). This result indicates that there was no significant 
detach of the IA layer and the IA layer can be maintained stable for long enough time 
required for additive assay. 
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Figure 3-2: Baseline drift at the injection of blank samples (10 mM PBS) to the BSA 
layer (n=16). The stability of the IA layer (BSA layer) was estimated by measuring the baseline 
drift by repeated injection of blank sample (10mM PBS). Baseline drift after repeated blank sample 
injection was estimated to be -0.1 ± 0.9 milli° (n = 16). This value is also similar to the baseline drift 
on the bare gold sensor surface without IA layer (0.9 ± 0.4 mili°).  
 
(3) Stability of antigen-antibody interaction. 
 
As previously mentioned, the additive assay is based on the correlation between the 
accumulated signal and the accumulated concentration. This means that the analytes bound 
to the IA layer should be maintained during additive assay. If analytes are dissociated from 
IA layer, the accumulated signal is decreased. In this case, the correlation between the 
accumulated concentration of additively injected sample and accumulated signal will be 
changed and the correlation curve can not be used for measurement. The stability between 
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the IA layer and analytes is in proportion to the value of affinity constant (KA) representing 
the final ratio between bound and unbound analytes to the IA layer. Therefore, the valid 
range of KA can be used to select a suitable pair of IA layer and analytes. In this experiment, 
BSA (IA layer) and anti-BSA antibodies (analytes) were estimated to be a suitable antigen-
antibody pair for the additive assay. By using several sensorgrams of different 
concentrations, KD can be calculated (see section 2.2.2(1)) and KA is an inverse number of 
KD. From the four sensorgrams (54.8, 65.4, 109 and 326 nM of anti-BSA antibodies), the 
KA value for BSA and anti-BSA antibodies was calculated to be 1.17 ⅹ 106 [1/M] by using 
the Biacore evaluation software 3.1 with a 1:1 binding model (see Figure 3-3). Therefore, 
the additive assay can be applied for a pair of antigen and antibody which has higher KA 
value than 106 [1/M]. 
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Figure 3-3: The sensorgram for calculation of affinity constant (KA). BSA and anti-BSA 
antibodies were used as IA layer and analytes, respectively. From the four sensorgrams (54.8, 65.4, 
109 and 326 nM of anti-BSA antibodies), the KA value for BSA and anti-BSA antibodies was 
calculated to be 1.17 ⅹ 106 [1/M] by using the Biacore evaluation software 3.1 with a 1:1 binding 
model. 
 
3.1.3 Correlation curve for the additive assay 
 
In the additive assay, measurements are performed without regeneration step to remove the 
already bound analytes. As the number of free binding sites is reduced by the binding of 
analytes to the IA layer, the sensor response of next measurement is different from that of a 
freshly prepared sensor. Even if the sample at the same concentration is injected repeatedly, 
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the number of free binding sites decreases and the corresponding sensor response also 
decreases as shown in Figure 3-4. To indicate accumulation of analyte by repeated injection, 
the X-axis was represented to be the addition of concentrations of injected samples from the 
first injection (accumulated concentration) and signal responses for each measurement were 
plotted as Y-axis. When the first sample at the concentration of x nM obtains the sensor 
signal of y1 milli° and the second sample at the same concentration obtains the sensor signal 
of y2 milli°, the first sample and the second sample are plotted to be (x, y1) and (2x, y2), 
respectively. The physical meaning of accumulated concentration is directly related to the 
amount of adsorbed analyte to the IA layer. 
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Figure 3-4: Signal decrease by additive injection of samples at the same concentration. 
For each curve, the samples at the same concentration were repeatedly injected to one sensor chip 
and these experiments were carried out with several concentrations of anti-BSA antibodies (81.7, 
163.3, 245, 326.7 nM). The X-axis was calculated by simply adding the concentrations of injected 
samples from the first injection (accumulated concentration) and signal responses for each 
measurement were plotted as Y-axis. When the first sample at the concentration of x nM obtains the 
sensor signal of y1 milli° and the second sample at the same concentration obtains the sensor signal 
of y2 milli°, the first sample and the second sample are plotted to be (x, y1) and (2x, y2), respectively. 
Even if the samples at the same concentration are repeatedly injected, the number of free binding 
sites decreases and the corresponding sensor response also decreases. 
 
For the calculation of sample concentration from the actually measured sensor response by 
using the correlation curve, the accumulated signal is required, which is recorded from the 
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first sample measurement. As the history of measurement indicates the number of occupied 
binding sites on the IA layer, the accumulated signal can be used to correlate the actual 
signal to the actual concentration. If the Y-axis is assigned to be the accumulated signal, the 
curves approach into a single curve, even if each curve was obtained by the repeated 
injections of respective concentrations (see Figure 3-5A). Each point of Figure 3-5A was 
obtained by accumulated addition of injected concentration and measured signal. When the 
first sample at the concentration of x1 nM obtains the sensor signal of y1 milli° and the 
second sample at the concentration of x2 nM obtains the sensor signal of y2 milli°, the 
positions of the first sample and the second sample are (x1, y1) and (x1 + x2, y1 + y2), 
respectively.  
 
A           B 
 
Figure 3-5: Correlation curve for the additive assay. For the calculation of sample 
concentration from the actually measured sensor response, the calculation curve is required. For 
preparion of the correlation curve, the accumulated signal (Y-axis) and the accumulated 
concentration (X-axis) were calculated by simply adding the measured signals and the 
concentrations of injected analytes from the first injection. (A) Repeated injections of samples at the 
same concentration. From the data of Figure 3-4, signals of each plot were changed as accumulated 
signals (Y-axis). (B) Non-linear curve fit of the plot of repeated injections. After calculating mean 
values of accumulated signals from all points in Figure 3-5A, non-linear curve fit of the plot was 
applied with a binding model: R = [Rmax · C / (K + C)] (r2=0.995). In our model, “R” and “Rmax” 
(664.3 milli°) represent accumulated signal and maximum accumulated signal, respectively. “C” 
represents accumulated concentration and “K” (2369.1 nM) represents the accumulated 
concentration at the half of Rmax.  
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For the non-linear curve fitting of the repeated injection of Figure 3-5B, the equation of 
Langmuir isotherm (O’Shannessy et al., 1993; Morton et al., 1995; Karlsson and Faelt, 
1997) was applied as a binding model: R = [Rmax · C / (K + C)]. In our model, “R” and 
“Rmax” (664.3 milli°) represent accumulated signal and maximum accumulated signal, 
respectively. “C” represents accumulated concentration and “K” (2369.1 nM) represents the 
accumulated concentration at the half of Rmax. Although the result of repeated injection has 
no concrete relation to the model of Langmuir isotherm, the plot of accumulated 
concentration and the accumulated signal of Figure 3-5A closely fits to the calculated curve 
(r2=0.995) as shown in Figure 3-5B.  
 
The availability of this correlation curve was tested by the injection of samples at mixed 
concentrations. When the several analytes with different concentrations were injected in 
arbitary sequence, the respective concentrations were calculated from each signal by using 
the obtained correlation curve and compared with those of real values to evaluate the 
average error of the additive assay (see Figure 3-6).  
As shown in Figure 3-6, the signals by samples at mixed concentration were found to be 
plotted closely on the correlation curve. Twelve samples of anti-BSA antibodies were 
injected according to the following sequence: 163.3 Æ 65.3 Æ 98.0 Æ 130.7 Æ 130.7 Æ 
98.0 Æ 65.3 Æ 163.3 Æ 65.3 Æ 98.0 Æ 130.7 Æ 165.3 nM. When the accumulated 
signals and the accumulated concentrations for each sample were plotted together with the 
correlation curve, each point closely plotted to the correlation curve. The deviation of each 
point from the correlation curve was calculated to be 2.6 % (n=12). This means that the 
correlation curve by repeated injection of sample at the same concentration can be used to 
calculate the concentration of an unknown sample.  
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Figure 3-6: The signals by injection of samples at mixed concentrations plotted on the 
correlation curve. For the availability test of the correlation curve from Figure 3-5B, several 
analytes with different concentrations were injected in arbitary sequence. The respective 
concentrations were calculated from each signal by using the correlation curve and compared with 
those of real values to evaluate the average error of the additive assay. The signals by samples at 
mixed concentration were found to be plotted closely on the correlation curve. Twelve samples of 
anti-BSA antibodies were injected according to the following sequence: 163.3 Æ 65.3 Æ 98.0 Æ 
130.7 Æ 130.7 Æ 98.0 Æ 65.3 Æ 163.3 Æ 65.3 Æ 98.0 Æ 130.7 Æ 165.3 nM. The deviation of 
each point from the correlation curve was calculated to be 2.6 % (n=12). This low value of deviation 
means the correlation curve made by repeated injection of sample at the same concentration can be 
used to calculate the concentration of an unknown sample. 
 
Calculation of analyte concentration by using correlation curve  
 
When several samples at different concentrations were additively injected to the IA layer, 
the concentration of each sample can be calculated from the actually measured sensor 
response by using the correlation curve. In details, if the sensor response from the first 
injection is S1, the concentration of the first sample is estimated to be C1 which matches to 
the sensor signal of S1 on the correlation curve. And the accumulated signal is recorded to 
be S1 as shown in Figure 3-7. If the second sample produces the sensor response of S2, the 
accumulated concentration is estimated on the correlation curve, which matches to the 
accumulated signal of S1 + S2. As this accumulated sensor signal corresponds to the 
accumulation concentration of C1 + C2 on the correlation curve, the concentration of second 
sample was calculated as C2 by subtracting the concentration of C1 which actually 
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corresponds to the accumulated concentration before second sample injection. For the next 
measurement, the accumulated signal is updated to be S1 + S2. 
 
 
Figure 3-7: Calculation of sample concentration by using the correlation curve. If the 
sensor response from the first injection is S1, the concentration of the first sample is estimated to be 
C1 and the accumulated signal is recorded to be S1. If the second sample produces the sensor 
response of S2, the accumulated concentration is estimated on the correlation curve, which matches 
to the accumulated signal of S1 + S2. As this accumulated sensor signal corresponds to the 
accumulation concentration of C1 + C2 on the correlation curve, the concentration of second sample 
was calculated as C2 by subtracting the concentration of C1 which actually corresponds to the 
accumulated concentration before second sample injection. 
 
Feasibility test of additive assay  
 
The applicable range of accumulated concentration of the correlation curve was determined 
by using the uncertainty of signal measurement as a boundary condition. The data at the 
valid range of accumulated concentration was selected by considering the restrictions of 
correlation curve. The deviation (sd) of baseline stability was calculated to be ± 0.6 milli°. 
According to the accumulated signal point (R, Y-axis), this baseline uncertainty (α) of ± 0.6 
milli° makes a different uncertainty of concentration (∆C1 < ∆C2) at the accumulated 
concentration (C, X-axis) (see Figure 3-8). After the preparation of BSA layer, the lower 
limit of detection (LLD) was calculated to be 2.3 milli° by using m + 3sd of baseline 
stability, where “m” is mean signal (0.5 milli°) and “sd” is standard deviation (± 0.6 milli°) 
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in absensce of anti-BSA. The detection limit of concentration corresponding to the signal 
(2.3 milli°) was 8.3 nM in the correlation curve. Generally, the uncertainty of measurement 
is specified to be the gray zone of measurement. If the valid uncertainty of accumulated 
concentration is defined to be the detection limit (8.3 nM), the applicable range of 
accumulated concentration is determined by solving the following equations: 
 
∆C = C2 - C1 ≤ 8.3 nM 
R - α= Rmax ⅹ C1 / (K + C1) 
 R + α = Rmax ⅹ C2 / (K + C2) 
R = Rmax ⅹ C / (K + C) 
 
With the Rmax and K in Figure 3-5B, the accumulated concentration (C) was determined to 
be lower than 930.2 nM by solving the above equations, so the valid range of accumulated 
concentration was determined to be 8.3 – 930.2 nM by considering the detection limit. 
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Figure 3-8: The uncertainty of the calculated concentration by using the correlation 
curve. According to the level of accumulated signal, the baseline uncertainty (α) of signal (± 0.6 
m°) makes a different uncertainty of concentration (∆C1 < ∆C2) at the accumulated concentration.  
 
In the valid range of accumulated concentration (8.3 – 930.2 nM), the calculated analyte 
concentrations ([αBSA] M) in Figure 3-6 were compared with those of real values 
([αBSA]R) and the average error of additive assay was determined to be 5.4 % (n = 8) (see 
Table 3-2). This result shows that the additive assay is feasible for the immunosensors. 
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Table 3-2: Deviation of the analyte concentration from the additive assay method.  
Nr. SignalA  
(milli°) 
SignalM  
(milli°) 
[αBSA]A  
(nM) 
[αBSA]M 
(nM) 
[αBSA]R 
(nM) 
Error  
(%) 
1 40.2 40.2 152.6 152.6 163.3 -6.6 
2 54 13.8 209.6 57 65.3 -12.7 
3 76.5 22.5 308.3 98.7 98.0 0.7 
4 103.3 26.8 436.2 127.9 130.7 -2.1 
5 127.9 24.6 564.9 128.7 130.7 -1.5 
6 145.9 18 666.8 101.9 98.0 4.0 
7 157.2 11.3 734.5 67.7 65.3 3.5 
8 185.4 28.2 917.2 182.7 163.4 11.8 
                                                   The average error (%) = 5.4 
* Abbreviations: ‘SignalA’and ‘SignalM’ mean accumulated signal and signal from measured data, 
respectively. ‘[αBSA]A’ and ‘[αBSA]M’ represent the accumulated concentration and concentration 
from measured data, respectively. ‘[αBSA]R’ is a real concentration of anti-BSA antibodies. Error 
(%) was calculated by ([αBSA] M - [αBSA] R)⋅100/ [αBSA]R. The average error is calculated from 
the absolute errors. 
 
Additive assay by using BiacoreTM system 
 
The additive assay was also evaluated by using another SPR biosensor called Biacore 3000. 
In previous work, the IA layer was prepared by immobilization of BSA to the SAM layer of 
SpreetaTM chip. In the case of Biacore, the modified cellulose layer of CM5 chip was used 
for the preparation of the IA layer. As shown in Figure 3-9, the correlation curve of the 
Biacore shows a different correlation curve with different fitting parameters of Rmax (177.7 
milli°) and K (543.8 nM) compared with the additive assay by SpreetaTM system. The 
accuracy of the additive assay using Biacore was also calculated with the detection limit of 
0.3 nM, which was calculated by using m+3sd of baseline uncertainty (0.1 milli°) according 
to the former procedure. If valid uncertainty of measurement is set to be 8.3 nM (detection 
limit of spreetaTM), the valid range of accumulated concentration was calculated to be 0.3 – 
1156 nM. In this concentration range, the average error was calculated to be far more than 
5 %. With the detection limit of 0.3 nM, the valid range of accumulated concentration was 
calculated to be less than zero. When the uncertainty is set to be 1 nM, the valid range was 
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calculated to be 0.3 – 435.5 nM and the average error was calculated to be 4.4 %. This 
result shows that the additive assay is feasible for Biacore as well as SpreetaTM with the 
average of error less than 5 %. Although the valid range of accumulation concentration was 
narrower than that of SpreetaTM, the Biacore was determined to achieve a far higher 
accuracy of measurement than that of SpreetaTM.  
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Figure 3-9: Correlation curve for additive assay by using BiacoreTM (▲) and 
SpreetaTM (■). Although the valid range of accumulation concentration was narrower than that of 
SpreetaTM, the Biacore was determined to achieve a far higher accuracy of measurement than that of 
SpreetaTM.  
 
3.1.4 The medical application of additive assay with the serum sample. 
 
The serum samples in the medical diagnosis include the target analytes as well as other 
components which can interrupt effective detection of the target analyte by non-specific 
binding or interference to decrease analyte binding. Such non-specific binding makes some 
deviation in correlation curve by changing the signal to concentration ratio. For the 
feasibility test of the additive assay with the serum sample, HRP and anti-HRP antibodies 
were used as a model Ag-Ab pair and the concentration of total protein was set to be upto ~ 
50 mg/ml by mixing calf serum. When the relation between accumulated concentration and 
accumulated signal were plotted with three concentrations (28.96, 14.48 and 7.24 µg/ml), 
the sample with 50 % serum showed larger deviation among the other correlation curves 
than the sample without serum (see Figure 3-10). At the serum concentration of 50 %, 
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standard correlation curve with small deviation could not be calculated from several 
concentrations of samples and the additive assay was not suitable for medical diagnosis. 
The non-specific binding of serum was regarded to be the major reason. 
 
A      B 
 
Figure 3-10: Deviation among each correlation curve from several concentrations with 
the sample in the 0 % and 50 % serum. The IA layer was made by HRP and target analytes 
were anti-HRP antibodies (■: 28.96 µg/ml, ▲: 14.48 µg/ml, ◆: 7.24 µg/ml). (A) Sample in the 0 % 
serum. (B) Sample in the 50 % serum. The sample with 50 % serum showed larger deviation among 
individual correlation curves than the sample with no serum. With the 50 % serum concentration, 
the additive assay was not suitable for medical diagnosis and the non-specific binding of serum was 
regarded to be the major reason. 
 
The effect of non-specific binding by serum is shown in Table 3.3. The absolute signal of 
the sample in 50 % serum was higher than the signal of the sample without serum (sample 
in PBS). Furthermore, the signal to concentration ratio calculated according to the formula: 
(signal of high concentration) / (signal of low concentration) was not uniform for different 
analyte concentration. This increase seemed to be made from non-specific binding of the 
proteins in the serum. As the changes of absolute signal value and signal ratio were major 
reasons for dispersion of individual correlation curves, the minimization of non-specific 
binding was required for the realization of the additive assay. 
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Table 3.3: The effect of serum concentration to the SPR signal. 
with 0% serum with 50% serum Analyte 
(µg/ml) Signal (millio) Signal ratio Signal (millio) Signal ratio 
7.24 27.8 1 51.5 1 
14.48 44.4 1.6 88.5 1.7 
28.96 81.2 2.9 173 3.4 
  
For the application of additive assay, all individual correlation curves from several 
concentrations should be fit into a single standard correlation curve. Without decreasing 
non-specific binding, the ‘gray zone’ of correlation curve was too broad to ensure the 
acceptable error range (below 5%) for medical diagnosis. This minimization of deviation 
can be realized by the minimization of non-specific binding of serum to the IA layer. The 
dilution of sample can be one solution to decrease the non-specific binding for the medical 
application of additive assay with the serum sample. 
 
The additive assay was tested by using serum samples at several dilution factors. The 
accuracy of the additive assay was influenced by the dilution factor of the serum. With the 
three concentrations of 7.24, 14.48, 28.96 µg/ml, samples at the same concentration were 
repeatedly injected to a SPR biosensor and all points of individual response curves of 
respective concentrations were summated statistically with mean value of signal to obtain a 
standard correlation curve as shown in Figure 3-11. The fitting result for correlation 
coefficient (r2) of 0 %, 5 %, 10 % and 50 % serum were calculated to be 0.999, 0.996, 0.971 
and 0.945, respectively. As the concentration of serum was increased, the square of the 
correlation coefficient (r2) was decreased. Moreover, the standard deviation of each point in 
the correlation curve was also increased according to the increase of serum concentration, 
which made large error in the real application of additive assay. 
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Figure 3-11: The correlation curve of additive assay according to the dilution factor of 
serum sample. (A) 0 % serum (r2 = 0.999). (B) 5 % serum (r2 = 0.996). (C) 10 % serum (r2 = 
0.971). (D) 50 % serum (r2 = 0.945). 
 
The feasibilities of each correlation curve were tested by repeated injections of target 
analyte (14.48 µg/ml, n=4), which compared the calculated concentrations with the real 
values to calculate the error values (see Table 3.4). The mean error values of 0 %, 5 %, 
10 % and 50 % serum were calculated to be 6.4, 9.9, 29.4 and 29.3 %, respectively. In the 
high concentration of serum (10 % and 50 % serum), the mean error values were calculated 
to be as high as 30 % and the additive assay could not be performed with these error values 
by using the correlation curve. The result showed that the serum content of less than 5 % is 
adequate for the additive assay to have a mean error value less than 10 %. However, the 
blocking method of IA layer instead of dilution should be improved to minimize the non-
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specific binding because dilution of sample also decreases the positive signal of sample.  
 
Table 3.4: The feasibility of correlation curve according to the dilution factor of serum 
sample. 
0 % serum 5 % serum 10 % serum 50 % serum  
No. of 
injection 
*[C]cal 
(µg/ml) 
**Error 
(%) 
[C]cal 
(µg/ml)
Error 
(%) 
[C]cal 
(µg/ml)
Error 
(%) 
[C]cal 
(µg/ml) 
Error 
(%) 
1 13.6 -6.1 13.3 -8.1 11.3 -22.0 16.5 14.0 
2 13.9 -4.0 13.5 -6.8 10.6 -26.8 12.3 -15.1 
3 13.6 -6.1 12.8 -11.6 9.3 -35.8 9.3 -35.8 
4 13.1 -9.5 12.6 -13.0 9.7 -33.0 6.9 -52.3 
Mean   6.4  9.9  29.4  29.3 
*[C]cal is a calculated concentration. 
**Error is a deviation between real concentration and calculated concentration. 
 
3.1.5 Additive assay of a tumor marker, carbohydrate antigen 19-9 (CA 19-9)  
 
The application of the additive assay was demonstrated by the detection of a cancer marker 
called CA 19-9. The CA 19-9 is a tumor marker from patients with gastrointestinal 
malignancies and it is reported to be frequently found in the patients with pancreatic cancer 
with a high score of over 79 % (see section 1.4). In this work, the SPR biochip of Texas 
Instrument (TI, Dallas, USA) was used for the detection of CA 19-9 by using an IA layer 
prepared on the gold surface of the SPR biochip. For the improvement of detection limit, a 
signal amplification method was also tested by additional treatment of anti-CA 19-9 
antibodies after the sample injection.  
 
Detection time for the CA 19-9 
 
For the detection of CA 19-9, the IA layer of anti-CA 19-9 antibodies was prepared on the 
SPR biosensor. The SPR sensor responses in Figure 3.12 were obtained by the injection of 
CA 19-9 samples in 10 mM PBS (pH 7.4) to a freshly prepared IA layer. As shown in 
Figure 3-12A, the SPR sensor response reaches a signal plateau after a certain incubation 
time and the signal at 30 min was estimated to be over 85 % of the value at signal plateau. 
From this result, the incubation time was determined to be 30 min. Figure 3-12B shows the 
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response curve prepared by injection of CA 19-9 samples at different concentrations when 
the incubation time was set to be 30 min. The response curve was fit well (r2=0.993) to the 
model response curve based on the simple binding model: R = [Rmax·C / (KD+C)]. Here, ‘R’ 
and ‘C’ represent the sensor response and concentration of CA 19-9, respectively. KD is the 
dissociation constant and Rmax is the maximal sensor response. The detection limit was 
calculated to be 410.9 U/ml at the baseline drift of ± 0.8 milli° according to the 
conventional calculation method for immunoassay (Ezan and Grassi, 2000). 
 
A          B 
 
Figure 3-12. SPR sensor response by the injection of CA 19-9 sample. The SPR sensor 
responses were obtained by the injection of CA 19-9 samples in 10 mM PBS (pH 7.4) to a freshly 
prepared IA layer. (A) Dependence of SPR sensor response on the incubation time. The SPR sensor 
response reaches a signal plateau after a certain incubation time (~60 min). The signal at 30 min was 
estimated to be over 85 % of the value at signal plateau. From this result, the incubation time was 
determined to be 30 min. (B) Does-response curve for CA 19-9. The response curve was prepared 
by injection of CA 19-9 samples at different concentrations when the incubation time was set to be 
30 min. The detection limit was calculated to be 410.9 U/ml at the baseline drift of ± 0.8 milli°. 
 
Feasibility test of additive assay for the CA 19-9 
 
The correlation curve for the detection of CA 19-9 was prepared according to the previously 
discribed method (section 3.1.3). As shown in Figure 3-13A, several samples of different 
concentrations at the target analysis range were prepared, and then the sample at each 
concentration was repeatedly injected. The sensor responses were plotted on the graph with 
the X axis of accumulated concentration and the Y axis of accumulated signal. As shown in 
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Figure 3-13B, the correlation curve could be obtained by averaging the responses in Figure 
3-13A and it was fit by using simple binding model: R = [Rmax·C / (K+C)]. Here, ‘R’ and 
‘Rmax’ (92.7 millio) represent ‘accumulated signal’ and ‘maximal accumulated signal’, 
respectively. ‘C’ and ‘K’ (14.3 kU/ml) represent ‘accumulated concentration’ and 
‘accumulated concentration at the half of Rmax’, respectively. Although any concrete 
physical relation was not in this fitting model, the obtained correlation curve was apparently 
fit well to the simple binding model (r2=0.993). 
 
A         B 
 
Figure 3-13: Correlation curve for the dectection of CA 19-9. (A) The accumulated sensor 
response by repeated injection of CA 19-9. The accumulated signal (Y-axis) and the accumulated 
concentration (X-axis) were calculated by simply adding the measured signals and the 
concentrations of injected analytes from the first injection. (B) Correlation curve for the additive 
assay of CA 19-9. After getting mean values of accumulated signals from all points in Figure 3.13A, 
non-linear curve fit of the plot was applied with a binding model: R = [Rmax · C / (K + C)]. In our 
model, the obtained correlation curve was apparently fit well to the simple binding model (r2=0.993). 
 
To demonstrate the feasibility of the correlation curve for the additive assay of CA 19-9, 
four CA 19-9 samples in PBS at different concentrations were sequentially injected as 
follows: 1.3 Æ 2.5 Æ 5.0 Æ 6.7 kU/ml. Then, the concentration of each sample was 
calculated from the measured sensor response by using the correlation curve of Figure 3-13. 
When the measured accumulated signals and the real accumulated concentrations of four 
samples were plotted together with the correlation curve of CA19-9, each point closely 
matched to the correlation curve as shown in Figure 3-14.  
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Figure 3-14: The SPR signals of four samples at the mixed concentration plotted on 
the correlation curve. Four CA 19-9 samples in PBS at different concentrations were 
sequentially injected as follows: 1.3 Æ 2.5 Æ 5.0 Æ 6.7 kU/ml. When the measured accumulated 
signals and the real accumulated concentrations of four samples were plotted together with the 
correlation curve of CA 19-9, each point closely matched to the correlation curve. 
 
When the concentrations of the four samples were analyzed by using the correlation curve 
of CA 19-9, the average deviation of the calculated concentrations from the real 
concentrations was estimated to be 5.3 % as summarized in Table 3-5. 
 
Table 3-5: The deviation of additive assay for the analysis of CA 19-9. 
No. SignalM (milli°) [CA19-9]C (kU/ml) [CA19-9]R (kU/ml) Error (%) 
1 7.2 1.2 1.3 -3.9 
2 12.2 2.6 2.5 3.0 
3 14.8 4.6 5.0 -8.6 
4 13.1 6.5 6.7 -3.5 
The average error (%) = 5.3
*Abbreviations: ‘SignalM’ represents the measured signal. ‘[CA 19-9]R’ and ‘[CA 19-9]C’ represent 
the real and the calculated concentration, respectively. Error (%) was calculated by ([CA 19-9]C − 
[CA 19-9]R)·100/[CA 19-9]R. 
 
Signal amplification by sandwich assay 
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Usually in medical diagnosis of CA 19-9 based on the immunoassay, the positiveness of 
sample is determined by establishing the cut-off value which is reported to be 37 U/ml for 
CA 19-9. The concentration range of CA 19-9 is known to be in the range of 400 – 192,000 
U/ml for most patient samples with pancreatic cancer (Del Villano et al., 1983). As the 
detection limit of CA 19-9 was estimated to be 410.9 U/ml, further improvement of 
sensitivity is required for the medical diagnosis of CA 19-9.  
Usually for the amplification of SPR response, the formation of complex is performed by 
using antibodies (Goh et al., 2003), latex particle (Severs and Schasfoort, 1993), gold 
colloid (Leung et al, 1994), liposome (Wink et al, 1998), peroxidase-anti-peroxidase (PAP) 
complex (Chung et al., 2005) and so on which produce an increased refractive index change 
by binding to the already bound analytes to the IA layer.  
 
In this work, the additional injection of antibodies against CA 19-9 was tested to achieve 
the signal amplification through the sandwich formation to the already bound CA 19-9 of 
IA layer. As shown in Figure 3-15, the sensor responses were amplified as much as six-fold 
in the range of 600-2500 U/ml and the detection limit by the sandwich assay was calculated 
to be 66.7 U/ml with the baseline drift of 1.3 ± 0.3 milli°. This value is quite close to the 
cut-off value for positive determination of CA 19-9 in medical diagnosis.  
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Figure 3-15: Signal amplification by sandwich assay. The sandwich labels of anti-CA 19-9 
antibodies were treated to the already bound CA 19-9 for signal amplification. The sensor responses 
were amplified as much as six-fold in the range of 600-2500 U/ml and the detection limit by the 
sandwich assay was calculated to be 66.7 U/ml with the baseline drift of 1.3 ± 0.3 milli°. This value 
is quite close to the cut-off value for positive determination of CA 19-9 in medical diagnosis. 
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In the case of sandwich assay, analytes on the IA layer were not totally saturated by one 
treatment of sandwich labels, and it caused relatively higher error for additive assay. 
Moreover, many interrupting materials in blood usually make a non-specific binding to 
increase detection limit in the real medical application. For the real medical application of 
additive assay to medical diagnosis of CA19-9, the selection of an effective amplification 
method as well as the studies to prevent the non-specific binding are required.  
 
3.2 The simultaneous detection of multiple analytes in a single sensing element 
 
‘Simultaneous detection’ aims to the analysis of multiple analytes by using a single sensor 
element. In the ‘simultaneous detection’, the sample with several analytes is injected to a 
single sensing region which has multiple receptors for each target analyte. By using the 
respective standard curves correlating the signal to concentration, the feasibility of 
‘simultaneous detection’ was tested by using two model antigen-antibody pairs. The real 
medical diagnosis of simultaneous detection was demonstrated by analysis of human 
chorionic gonadotropin (hCG) and human albumin (hA) in human urine, which is known to 
be related to the abortion and the preterm delivery of patients with diabetes. 
 
In this work, two simultaneous detection models were suggested according to the 
responding signal ratio of the target analytes in a sample.  
Model 1 is applicable for the sample with two analytes at the far different signal range. In 
this case, analyte 1 produces a detectable signal and analyte 2 makes no signal to be 
detected without the treatment of additional label. As shown in Figure 3-16A, the sample 
with two analytes was injected and the signal was measured. As analyte 2 in sample does 
not make a detectable signal, the first measured signal (Signal 1) is correlated to the 
concentration of analyte 1. Then, a label for analyte 2 is injected and the measured signal is 
correlated to the concentration of analyte 2.  
Model 2 can be applied for the sample with two analytes which produce signals only with 
additional labels. Therefore, the signal of each analyte is measured separately by injection 
of corresponding labels as shown in Figure 3-16B. After the sample injection, the label for 
analyte 1 makes a signal (Signal 1) which is correlated to the concentration of analyte 1. 
Then, additional label for the analyte 2 is injected to make a signal (Signal 2) which is 
correlated to the concentration of analyte 2.  
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Figure 3-16: Schematic diagram of simultaneous detection models. (A) Model 1. The 
sample with two analytes was injected and the signal was measured. As analyte 2 in sample does not 
make a detectable signal, the first measured signal (Signal 1) is correlated to the concentration of 
analyte 1. Then, a label for analyte 2 is injected and the measured signal is correlated to the 
concentration of analyte 2. (B) Model 2. After the sample injection, the label for analyte 1 makes a 
signal (Signal 1) which is correlated to the concentration of analyte 1. Then, additional label for the 
analyte 2 is injected to make a signal (Signal 2) which is correlated to the concentration of analyte 2. 
 
3.2.1 Standard curves for simultaneous detection using Model 1 and Model 2 
 
The standard curves for analysis were prepared for Model 1 and 2 by using two antigen-
antibody pairs: (1) BSA and anti-BSA antibodies, (2) HRP and anti-HRP antibodies. The IA 
layer for each model was prepared by immobilization of anti-HRP antibodies and BSA 
together. The samples were prepared by mixing HRP (42 kDa) and anti-BSA antibodies 
(150 kDa) at appropriate concentrations in 10 mM PBS (pH 7.0). The measurements for 
standard curves were made by injection of each analyte at the known concentration, which 
was adjusted for the application of Model 1 and Model 2.  
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The standard curve for Model 1 
 
The sample concentration for Model 1 was adjusted for one analyte (anti-BSA antibodies) 
to make detectible signals without additional label and for the other analyte (HRP) to make 
detectible signal only with additional label (anti-HRP). Schematic diagram of Model 1 is 
shown in Figure 3-17A and the standard curve for Model 1 is shown in Figure 3-17B where 
two analytes have significantly different concentration ranges.  
The standard curves for anti-BSA antibodies and HRP were separatetly made by the 
injection of single analyte. Each curve was made with several concentrations and the signal 
value for one concentarion was calculated from the mean value (n=3). The curve fit was 
performed by using the Langmuir isotherm as a fitting model: R =[C⋅Rmax/ (C+K)], where R 
is the sensor response, C is the concentration of analyte in solution, Rmax and K are 
constants which mean the maximal sensor response and the concentration which make a 
half size of Rmax, respectively (Faegerstam et al., 1992; O’Shannessy et al., 1993). In this 
work, the sensor response (R) was measured at the incubation time of 10 min. For the 
concentration range used in this work, this signal value was estimated to be 80 % of the 
signal at equilibrium. Although K is related to the dissociation constant, it does not exactly 
mean the dissociation constant. The simple binding model was used only to get an empirical 
curve which apparently fits well to the experimental data. The standard curves for anti-BSA 
antibodies and HRP have the parameters of Rmax=455.8 (millio), K=5365.9 (nM) and 
Rmax=176.3 (millio), K=107.7 (nM), respectively. The non-linear fitting based on the simple 
binding model was performed using Origin™ software (Microcal Software, Inc., MA, 
USA). From the baseline drift by blank samples, the limit of detections for anti-BSA 
antibodies and HRP were determined to be 21.3 and 1.1 nM (n=8), respectively (Ezan and 
Grassi, 2000). The standard curves of anti-BSA antibodies (r2=0.997) and HRP (r2=0.991) 
fit well to the fitting model. This result shows that two curves by Model 1 could be used as 
standard curves of correlation between the signal and the concentration. 
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Figure 3-17: Standard curve for Model 1. (A) Schematic diagram of simultaneous detection 
Model 1. The sample concentration for Model 1 was adjusted for one analyte (anti-BSA antibodies) 
to make detectible signals without additional label and for the other analyte (HRP) to make 
detectible signal only with additional label (anti-HRP antibodies). (B) Standard curve for Model 1. 
The standard curves for anti-BSA antibodies and HRP were separatetly made by the injection of 
single analyte. Each curve was made with several concentrations and the signal value for one 
concentarion was calculated from the mean value (n=3). As the curve fits were performed by using 
the Langmuir isotherm as a fitting model, the does-response curves of anti-BSA antibodies 
(r2=0.997) and HRP (r2=0.991) fit well to the fitting model. This result shows that two curves by 
Model 1 could be used as standard curves of correlation between the signal and the concentration. 
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The standard curve for Model 2 
 
The same IA layer of Model 1 was used for the preparation of the standard curve of Model 
2. A schematic diagram of Model 2 is shown in Figure 3-18A. Each analyte was injected 
and the signal was measured after the injection of additional label. As the label for analytes 
(anti-BSA antibodies and HRP), anti-rabbit IgG and anti-HRP antibodies were used at the 
concentrations of 173 and 320 nM, respectively. The standard curve for Model 2 was 
prepared for the analytes at similar concentration ranges as shown in Figure 3-18B.  
The standard curves for anti-BSA antibodies and HRP were separatetly made by the 
injection of single analyte. Each curve was made with several concentrations and the signal 
value for one concentarion was calculated from the mean value (n=3). The curve fit was 
performed by using the Langmuir isotherm as a fitting model: R =[C⋅Rmax/ (C+K)]. The 
fitting parameters of the standard curve for anti-BSA antibodies was calculated to be Rmax= 
106.8 (millio), K=152.2 (nM), and the standard curve for HRP has the parameters of 
Rmax=84.6 (millio), K=21.0 (nM). The limit of detections for anti-BSA antibodies and HRP 
were determined to be 2.6 and 0.5 nM (n=8), respectively. The does-response curves of 
anti-BSA antibodies (r2=0.993) and HRP (r2=0.997) fit well to the fitting model. This result 
shows that two curves by Model 2 could be used as standard curves of correlation between 
the signal and the concentration. 
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Figure 3-18: Standard curve for Model 2. (A) Schematic diagram of simultaneous detection 
Model 2. Each analyte was injected and the signal was measured after the injection of additional 
label. As the label for analytes (anti-BSA antibodies and HRP), anti-rabbit IgG and anti-HRP 
antibodies were respectively used. (B) Standard curve for Model 2. The standard curves for anti-
BSA antibodies and HRP were separatetly made by the injection of single analyte. Each curve was 
made with several concentrations and the signal value for one concentarion was calculated from the 
mean value (n=3). As the curve fits were performed by using the Langmuir isotherm as a fitting 
model, the does-response curves of anti-BSA antibodies (r2=0.993) and HRP (r2=0.997) fit well to 
the fitting model. This result shows that two curves by Model 2 could be used as standard curves of 
correlation between the signal and the concentration. 
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The feasibility test using Model 1 
 
The standard curve for each analyte was independently prepared by injection of only one 
kind of analyte. When two analytes are simultaneously injected into the same IA layer, the 
cross-reaction with another receptor in the IA layer can occurr and a false positive signal or 
interference can be made by the other proteins.  
The samples were prepared by mixing anti-BSA antibodies and HRP at known 
concentrations and the signal was measured before and after injection of additional label 
(anti-HRP antibodies at the concentration of 320 nM). The concentrations of anti-BSA 
antibodies and HRP in test sample were prepared to be 81.7 – 490 nM, 9.5 – 38.1 nM, 
respectively. Additionally, samples at three random pairs of concentrations were measured. 
As shown in Table 3-6, Model 1 was feasible for the detection of both analytes at the 
described concentration ranges. The concentration of each analyte was calculated by using 
the standard curve and compared to actual concentration. Errors between the two values 
were calculated. As summarized in Table 3-6, the average error of simultaneous detection 
based on Model 1 was calculated to be 3.3 and 3.1 % for anti-BSA antibodies and HRP, 
respectively.  
 
Table 3-6: The deviation of simultaneous detection method (Model 1. n=3). 
Injected concentration (nM) Calculated concentration (nM) Error (%) 
Anti-BSA HRP Anti-BSA HRP Anti-BSA HRP 
490.0 9.5 486.6 ± 48.4 8.7 ± 1.7 -0.7 -8.4 
490.0 38.1 501.2 ± 60.8 36.2 ± 3.3 2.3 -5.0 
81.7 9.5 86.3 ± 8.1 9.8 ± 1.2 5.6 3.2 
81.7 38.1 83.4 ± 13.4 39.1 ± 5.3 2.1 2.6 
326.7 38.1 335.3 ± 42.6 38.1 ± 2.2 2.6 -0.1 
108.9 19.0 110.6 ± 14.6 19.1 ± 3.1 1.6 0.3 
81.7 14.3 75.3 ± 23.2 14.6 ± 1.8 -7.9 2.4 
 3.3* 3.1* 
* Mean of the absolute values of the error 
 
The feasibility test using Model 2 
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The simultaneous detection Model 2 was also tested using a standard curve. The 
measurement was made for the sample containing anti-BSA antibodies and HRP by 
adjusting the concentrations of these analytes and their labels to the range which is used for 
the preparation of the standard curve. The concentrations of anti-BSA antibodies and HRP 
in test sample were prepared to be 8.2 – 490 nM, 3.1 – 71.4 nM, respectively. Additionally, 
samples at four random pairs of concentrations were measured. As shown in Table 3-7, 
Model 2 was feasible for the detection of both analytes at the described concentration 
ranges and the average error of analysis based on Model 2 was calculated to be 4.5 and 
6.0 % for anti-BSA antibodies and HRP, respectively.  
 
Table 3-7: The deviation of simultaneous detection method (Model 2. n=3). 
Injected concentration (nM) Calculated concentration (nM) Error (%) 
Anti-BSA HRP Anti-BSA HRP Anti-BSA HRP 
490.0 3.1 456.5 ± 29.4 3.5 ± 0.5 -6.8 12.9 
490.0 71.4 465.1 ± 33.3 71.9 ± 11.9 -5.1 0.7 
8.2 3.1 7.6 ± 0.9 2.9 ± 0.4 -7.3 -6.5 
8.2 71.4 8.3 ± 2.0 63.4 ± 8.0 1.2 -11.2 
32.7 6.0 34.6 ± 5.7 5.9 ± 1.2 6.0 -1.3 
82.0 71.4 83.7 ± 7.2 76.1 ± 14.5 2.1 6.5 
98.0 23.8 96.4 ± 2.9 24.8 ± 3.8 -1.7 4.1 
490.0 9.0 463.5 ± 27.8 9.2 ± 0.1 -5.4 1.3 
 4.5* 6.0* 
* Mean of the absolute values of the error 
 
3.2.2 Optimization of the IA layer for simultaneous detection 
 
3.2.2.1 Minimization of cross-reactions  
 
As the simultaneous detections of Model 1 and Model 2 use several antigens and antibodies 
on the same IA layer, a cross-reaction among the participating antigens and antibodies can 
result in a false positive signal.  
 
The cross reaction in Model 1 should be tested as shown in Figure 3-19. The concentrations 
of target analytes (anti-BSA antibodies and HRP) were adjusted to be high enough to 
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achieve saturated signals (1633 and 909 nM, respectively). The cross-reactions of anti-BSA 
antibodies (analyte) with HRP (co-injected analyte) and anti-HRP antibodies (IA layer for 
HRP) were measured as shown in Figure 3-19A. The IA layer was prepared by 
immobilizing anti-HRP antibodies. When HRP was injected, a signal of 11.9 milli° was 
observed. Then, the anti-BSA antibodies were injected and the signal was found to be less 
than zero. This result shows that the anti-BSA antibodies (analyte 1) for Signal 1 do not 
cross-react with HRP (analyte 2) and anti-HRP antibodies (IA layer for analyte 2). In a 
separated test, the IA layer was prepared by immobilizing BSA and anti-HRP antibodies as 
shown in Figure 3-19B. Then, anti-BSA antibodies (analyte 1) were injected and signal was 
found to be 49.1 milli°. When anti-HRP antibodies (label for analyte 2) were injected, the 
signal was estimated to be as small as 0.8 milli°. This result shows that anti-HRP antibodies 
(the label for analyte 2) for Signal 2 do not cross-react with anti-BSA antibodies (analyte 1) 
and the IA layer (IA layer for analyte 1 and analyte 2). From these results, the participating 
antigens and antibodies were determined to make no significant cross-reaction and no false 
positive signal was measured for the simultaneous detection based on Model 1. 
 
The simultaneous detection based on Model 2 uses labels for each analyte. The test for the 
cross-reactivity of each label was made as follows. The IA layer was prepared by 
immobilizing the BSA (receptor 1 of analyte 1) and anti-HRP antibodies (receptor 2 of 
analyte 2) together. As shown in Figure 3-20A, HRP (analyte 2) was injected and the signal 
was found to be 5.1 milli°. Then, the anti-rabbit IgG (label 1 for analyte 1) for Signal 1 was 
injected and no significant signal (0.1 milli°) was measured. This result shows that anti-
rabbit IgG (label 1 for analyte 1) does not cross-react with the other analyte (analyte 2) and 
the IA layer. When anti-HRP antibodies (label 2 for analyte 2) were injected, a signal of 59 
milli° was measured. This result shows that the HRP injected first was still bound to the IA 
layer. In a separated test, anti-BSA antibodies (analyte 1) were injected and the signal was 
found to be 48.7 milli° as shown in Figure 3-20B. Then, the anti-rabbit IgG (label 1 for 
analyte 1) was injected and a signal of 118 m° was measured. When anti-HRP antibodies 
(label 2 for analyte 2) for Signal 2 were injected, no significant signal (1.6 milli°) was 
measured. This result indicates that anti-HRP antibodies (label 2 for analyte 2) also do not 
cross-react with the other analyte (analyte 1), the other label (label 1 for analyte 1) and the 
IA layer. From these results, the participating antigens and antibodies were determined to 
make no significant cross-reaction and no false positive signal was measured for the 
simultaneous detection based on Model 2. 
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Figure 3-19: Test of cross-reaction in the Model 1. (A) The reaction scheme for the cross 
reaction of anti-BSA antibodies (analyte 1) and the SPR sensorgram of the reaction. The IA layer 
was prepared by immobilizing anti-HRP antibodies (IA layer for HRP). The cross-reactions of anti-
BSA antibodies (analyte 1) with HRP (analyte 2) and anti-HRP antibodies (IA layer for analyte 2) 
were measured. When HRP was injected, a signal of 11.9 milli° was observed. Then, the anti-BSA 
antibodies were injected and the signal was found to be less than zero. This result shows that the 
anti-BSA antibodies (analyte 1) for Signal 1 do not cross-react with HRP (analyte 2) and anti-HRP 
antibodies (IA layer for the analyte 2) (B) The reaction scheme for the cross reaction of HRP 
antibodies (label for HRP) and the SPR sensorgram of the reaction. The IA layer was prepared by 
immobilizing BSA and anti-HRP antibodies. Then, anti-BSA antibodies (analyte 1) were injected 
and signal was found to be 49.1 milli°. When anti-HRP antibodies (label for HRP) for Signal 2 were 
injected, the signal was estimated to be as small as 0.8 milli°. This result shows that the anti-HRP 
antibodies (label for analyte 2) do not cross-react with anti-BSA antibodies (analyte 1) and the IA 
layer (IA layer for the analyte 1 and analyte 2). From the results of (A) and (B), the participating 
antigens and antibodies were determined to make no significant cross-reaction and no false positive 
signal was measured for the simultaneous detection based on Model 1. 
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Figure 3-20: Test of cross-reaction in the Model 2. (A) The reaction scheme for the cross reaction 
of label 1 and the SPR sensorgram of the reaction. The analyte 2 was injected and the signal was 
found to be 5.1 milli°, and the label 1 generated no significant signal (0.1 milli°). This result shows 
that label 1 does not cross-react with the analyte 2 and the IA layer. When label 2 was injected, a 
signal of 59 milli° was measured, which shows that the analyte 2 injected first was still bound to the 
IA layer. (B) The reaction scheme for the cross reaction of label 2 and the SPR sensorgram of the 
reaction. Analyte 1 was injected and the signal was found to be 48.7 milli°. Then, the label 1 
generated a signal of 118 milli°. When label 2 was injected, no significant signal (1.6 milli°) was 
measured. This result indicates that label 2 also do not cross-react with the analyte 1, the label 1 and 
the IA layer. From these results, the participating antigens and antibodies made no significant cross-
reaction and no false positive signal was measured for the simultaneous detection based on Model 2. 
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3.2.2.2 Optimal division of the IA layer  
 
The simultaneous detection based on Model 1 and Model 2 was performed by two 
molecular recognition elements on the same IA layer. In order to make each molecular 
recognition part to produce a detectable signal, the restricted area of IA layer should be 
effectively divided for the binding of each analyte. In this work, the surface area of IA layer 
was divided by controlling the concentration ratio of the molecular recognition elements 
(BSA and anti-HRP antibodies) at the immobilization step. The correlation between the 
concentration ratio and the analyte binding capacity was estimated by the comparison of 
maximum response (Rmax) of the IA layer. As shown in Figure 3-21, the concentration ratio 
([anti-HRP antibodies] / [BSA]) was changed from 0.002 to 10000 (0.002, 0.24, 0.48, 2.40, 
20, 200 and 10000), and each maximum response (Rmax) was calculated from the standard 
curves. This result shows that the optimal IA layer should be prepared by controlling the 
concentration ratio of analyte binding molecules according to certain detection ranges of the 
analytes in a specific test.  
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Figure 3-21: Correaltion between analyte binding capacity and the concentration ratio of 
molecular recognition elements at the immobilization step. The surface area of IA layer was 
divided by controlling the concentration ratio of the molecular recognition elements ([anti-HRP 
antibodies]/[BSA]) at the immobilization step. The correlation between the concentration ratio and 
the analyte binding capacity was estimated by the comparison of maximum response (Rmax) of the 
IA layer. Each Rmax was calculated from the standard curves. This result shows that the optimal IA 
layer should be prepared by controlling the concentration ratio of analyte binding molecules 
according to certain detection ranges of the analytes in a specific test. 
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3.2.3 Simultaneous detection of human chorionic gonadotropin (hCG) and human 
albumin (hA) in urine 
 
The level of human chorionic gonadotropin (hCG) and human albumin (hA) in urine was 
determined by using the simultaneous detection method. These two proteins can be used for 
preliminary diagnosis for the abortion and the preterm delivery during early pregnancy (see 
section 1.4).  
With the concentration ranges for medical application, signal differences were not distinct 
to use Model 1. Accordingly, Model 2 was applied for the analysis of hCG and hA. The IA 
layer was prepared by immobilizing polyclonal anti-hCG antibodies (500 µg/ml) and 
polyclonal anti-hA antibodies (100 µg/ml) together, which was controlled to make each 
detection limit to be similar with the cut-off value for diagnosis. The known concentrations 
of both analytes were dissolved in 10-fold diluted urine which was from healthy male 
volunteers without diabetes (random capillary blood glucose level ≤ 200 mg/dL (Clark, 
2001)). When the urine sample without analyte was injected, no significant signal was 
detected. The concentration range of hCG for the standard curve was adjusted according to 
the concentration level of hCG at the 4-12 weeks of pregnancy (415 – 46,100 mIU/ml) 
(Chard, 2001). The concentration range of hA for standard curve was adjusted according to 
the concentration level of microalbuminuria (20 – 200 µg/ml) (Clark, 2001). Polyclonal 
anti-hCG antibodies (100 µg/ml) and polyclonal anti-hA antibodies (100 µg/ml) were used 
as labels for hCG and hA, respectively.  
 
After adjusting optimal sharing of the IA layer by controlling concentrations of both 
antibodies at the immobilization step, standard curves of the two analytes were obtained for 
the detectable concentration ranges of each analyte (see Figure 3-22). The fitting parameters 
of standard curves for hCG and hA were calculated to be r2 = 0.964 and r2 = 0.954, 
respectively. For the estimation of non-specific binding of labels, label 1 (anti-hCG 
antibodies for signal 1) was injected after injection of analyte 2 (hA) to the IA layer, and 
label 2 (anti-hA antibodies for signal 2) was injected after injection of analyte 1 (hCG) and 
label 1 to the IA layer. The non-specific binding of labels (anti-hCG antibodies and anti-hA 
antibodies) were measured to be 3.0 ± 0.2 millio and 1.6 ± 0.9 millio (n=3), respectively. 
From these data, the non-specific bindings of labels were determined to be insignificant. By 
using respective standard curves and baseline drift, the detection limits for hCG and hA of 
10-fold diluted samples were determined to be 46.4 mIU/ml (464 mIU/ml in undiluted 
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sample) and 2.5 µg/ml (25 µg/ml in undiluted sample), respectively. In comparison with the 
cut-off levels of 4th weeks of pregnancy and microalbuminuria, the simultaneous detection 
seemed to be feasible to determine pregnancy and to alarm preterm delivery for pregnant 
woman with type I diabetes. 
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Figure 3-22: Simultaneous detection of hCG (■) and hA (▲) using Model 2. Two curves 
were made by using 10-fold diluted samples and the fitting parameters of standard curves for hCG 
and hA were calculated to be r2 = 0.964 and r2 = 0.954, respectively. By using respective standard 
curves and baseline drift, the detection limits for hCG and hA of 10-fold diluted samples were 
determined to be 46.4 mIU/ml (464 mIU/ml in undiluted sample) and 2.5 µg/ml (25 µg/ml in 
undiluted sample), respectively. These values correspond to the cut-off levels of 4th weeks of 
pregnancy and microalbuminuria, respectively. From this result, the simultaneous detection seemed 
to be feasible to determine early pregnancy and to alarm preterm delivery for pregnant woman with 
type I diabetes. 
 
The concentrations of hCG and hA in the test sample were prepared to be 500 – 5000 
mIU/ml, 20 – 100 µg/ml, respectively. Additionally, samples at three random pairs of 
concentrations were measured. As shown in Table 3-8, Model 2 was feasible for the 
detection of both analytes at the described concentration ranges and the average error of 
analysis based on Model 2 was calculated to be 6.5 and 5.9 % for hCG and hA, respectively.  
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Table 3-8: Results of simultaneous detection of hCG and hA based on Model 2 (n=3). 
Injected concentration  Calculated concentration  Error (%) 
hCG (mIU/ml) hA (µg/ml) hCG (mIU/ml) hA (µg/ml) hCG hA 
5000 20 4635.5 ± 399.2 17.1 ± 3.5 -7.3 -14.5 
5000 100 4711.4 ± 416.4 103.1 ± 3.9 -5.8 3.1 
500 20 463.2 ± 45.3 18.6 ± 1.6 -7.4 -7 
500 100 478.4 ± 35.7 97.2 ± 7.4 -4.3 -2.8 
500 50 438.2 ± 50.8 49.9 ± 3.6 -12.4 -0.3 
1000 100 966.3 ± 94.5 104.3 ± 4.0 -3.4 4.0 
1500 75 1575.1 ± 17.7 67.6 ± 8.1 5.0 -9.9 
 6.5* 5.9* 
* Mean of the absolute values of the error. 
 
3.3 Signal amplification of SPR biosensor 
 
The mass change caused by the binding of analyte to the sensor surface affects the amount 
of plasmons to change the SPR angle, which is converted to the binding amount of analyte 
in the SPR-immunosensor. Generally, the sensitivity of immunosensors can be improved by 
the mass label and the control of the IA layer (orientation & density). Because the 
sensitivity of the SPR biosensor is usually not high enough for medical diagnosis, signal 
amplification is required. In this work, two amplification methods were tested.  
As described in introduction (section 1.2.3), the first method is to increase the signal by 
using label proteins. Various label proteins have been added to the already bound analyte on 
the sensor surface to increase the sensitivity of the biosensor (Mullett et al., 2000). When 
labels are attached to target analytes, the mass on the surface of the SPR biosensor is 
increased and the SPR signal relative to the amount of target analytes is also increased. 
Especially for the SPR biosensor, several methods using various kinds of label proteins 
have been reported, such as secondary antibody (Goh et al., 2003), latex particle (Severs 
and Schasfoort, 1993) and avidin-biotinylated liposome (Wink et al.,1998).  
The second method is to control the orientation of the IA layer composed of antibodies. The 
antibody is well known to have a ‘Y’ shaped structure with two binding sites at two variable 
regions called F(ab’)s. For the effective detection of analyte by using immunosensors, the 
variable region (F(ab’)) of the antibody should be exposed to the analyte (Liddell, 2001). 
For the control of orientation, avidin, LB film, self-assembly and protein A have been 
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widely used and the surface density and orientation of antibodies could be improved. 
 
3.3.1 Signal amplification by using mass label  
 
The signal amplification by using mass label proteins was tested and the improvement of 
the sensitivity of the IA biosensor was measured. In order to select the most efficient signal 
amplification method, the efficiencies of several amplification methods were compared 
with a direct assay by using secondary antibodies, avidin-biotynylated antibodies and 
peroxidase-anti-peroxidase (PAP) complex. By applying the selected amplification method, 
the medical diagnosis of human hepatitis B virus (hHBV) requiring of very high detection 
limit was demonstrated to approach closely the cut-off value for the diagnosis of hHBV 
from a commercial ELISA kit. 
 
3.3.1.1 Comparison of the standard curves for the hHBV antibodies using ELISA and 
SPR biosensor 
 
For the application of the signal amplification method, the SPR biosensor was applied to 
detect the anti-hHBV antibody which is used to confirm recovery and immunity in patients 
with acute hepatitis or to check the effectiveness of vaccination (see section 1.4). By using 
the SPR biosensor, a standard curve as shown in Figure 3-23 was obtained by injection of 
samples at known concentrations of hHBV antibodies in 5 % calf serum (in 10 mM PBS). 
The detection range of the standard curve was determined by comparing with the cut-off 
line of the commercial medical diagnosis. Each point in the Figure 3-23 indicates a mean 
value of SPR signals from the repeated measurements (n=3) of a sample at the specified 
concentration. The parabolic curve in Figure 3-23 was obtained by non-linear fit function of 
a statistical software, Origin™ (USA) and Langmuir isotherm was used as a fitting model: R 
= Rmaxⅹ[Ab] / (KD + [Ab]) (Faegerstam et al., 1992), where R represents the response by 
analyte, Rmax represents the maximum response, [Ab] represents the concentration of hHBV 
antibodies, and KD means the dissociation constant of hHBV antibodies from the IA layer. 
From this fitting, the maximum SPR response was estimated to be 387.6 milli° with a 
standard deviation of 55.0 milli° where the SPR biosensor signal is saturated and the KD 
value was calculated as 2614.6 nM. This standard curve of anti-hHBV antibodies showed 
high correlation coefficient (r2 = 0.974). Based on this result, the detection range of hHBV 
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antibodies was estimated to be from 10 nM to 2 µM hHBV antibodies. This detection range 
was determined to be similar to the result for hIgG antibodies (Huber et al., 1992). 
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Figure 3-23: SPR sensor response to the concentration of the hHBV antibodies. A 
standard curve between SPR signal and concentration was obtained by injection of samples at 
known concentrations of hHBV antibodies in 5 % calf serum (in 10mM PBS) (r2 = 0.974). 
 
For the medical application, the detection range of the SPR biosensor was compared with 
that of a commercial ELISA kit as shown in Figure 3-24. The ELISA method determines 
the positiveness of hHBV antibodies using a cut-off value. With the commercial ELISA kit, 
the optical density (OD) of mean negative control value was detected as 0.03 (OD) and the 
cut-off value was determined to be around 0.10 (OD) corresponding to the 0.24 nM of 
hHBV antibodies. By using the standard curve of Figure 3-23, the SPR signal of hHBV 
antibodies at the concentration of 0.24 nM was estimated to be 0.03 milli°, which was far 
less than the detection limit of SPR IA biosensor and the cut-off value can not be detected 
by SPR signal by this direct detection method. From this result, signal amplification method 
should be used for detection limit of SPR signal to be improved as the cut-off value. 
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Figure 3-24: Comparison of the detection range of hHBV antibodies by SPR 
measurement with ELISA (n=3). The ELISA method determines the positiveness of hHBV 
antibodies using a cut-off value. With the commercial ELISA kit, the optical density (OD) of mean 
negative control value was detected as 0.03 (OD) and the cut-off value was determined to be around 
0.10 (OD) corresponding to the 0.24 nM of hHBV antibodies. By using the standard curve of the 
SPR signal, hHBV antibodies at the concentration of 0.24 nM was estimated to be 0.03 milli°, 
which was far less than the detection limit of SPR IA biosensor. This result shows that signal 
amplification method is required to reach the cut-off value. 
 
3.3.1.2 Selection of optimal label  
 
In this work, three kinds of amplification methods were tested to improve the sensitivity of 
the SPR biosensor. The direct assay without label is shown in Figure 3-25A. The standard 
curve between SPR signal and the concentration of hHBV antibodies was explained in the 
previous section. Because the signal amplification was achieved by increasing the effective 
mass of the already bound analyte using label proteins, the amplified signal is expected by 
using heavy label proteins. 
 
The amplification method based on a sandwich assay is shown in Figure 3-25B. In the 
sandwich assay, additional antibodies (secondary antibodies) as labels are attached to the 
target analyte after attachment of the target analyte to the IA layer and the signal is 
increased in proportion to the mass of labels. This sandwich assay has been reported to 
improve the sensitivity of the diffraction-based immunoassay as much as 3.5-fold (Goh et 
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al., 2003). 
 
To further improve the efficiency of the signal amplification, the avidin-biotin interaction 
(Jordan et al., 1997) was applied as shown in Figure 3-25C. This method aims to bind more 
than one secondary antibody to each bound analyte by using the avidin protein.  
 
Conventionally, the peroxidase-anti-peroxidase (PAP) complex has been used in ELISA to 
increase the sensitivity by using several peroxidases against one target analyte. The PAP 
complex was prepared by the method of Sternberger et al. (Sternberger et al., 1970). 
Theoretically, the PAP complex consists predominantly of two anti-horseradish peroxidase 
antibodies with three molecules of horseradish peroxidase with a heavy molecular weight 
(> 430 kDa). After attachment of secondary antibodies (anti-Rabbit IgG) to the target 
analyte (rabbit anti-hHBV antibodies), the PAP complex composed of antibodies from 
rabbit could be attached to the secondary antibodies and then additional secondary 
antibodies were injected to maximize the effect of amplification as shown in Figure 3-25D. 
 
 
Figure 3-25: Schematic view of three amplification methods: (A) Direct assay. (B) 
Amplification using sandwich assay. (C) Avidin- biotinylated antibodies. (D) Peroxidase-anti-
peroxidase (PAP) complex. 
 
To compare the efficiency of the amplification methods (see Figure 3-26), a sample at a 
concentration of 30 nM of hHBV antibodies was injected and it resulted in a SPR signal of 
4.9 milli° (n=3) by direct assay. The label proteins were also prepared in 5 % calf serum (in 
10 mM PBS). The negative signal by non-specific binding of label proteins was determined 
by the treatment of blank buffer as an analyte and it was subtracted from the positive signal 
(Signal of sample – Signal of blank) and this value was compared with the result of the 
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direct assay. From the calculation, the sandwich assay by the application of secondary 
antibodies was determined to achieve a signal amplification of 7-fold compared with the 
direct assay. The amplification ratio using the avidin-biotin-label was estimated to be as 
much as 14-fold and the effective amplification ratio using the PAP complex was calculated 
to be 17-fold higher than the direct assay by considering the non-specific binding of label 
proteins. From these results, the amplification using the PAP complex was selected as the 
most efficient method among the three described amplification methods. 
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Figure 3-26: Comparison of the efficiencies of three amplification methods: (A) Direct 
assay. (B) Amplification using sandwich assay. (C) Avidin-biotinylated antibodies. (D) Peroxidase-
anti-peroxidase (PAP) complex.  
 
The typical sensorgram of the signal amplification by the PAP complex is shown in Figure 
3-27 and this method consists of four steps: (1) injection of sample, (2) injection of 
secondary antibodies, (3) injection of PAP complex and (4) injection of secondary 
antibodies against PAP complex. The non-specific binding of the label proteins in each 
amplification method was estimated by injection of a blank sample (a sample without 
hHBV antibodies) followed by an injection of the corresponding label proteins. As shown 
in Figure 3-27A, the non-specific bindings at the injection step of sample and label proteins 
were represented as ‘NS 1’ and ‘NS 2’, respectively. The signal of the blank sample was 
first measured (NS 1), and then the signals by the label proteins were measured (NS 2). The 
‘NS 1’ and ‘NS 2’ were regarded as the background of the signal before and after signal 
amplification step, respectively. The signals before and after the signal amplification were 
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indicated as ‘Signal 1’ and ‘Signal 2’, respectively (see Figure 3-27B). The signal of the 30 
nM hHBV antibodies was first measured (Signal 1), and then the signals by the label 
proteins were measured (Signal 2).  
 
A          B 
 
Figure 3-27: The sensorgram of the signal amplification using the PAP complex: (A) 
Signal amplification after blank sample injection. (B) Signal amplification after a sample (with 30 
nM hHBV antibodies) injection. ‘A’ indicated the sample injection, ‘B’ indicates the injection of 
secondary antibodies, ‘C’ indicates the injection of the PAP complex, ‘D’ indicates the injection of 
secondary antibodies against the PAP complex. ‘NS 1’ and ‘NS 2’ indicate the non-specific bindings 
at the injection step of sample and label proteins, respectively. ‘Signal 1’ represents the signal 
without amplification, and the ‘Signal 2’ represents the signal after amplification. 
 
In the real application, the signal was calculated by the difference between the signal by the 
sample treatment and negative signal by the blank treatment (Signal of sample – Signal of 
blank). The efficiency of the PAP method for the signal amplification was calculated at 
several analyte concentrations by comparing the net signals of the direct assay and the PAP 
method and it was defined to be the ratio of amplification. Net signal (Signal – NSB) was 
determined by the difference between signal of sample (positive signal) and signal of non-
specific binding (NSB) (negative signal). Net signals of direct assay and PAP method were 
calculated as (SignalDirect assay - NSBDirect assay) and (SignalPAP - NSB PAP) by considering the 
non-specific binding (NSB) of the direct assay and the PAP method as 0.6 and 4.4 milli°, 
respectively. The ratio of amplification was calculated as comparing these net signals 
(SignalPAP - NSB PAP) / (SignalDirect assay - NSBDirect assay). 
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As shown in Table 3-9, the signal from injection of hHBV antibodies at the concentration of 
3.3 nM was 2.6 milli° and the signal after amplification was 29.3 milli°. By considering 
non-specific binding, the net signals (signal – noise) were calculated to be 2 and 24.9 milli°, 
respectively. The ratio of amplification was calculated to be 12.5 by using these two values. 
For the other concentrations of 6.7, 30 and 66.7 nM, the ratio of amplification was 
calculated as 28.1, 23.4 and 17.1. This result shows that the PAP method is feasible for 
signal amplification. 
 
Table 3-9: Signal amplification by the PAP method. 
Direct assay PAP method 
Concentration 
(nM) Signal  
(millio) 
* (Signal - NSB) 
(millio) 
Signal 
(millio) 
* (Signal - NSB)  
(millio) 
** Ratio of 
amplification
3.3 2.6 2 29.3 24.9 12.5 
6.7 2.3 1.7 51.9 47.5 28.1 
30.0 4.9 4.3 104.9 100.5 23.4 
66.7 9.8 9.2 161.5 157.5 17.1 
* Net signal was the difference between signal of sample and signal of nonspecific binding (Signal - 
NSB). Net signal of direct assay and PAP method were calculated as (SignalDirect assay - NSBDirect assay) 
and (SignalPAP - NSB PAP) by considering the non-specific binding (NSB) of direct assay and PAP 
method as 0.6 and 4.4 milli°, respectively. 
** Ratio of amplification = (SignalPAP - NSB PAP) / (SignalDirect assay - NSBDirect assay). 
  
3.3.1.3 Application of signal amplification by the PAP complex for medical diagnostics 
of hHBV antibodies.  
 
For the practical application of the SPR biosensor to the medical diagnosis of hHBV 
antibodies, the sensitivity of the SPR biosensor should be considerably improved as 
discussed in the previous section. Here, the selected amplification methods (PAP complex 
method) were applied for the detection of hHBV antibodies. As shown in Figure 3-28, the 
sensitivity of the SPR biosensor was increased by using the PAP complex method in 
comparison to the sandwich assay and the direct assay method. Especially, the sensitivity of 
the SPR measurement with PAP complex approached closely to the commercial ELISA kit. 
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Figure 3-28: Comparison of the detection range for the detection of HBV antibodies. 
The sensitivity of the SPR biosensor was increased by using the PAP complex method (▲) in 
comparison to the sandwich assay (▲) and the direct assay method (□). Especially, the sensitivity of 
the SPR measurement with PAP complex approached closely to the commercial ELISA kit (◇). The 
(+) dots represent the fitting result using Langmuir isotherm model. 
 
As shown in Table 3-10, the detection limit of the SPR biosensor was also significantly 
improved in comparison to the direct assay. The detection limits of SPR measurements by 
direct assay, sandwich assay and PAP complex method were calculated to be 9.20, 4.39 and 
0.64 nM, respectively. In comparison to the detection limit of the direct assay, those of the 
sandwich assay and PAP method were determined to be improved by 2- and 14-fold, 
respectively. The result from the PAP method shows that the detection limit of the SPR 
biosensor (0.64 nM) approached closely the cut-off value for medical diagnosis (0.24 nM) 
by using the commercial ELISA kit. 
 
Table 3-10. The comparison of the detection limits by the signal amplification methods.  
Method Detection limit  (nM) 
Direct assay 9.20 
Sandwich assay  4.39 
PAP method  0.64 
Cut-off value (ELISA) = 0.24 nM 
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3.3.2 Signal amplification by orientation control of the IA layer 
 
3.3.2.1 Introduction 
 
The sensitivities of immunosensors are known to be improved by the control of the IA layer 
(orientation & density). As more target analytes can be attached to this controlled IA layer, 
the signal at the same concentration of target analyte can be increased. For the selection of 
most effective orientation control and the density control of antibodies, several methods 
were compared by using avidin, NeutrAvidin, protein A, NeutrAvidin-protein A complex 
layer and the biotin-labelled SAM. For the feasibility test of orientation control by using 
selected layer, the SPR biosensor was applied for the detection of a cancer marker called 
carcinoembryonic antigen (CEA).  
 
3.3.2.2 Orientation control of the IA layer on gold surface of SPR biosensor 
 
In order to compare the effect of orientation, several kinds of IA layers such as NeutrAvidin 
layer, Protein A layer and NeutrAvidn-protein A complex layer were prepared on the 
differently modified gold surface (see Figure 3-29A). First, receptor (anti-hIgG) was added 
to the differently modified gold surface to compare the surface density of receptors and then, 
the ligand (hIgG) was added to the receptor (anti-hIgG) bound gold surface in order to 
compare the effect of orientation control of IA layer (see Figure 3-29B).  
The amount of bound IgG was estimated by the corresponding SPR signal. The higher the 
SPR signal means the larger amount of the bound receptor IgG to the surface. Then, the 
ligand IgG was added to the receptor IgG bound surface which could selectively bind the 
ligand IgG and then the SPR signal was additionally measured. As two binding sites at two 
variable regions called F(ab’)s are localized, the binding sites should be oriented to bind the 
ligand IgG.. This means that the bound amount of the ligand IgG is related to the amount of 
well-oriented receptor IgG and not to the total amount of the receptor IgG. And the ratio of 
two signal (Signal ligand IgG / Signal receptor IgG) can be used to compare the binding ratio of 
ligand IgG per receptor IgG indicating the effect of orientation control of receptor layer (IA 
layer). 
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A          B 
 
Figure 3-29: Comparison of three differently modified gold surface. The receptor IgG 
(anti-hIgG) was added to the differently modified gold surface to make IA layer and then, the ligand 
IgG (hIgG) was added to the receptor (anti-hIgG) as an analyte. (A) Schematic view of three 
differently modified gold surface. (B) Comparison of the binding amount of the receptor and ligand 
on the differently modified gold surface. ‘A and Gold’ represents the bare gold surface. ‘B and 
NeutrAvidin’, ‘C and Protein A’ and ‘D and Neu-ProA’ represent NeutrAvidin layer, Protein A layer 
and NeutrAvidin-protein A complex layer on the gold surface, respectively. The ratio of two signal 
(Signal ligand IgG / Signal receptor IgG) can be used to compare the binding ratio of ligand IgG 
per receptor IgG indicating the effect of orientation control of receptor layer (IA layer). 
 
The NeutrAvidin layer (see Figure 3-29A(B)) 
 
The NeutrAvidin layer was prepared on the gold surface of the SPR biochip by physical 
adsorption. In comparison with the sensor responses at the bare gold surface (receptor IgG: 
186.9 millio, ligand IgG: 68.0 millio), the sensor responses at the NeutrAvidin layer by the 
attachment of the receptor (223.6 millio) and the ligand IgG (118.7 millio) were increased to 
120 % (186.9 Æ 223.6 millio) and 175 % (68.0 Æ 118.7 millio), respectively (see Figure 3-
29A(B)). The binding ratio of ligand antibody per receptor antibody was calculated by the 
ratio of the two signals (Signal ligand IgG / Signal receptor IgG) to be 1.5-fold higher than that of 
the bare gold surface. This result shows that the density of the receptor in the IA layer as 
well as the binding capacity per unit receptor was slightly increased.  
 
The Protein A layer (see Figure 3-29A(C)) 
 
Protein A is the surface protein of Staphylococcus aureus and it is well known to bind the 
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Fc region of antibodies (Hjelm et al., 1972). Such a property of protein A has been used for 
the orientation control of antibodies in immunoassays (Goding, 1978). In order to estimate 
the orientation of antibodies by protein A, the receptor and the ligand antibodies were added 
sequentially to the protein A bound SPR biosensor. In comparison to the bare gold surface 
of SPR biosensor, the binding of the receptor and the ligand antibodies were increased to be 
130 % (186.9 Æ 242.6 millio) and 241 % (68 Æ 164.2 millio), respectively. The binding 
ratio of ligand antibody per receptor antibody is thus improved to be 1.9-fold compared 
with bare gold surface. This result shows that the binding capacity per unit receptor was 
significantly increased. 
 
The NeutrAvidin-protein A complex layer (see Figure 3-29A(D)) 
 
NeutrAvidin-protein A complex layer was prepared as follows: After the preparation of 
NeutrAvidin layer on gold surface, the protein A layer was prepared above the layer of 
NeutrAvidin by treatment of biotin-labelled protein A molecules. The typical SPR 
sensorgram of Figure 3-30 shows the binding of receptor antibodies to the layer of protein A 
attached to the immobilized NeutrAvidin molecules on the bare gold surface.  
 
 
 
Figure 3-30: SPR responses during the preparation of NeutrAvidn-protein A complex 
layer. The NeutrAvidin layer was made on gold surface by treatment of NeutrAvidin molecules (1 
mg/ml for 90 min), and then the protein A layer was prepared above the layer of NeutrAvidin by 
treatment of biotin-labelled protein A molecules (1 mg/ml for 90 min). Receptor antibodies (anti-
hIgG antibodies; 1 mg/ml for 90 min) were attached to the NeutrAvidin-protein A complex layer. 
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By using the known correlation between the SPR signal and the absolute amount of protein 
(120 milli° = protein binding of 1 ng/mm2) (Stenberg et al., 1991), the saturating amount of 
NeutrAvidin molecules (60kDa), biotin-labelled protein A molecules (50kDa) and receptor 
antibodies (150kDa) was calculated as shown in Table 3-11. The ratio of biotin-labelled 
protein A per NeutrAvidin and the ratio of receptor antibodies per biotin-labelled protein A 
were estimated to be 0.4 and 1.1, respectively. 
 
Table 3-11: Surface density of the between-layers of Neutravidin-protein A complex 
layer.  
 Surface density Ratio 
 (ng/mm2) (moles/mm2)  
NeutrAvidin 2.7 4.6 * 10-14  
Biotin-labelled Protein A 0.9 1.8 * 10-14 0.4* 
Receptor antibodies 2.9 2.0 * 10-14 1.1** 
*Ratio of biotin-labelled protein A per NeutrAvidin  
**Ratio of receptor antibodies per biotin-labelled protein A 
 
The receptor and ligand antibodies were sequentially added to the NeutrAvidin-protein A 
complex. As shown in Figure 3-29B (‘Neu-ProA’), the absolute binding amount as well as 
the binding capacity per unit receptor molecule was significantly increased in comparison 
to the other layers. In comparison to the bare gold surface of the SPR biosensor, the amount 
of the receptor and the ligand antibodies were increased to be 189 % (186.9 Æ 352.9 millio) 
and 359 % (68 Æ 243.8 millio), respectively. The signal ratio by the binding of ligand 
antibody per receptor antibody is improved to be 1.9-fold compared with bare gold surface. 
 
For the binding capacity per unit receptor (orientation control effect of receptor), the 
NeutrAvidin-protein A complex layer (1.9-fold higher than the bare gold surface) showed 
similar result with the protein A layer (1.9-fold higher than the bare gold surface). In the 
both of the protein A layer and the NeutrAvidin-protein A complex layer, the receptor 
antibody was immobilized on the same factor of orientation control for protein A. This 
means that both layers had similar orientation control effect for antibodies, which has 
higher value of orientation control effect than the NeutrAvidin layer (1.5-fold higher than 
the bare gold surface) or bare gold surface. 
However, the orientation of protein A could be also controlled by interaction of biotin-
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labelled protein A and NeutrAvidin in the NeutrAvidin-protein A layer, and NeutrAvidin 
could always show similar orientation of binding sites for biotin because of four same 
domains for binding sites. From this result, binding sites of protein A in the NeutrAvidin-
protein A layer could be uniform for the receptor antibody to bind. On the contrary, protein 
A in the protein A layer bound to the gold surface without any orientation control. In this 
case, some binding sites of protein A could not be bind with the receptor antibody. As the 
protein A of NeutrAvidin-protein A layer seemed to have more controlled binding sites for 
receptor IgG than the protein A-only layer, the binding amount of receptor IgG (352.9 
millio) or ligand IgG (243.8 millio) on the NeutrAvidin-protein A complex layer were 
significantly increased in comparison to the protein A layer (receptor IgG: 242.6 millio, 
ligand IgG: 164.2 millio). Compared with the protein A layer, the NeutrAvidin-protein A 
complex improved the surface density of the receptor antibody. 
 
3.3.2.3 Orientation control of the IA layer on SAM surface of SPR biosensor 
 
The orientation control effect of NeutrAvidin-protein A complex was also tested by using 
the self-assembled monolayer (SAM) of the SPR biosensor. Because of the easy preparation 
and the high quality of the monolayered structure as well as low non-specific binding of 
biomolecules (Silin et al., 1997), SAM based on the thiolated carbohydrate molecules have 
been widely used for the surface functionalization of the SPR biosensor.  
In order to compare the signal amplification by orientation control on the SAM layer, 
NeutrAvidin-protein A layer on the biotinylated SAM layer and Chimeric complex layer 
were prepared on the biotinylated SAM layer (see Figure 3-31A) and the binding amount of 
the receptor (anti-hIgG) and ligand (hIgG) antibody on the differently modified SAM 
surfaces were measured (see Figure3-31B). And the ratio of two signal (Signal ligand IgG / 
Signal receptor IgG) were calculated to compare the binding ratio of ligand IgG per receptor 
IgG indicating the effect of orientation control of receptor layer (IA layer). 
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A           B 
 
 
Figure 3-31: Comparison of three differently modified SAM layers. The receptor IgG 
(anti-hIgG) was added to the differently modified gold surface to make IA layer and then, the ligand 
IgG (hIgG) was added to the receptor (anti-hIgG) as an analyte. (A) Schematic view of three 
differently modified SAM layers. (B) Comparison of the receptor and ligand antibody binding on 
the differently prepared SAM surface. ‘A and Gold’ means the bare gold surface of SPR biochip. ‘B 
and SAM’ and ‘C and S-Neu-ProA’ represent the SAM layer on the bare gold surface and 
NeutrAvidin-protein A complex layer on the biotinylated SAM layer, respectively. ‘D and S-
Chimeric’ means the purified NeutrAvidin-protein A chimeric complex immobilized on the biotin 
labelled SAM layer. The binding ratio of ligand IgG per receptor IgG can be used to indicate 
the effect of orientation control of receptor layer (IA layer). 
 
The SAM layer (see Figure 3-31A(B)) 
 
The SAM layer was prepared on the gold surface of the SPR biosensor by using 11-
mercaptoundecanoic acid. The receptor IgG was immobilized to the SAM by using 
coupling reagents (EDAC/NHS). As shown in Figure 3-31B (‘SAM’), the amount of the 
receptor and the ligand binding was increased to be 163 % (186.9 Æ 305.3 millio) and 
128 % (68 Æ 87 millio), respectively in comparison to that of bare gold surface (‘Gold’). 
The binding ratio per unit receptor was estimated to be as low as 0.8-fold of bare gold 
surface. This low binding ratio per unit receptor (0.8-fold) means that the orientation of the 
receptor layer should be controlled for the suitable binding of ligand IgG. If the receptor 
layer is well-oriented, the amount of the ligand binding can be increased even if the amount 
of the receptor does not increase significantly.  
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The NeutrAvidin-protein A complex on the biotinylated SAM layer (see Figure 3-
31A(C)) 
 
The NeutrAvidin-protein A complex was prepared on the biotinylated SAM layer by 
sequential treatment of NeutrAvidin and biotin-labelled protein A (‘S-Neu-ProA’ in Figure 
3-31B). When the receptor and the ligand antibodies were reacted to the layer, the amounts 
of binding were estimated to be increased as much as 133 % (186.9 Æ 248.3 millio) and 
282 % (68 Æ 191.9 millio), respectively in comparison to that of bare gold surface. 
Especially, the binding ratio of ligand per unit receptor was increased 2.1-fold compared 
with the bare gold layer. In comparison to the SAM layer, the binding ratio was improved 
as much as 2.7-fold, which clearly shows the effect of orientation control by Neutravidin-
protein A complex.  
 
The chimeric protein of NeutrAvidin-protein A complex on the biotin-labelled SAM 
surface (see Figure 3-31A(D)) 
 
The chimeric protein of NeutrAvidin-protein A complex was prepared by mixing equimolar 
biotin-labelled protein A and NeutrAvidin, and then the chimeric complex was purified by 
centrifugal filtration. When the chimeric protein was added to the biotin-labelled SAM 
surface (‘S-Chimeric’ in Figure 3-31B), the binding amount of the receptor and the ligand 
was estimated to be 45 % (186.9 Æ 85 millio) and 40 % (68 Æ 27 millio), respectively in 
comparison to the bare gold surface. The binding ratio per receptor was calculated to be 
90 % in comparison to the bare gold surface. This result shows that the orientation of the 
receptor was randomly controlled as in the case of the immobilization of receptor IgG to 
SAM layer or bare gold surface.  
 
As summarized in Table 3-12, NeutrAvidin-protein A layer on gold surface showed the 
highest binding amount of ligand antibodies. In the case of NeutrAvidin-protein A complex 
on the biotin-labelled SAM layer, the binding ratio per receptor antibody was estimated to 
be the highest among other layers.  
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Table 3-12: Comparison of binding amount of receptor and ligand antibodies to the 
differently modified SPR biosensor surface. 
Amount of binding* 
Surface 
Receptor Ab Lignad Ab 
Ratio of 
   Orientation** 
Bare gold 1 1 1 
NeutrAvidin 1.2 1.8 1.5 
Protein A 1.3 2.4 1.9 
NeutrAvidin-protein A 1.9 3.6 1.9 
SAM 1.6 1.3 0.8 
SAM-Biotin-NeutrAvidin-Protien A 1.3 2.8 2.1 
SAM-Biotin-Chimeric complex 0.5 0.4 0.9 
* Amount of binding was calculated in comparison to bare gold surface, which was (SPR Signalat 
each surface / SPR Signalat bare gold surface).  
**The ratio of orientation means the relative number of lignand Ab bound to unit receptor Ab in 
comparison to bare gold surface, which is calculated to be (Amount of bindingligand Ab / Amount of 
bindingreceptor Ab). 
 
3.3.2.4 Signal amplification for carcinoembryonic antigen (CEA) detection by using 
NeutrAvidin-protein A layer 
 
The NeutrAvidin-protein A complex was applied for the detection of a cancer marker called 
carcinoembryonic antigen (CEA) by using the SPR biosensor. CEA is considered one of the 
broad spectrum cancer markers (see section 1.4). The cut-off level of CEA is reported to be 
5 ~ 10 ng/ml and the detection range for diagnosis of CEA is reported to be between 0 and 
100 ng/ml (Nishizono et al., 1991; Suresh, 2001).  
For the detection of CEA, the IA layer of monoclonal anti-CEA antibodies was prepared on 
(1) bare gold surface of SPR biosensor and (2) the Neutravidin-protein A layer on bare gold 
surface. The injection of samples at the target concentration range for the diagnosis of CEA 
did not induce the sensor response higher than the level of baseline drift (0.8 milli°) by 
using both IA layers. In this work, the polyclonal anti-CEA antibodies were additionally 
injected for the formation of sandwich complex to the already bound CEA. For the 
improvement of sensitivity in the detection of CEA, NeutrAvidin-protein A layer was used 
and it was compared with the bare gold surface to measure the degree of “signal 
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amplification” (see Figure 3-32). The standard curves were fit by using the simple binding 
model: R = [C·Rmax / (C+KD)]. Here, ‘R’ and ‘C’ represent the sensor response and 
concentration of CEA, respectively. KD is dissociation constant and Rmax is the maximal 
sensor response (O’Shannessy et al., 1993). As shown in Figure 3-32, the experimental 
results seem to fit well (r2 > 0.99). By using the curve fit, the IA layer on the NeutrAvidin-
protein A complex layer showed higher sensitivity than the bare gold surface. The Rmax 
value was evaluated for NeutrAvidin-protein A layer and bare gold surface to be 85.8 milli° 
and 52.8 milli°, respectively. From the comparison of signals, the sensitivity with 
NeutrAvidin-protein A layer was determined to be improved 1.5-fold higher compared with 
the bare gold surface. The detection limit was also estimated for NeutrAvidin-protein A 
layer and bare gold surface to be 30 ng/ml and 36 ng/ml, respectively. This result shows 
that the NeurtAvidin-protein A complex can improve the sensitivity for the detection of 
CEA through the orientation control of antibodies in IA layer. 
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Figure 3-32. Standard curve for the detection of CEA in 10 mM PBS (pH 7.4). For the 
improvement of sensitivity in the detection of CEA, NeutrAvidin-protein A layer (■) was used and it 
was compared with the bare gold surface (▲) to measure the degree of “signal amplification”. Each 
signal was obtained by additional injection of anti-CEA antibodies (label proteins) to the already 
bound CEA for the formation of the sandwich complex. The standard curves were fit by using the 
simple binding model: R = [C·Rmax / (C+KD)]. The Rmax value was evaluated for NeutrAvidin-
protein A layer and bare gold surface to be 85.8 milli° and 52.8 milli°, respectively. This result 
shows that the sensitivity with NeutrAvidin-protein A layer was improved 1.5-fold higher compared 
with the bare gold surface for the detection of CEA through the orientation control of 
antibodies in IA layer. 
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4. Discussion 
 
4.1 Application of biosensor in medical diagnosis 
  
4.1.1 Introduction 
 
The biosensor has been proposed as a tool to improve the “sensitivity”, “selectivity” and 
“analysis time” by using biological materials, and this is composed of “biomaterial” and 
“transducer” (see introduction). According to the biomaterials for the molecular recognition, 
biosensor is classified into catalytic biosensors and affinity biosensors (Scheller and 
Schubert, 1992; Ramanavieius et al., 2005). In the catalytic biosensors, the recognition 
element (enzyme, cell and tissue) converts substrate molecules into product molecules, 
thereby making amplification of the signal possible. In the affinity biosensors, the 
recognition molecule (antibody, nucleic acid, peptide, cell receptor and protein) binds the 
analyte molecule. These two kinds of biosensors can be used with several transducers such 
as electrode, transistor, thermistor and optical device. 
 
Body fluids (humors) such as blood, urine, sweat, saliva, etc. includes various kinds of bio-
chemical materials and these bio-chemical materials related to any specific diseases are 
called biomarkers (see section 1.4). The biosensors have been used to detect the biomarkers 
in the body fluids for the medical diagnosis. Rapid and accurate detection of the biomarkers 
is one of the most important topics of modern medicine because it has a definite influence 
on the successful treatment of the patient.  
 
The representative catalytic biosensors using the electro-chemical sensors have been 
generally used for the medical diagnosis, detecting biomolecules such as insulin, glucose, 
hCG, theophylline, α1-glycoprotein, apolipoprotein E, FSH and LH in serum or urine 
(Morgan et al., 1996). Such electro-chemical sensors have several advantages such as 
simplicity and high sensitivity. The electro-chemical sensors have been reported to have 
several problems under the existence of the interferences in the body fluids, such as proteins 
in serum (low selectivity). However, the most successful type of biosensors until now is the 
enzyme-based amperometric type and they are commercially used for the detection of 
glucose, lactate, urea etc. as disposable sensors (Scheller and Schubert, 1992).  
 
Discussion                                                                           88 
 
 
Conventional IA-based bioassays such as radioimmunoassay (RIA), enzyme-linked 
immunosorbent assay (ELISA), immunoagglutination assays (IAA) and fluorescent 
immunoassays (FIA) have been generally used for the medical diagnosis and this bioassay 
has several advantages such as high sensitivity, low detection limit and broad detection 
range (Ngo, 2000). For example, ELISA showed the detection limit of 2 nM for the 
detection anti-AChR antibody (Franciotta et al., 1999). Although the development of 
immunoassays during the last three decades revolutionized medical diagnosis, these 
classical affinity assays such as ELISA takes more than one hour to achieve, and modern 
alternative tests are being examined as rapid screens. Moreover, assay system can not be 
used as continuous monitoring mode. The modern biosensor technology enables the label-
free detection, quantification and continuously working immunoassay system. The most 
representative affinity biosensor is the immunosensor where antibodies or antibody 
fragments are applied as biological element and this sensor can be categorized based on the 
detection principle applied (see section 4.1.3). The immunosensor has been used for the 
detection of high-molecular weight compound such as protein, antigen and hormone, which 
is necessary for the medical diagnosis. In this work, major parts of the immunosensor 
(molecular recognition part and transducer) will be discussed for the practical application to 
medical diagnostics. 
 
4.1.2. Molecular recognition part 
 
4.1.2.1 Antibodies as molecular recognition tool 
 
In the immunosensor, the biological component such as antibody or antigen is used as 
molecular recognition part and this part conveys selectivity and sensitivity to the sensor by 
the formation of complex between antigen-antibody.  
Two kinds of antibodies can be used for the immnosensor: polyclonal antibodies and 
monoclonal antibodies (Kane and Banks, 2000; Liddell, 2001). Polyclonal antibodies are 
still widely used as primary antibodies, particularly in competitive immunoassays, and the 
great majority of polyclonal antibodies are used as label antibodies. Its great advantage is 
the relative simplicity and low cost of the procedures used for raising them. Double-
antibody sandwich immunoassays can be set up with one kind of polyclonal antibodies and 
this is more simple system compared with the system with two kinds of monoclonal 
antibodies or a combination of polyclonal and monoclonal antibody. They are often 
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sufficiently specific for the purposes of their users and the long-term continuity of supply is 
possible by immunizing a large animal. However, polyclonal antibodies are a heterogeneous 
mixture of antibodies arising from a variety of constantly evolving B-lymphocytes, which 
have a varying binding affinities, isotype, and different specificities. As a consequence, even 
successive bleeds from one animal are always unique. In this case, uniform ratio of signal to 
concentration can be made by antibodies from only one bleed and mixture of polyclonal 
antibodies from several bleeds seems to change the ratio of signal in the immunoassay. This 
set limits to the quantity of antibodies to be used for uniform experiment by immunosensor. 
Moreover, polyclonal antibodies recognize epitopes both on the immunogen and any 
impurities injected with it. This can make a nonspecific binding to increase the detection 
limit of the immunosensor in the medical diagnosis. 
Although early immunoassay used polyclonal antibodies prepared from the sera of animals, 
the monoclonal antibodies produced by fusion technology (Kohler and Milstien, 1975) are 
preferred for the immunoassay industry. The hybridoma cell lines can secrete only one 
particular type of antibody (monoclonal antibodies).  
 
The production of new antibodies, whether polyclonal or monoclonal, always depends on 
new immunizations, which are lengthy and tedious procedures and do not always guarantee 
success. The genetic approach to antibody production has gained momentum due to the 
failure of the hybridoma method to produce human monoclonal antibodies reliably for 
therapeutic purposes. The production of recombinant antibodies (rAbs) will provide 
significant changes for antibody generation and diversification, which will provide a vast 
repertoire of new antibody types. New antibodies can be generated by selection from 
suitable antibody libraries, which can be constructed within shorter time. The main 
bottleneck is the handling and screening of large libraries for antibody genes (Hock, 1997). 
Antibodies in the immunosensors have been often used as conjugates with a variety of 
labels such as colorimetric enzymes, fluorescent and luminescent molecules and radiolabels. 
Genetically, recombinant antibody technology can be used to form antibody fusion proteins 
and this has potential to improve homogeneous production of conjugates in which antigen-
binding site should be unaffected. Several useful fusion proteins for immunoassay have 
been described as shown in the Table 4-1 (Liddell, 2001).  
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Table 4-1. Recombinant antibody fusion proteins of use in diagnostics 
Fusion partner Antibody fragment Use 
Alkaline phosphatase ScFv, F(ab’)2 Produces colorimetric product 
Avidin Fab, F(ab’)2, IgG Binds biotin conjugated proteins 
Biotin-carboxyl carrier 
protein 
Fab Biotin attached during secretion 
Protein A fragment ScFv Fc binding 
Metallothionein F(ab’)2 Allows subsequent binding of 99MTc 
Peptide ScFv Peptide chelates metal then binds to 99MTc 
Peptide ScFv Peptide can be enzymetically labeled with 32P
Amino terminal of E.coli 
major lipoprotein 
ScFv Attaches lipid during expression 
Streptavidin ScFv Binds biotin conjugated proteins. Also useful 
for producing tetramers. 
 
However, no fusion proteins are yet widely available. It has sometimes been difficult to 
express fully functional fusion proteins, and the capacity to vary the stability of the linkage 
as with chemical conjugation is lost. 
 
4.1.2.2 Alternative analyte-binding compounds for immunosensor  
 
Although immunosensors have generally used polyclonal or monoclonal antibodies, there 
are several limitations of these proteins for immuno-reaction as follows: (1) If working 
condition is different from body property, the structure of molecule can be changed to be 
unstable for immuno-reaction. (2) The treatment of regeneration can damage the 
immobilized antibodies or detach the immobilized antibodies from IA layer. An adequate 
analytical sensitivity can only be achieved if antibodies with increased affinity (>1010 M-1) 
(Hock, 1997). Therefore, a high-affinity constant and a labile immobilized antibody make 
regeneration of the surface difficult to realize in practice, limiting practical application of 
immunosensors to single-use devices (Morgan et al., 1996). (3) The reaction time between 
antibody and antigen is slower than the detection time by transducer, and all analysis time is 
extended. The following new tools as the molecular recognition part have been successively 
developed to solve above problems. 
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(1) Aptamers  
 
Aptamers are synthetic single-stranded DNA or RNA oligonucleotide sequences with the 
ability to recognize various target molecules such as nucleotides, drugs, proteins with high 
affinity and specificity (Luppa et al., 2001). Aptamers are identified by an in vitro selection 
process known as systematic evolution of ligands by exponential enrichment (SELEX), 
which allows the simultaneous screening of more than 1015 individual nucleic acid 
molecules for different functionalities (Tuerk and Gold, 1990). Aptamers may have 
advantages over antibodies in the ease of depositing them on sensing surface of 
immunosensor and the highly reproducible synthetic approach in any quantities. In the 
detection of thrombin, a fiber-optic microarray biosensor using aptamers as receptors was 
reusable and did not show any sensitivity change during the experiment (Lee and Walt, 
2000). However, the disadvantage of aptamer such as high cost and unstableness should be 
solved for the application of this in the IA biosensor. 
 
(2) Molecularly imprinted polymers (MIPs) 
 
Molecularly imprinted polymers (MIPs) is produced by polymerization of functional and 
cross-linking monomers in the presence of a molecular template (Boonpangrak et al., 2006). 
After polymerization and template removal, specific binding sites are left in the polymer 
material. Although natural receptors, enzymes and antibody have limitation of chemical and 
thermal instabilities limit, MIPs can withstand environments that would destroy natural 
antibodies, are easy to prepare at low cost, and can be prepared for compounds (e.g., 
immunosuppressive agents) against which it is difficult to produce natural antibodies (Li 
and Husson, 2006). In the detection of domoic acid (DA), MIP, comprising 2-(diethylamino) 
ethyl methacrylate as functional monomer and ethylene glycol dimethacrylate as cross-
linker, outperform monoclonal antibody natural receptors with a wide detection range and 
long stability (Lotierzo et al., 2004). However, the high detection limit owing to low affinity 
between antigen and MIPs should be improved for the application of MIPs to the IA 
biosensor (Boonpangrak et al., 2006). 
 
(3) Anticalin 
 
As a promising alternative to recombinant antibody fragments, lipocalin scaffold can be 
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employed for the construction of “anticalins”, which is made by subjecting various amino 
acid residues, distributed across the four loops, to targeted random mutagenesis. Lipocalins 
such as retinol-binding protein constitute a family of proteins for storage or transport of 
hydrophobic and/or chemically sensitive organic compounds (Luppa et al., 2001). These 
binding proteins share a conserved β–barrel, which is made of eight antiparallel β–strands, 
winding around a central core. For example, bilin-binding protein can be structurally 
reshaped in order to specifically complex potential antigens, such as digoxigenin 
(Schlehuber et al., 2000) However, there are several problems to be solved, such as the 
synthesis and stability of the anticalins, the magnitude of the affinity constants, and the 
versatility for being crafted against the large variety of ligands.   
 
4.1.2.3 Immobilization technique 
 
For the successful application of molecular recognition tools, immobilization technique for 
the connection of molecular recognition tools to the sensor surface should be developed. 
This technique is very important in the construction of molecular recognition part in order to 
avoid nonspecific binding and to improve sensitivity of IA biosensors. Immobilization can 
be achieved in several different ways: direct adsorption to the transducer surface, physical 
entrapment near the transducer surface (e.g. in a polymer layer or by use of a membrane), 
direct covalent coupling to the transducer surface, covalent coupling to a polymer layer on 
the transducer surface and use of ‘capture system’.  
In this work, we focused on the improvement of molecular recognition layer in order (1) to 
increase the density of IA molecules and (2) to optimize the orientation of IA molecules. For 
the orientation control of IA molecules, NeutrAvidin-protein A complex layer and biotin 
labeled SAM were used in this experiment (see section 3.3.2) and this orientation control 
showed the enhancement of the sensitivity. In this work, NeutrAvidin-protein A complex 
layer were made on the sensor surface by sequential injection of NeutrAvidin and protein A. 
By the sequential attachment, some NeutrAvidin on the sensor surface could not bind with 
protein A.  
As described in section 1.3.1, self-assemble monolayer (SAM) was used in this work, as a 
linker layer between molecular recognition part and gold layer of SPR transducer. The 
application of mixed SAMs have been reported by co-adsorption of mixtures of two thiols 
with different chain lenghs, has been shown to prevent denaturation and thus improve the 
bioactivity of a protein immobilized on such layer in comparison with the protein 
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immobilized on a pure SAM (Briand et al., 2006). Mixed SAMs are generally constituted of 
one long thiolate with a functional headgroup (like a carboxylic acid) at a low mole fraction 
and of another short “diluting” thiolate at a high mole fraction to minimize steric hindrance, 
partial denaturation of the protein (Guiomar et al., 1999) and non-specific interactions (Ge 
and Lisdat, 2002; Frederix et al., 2003). 
The prevention of nonspecific binding is also an important topic of immobilization method. 
In this work, various trials were performed and it will be separately discussed at section 4.3. 
 
4.1.3 Transducer for immunosensors 
 
Transducers of IA-biosensor can be divided as four types according to the principle of signal 
generation: electrochemical transducers (amperometric, potentiometric, conductometric, 
capacitative), optical transducers (fluorescence, luminescence, refractive index, 
ellipsometric, surface plasmon resonance, waveguide) or mass-sensitive transducers 
(piezoelectric, acoustic wave) or a thermal transducer (calorimetric). The IA-biosensor can 
be classified according to the detection method: (1) direct detection (2) indirect detection 
whether label is used for the detection of antigen-antibody reaction or not. (1) In the direct 
sensor, the binding event can change different physical properties such as the change of 
refractive index (SPR trasducer), mass change (QCM or SAW transducer) and change of a 
dielectric constant (electrochemical transducer). (2) The indirect sensor requires a signal-
generating label on one of the biomolecules in the immune complex formation and this label 
needs a separate step to produce a change in the property. This sensor can use a great variety 
of different labels, which have been usually used in immunoassay (Morgan et al., 1996; 
Luppa et al. 2001; D’Orazio, 2003).  
The direct sensors can save the analysis time and allow direct detection of analyte binding in 
real time. Without labels, these sensors can be more cost-effective. With the progress of 
MEMS technique, the development of direct sensors has been improved and recently, these 
sensors have been main type of immunosensors for medical application.  
Optical immunosensors are most popular for bioanalysis thesedays, which has the advantage 
of rapid signal generation and reading. Among the several optical immunosensors, direct 
optical transducer such as SPR transducer is most popular one to monitor immunoreactions 
in clinical chemistry (Luppa et al., 2001). The major advantage of direct optical transducer 
is the lack of need of a label for the detection of analyte, avoiding a separation step to 
remove free from bound label. Further, there is no penetration of the sensing wave beyond 
 
Discussion                                                                           94 
 
 
the immediate surface of the optical device being used, avoiding interference from 
substances present in the bulk sample (D’Orazio, 2003).  
Among the direct biosensors such as SPR biosensor of this work, quartz crystal 
microbalance (QCM) sensor is also generally used for transducer and it has a high 
sensitivity. Although a QCM technique detects not the change of optical property but the 
mass change, both SPR and QCM are wave-propagation phenomena and show resonance 
structure. The QCM has been widely used as direct immunosensors. The SPR technique 
measures changes in the refractive index adjacent to the surface, whereas QCM technique 
detects changes in the frequency, corresponding to changes in the amount of mass coupled 
to the surface. In the QCM sensor, the relationship of the frequency change and the mass 
loading on the surface of the crystal can be described by the Sauerbrey equation (Sauerbrey, 
1959):  
 
∆F=-2F02∆m/A(ρqµq)1/2 
 
Where ∆F is the measured frequency shift, F0 is the fundamental frequency of the Pz crystal, 
A is the area coated, ∆m is the mass change due to surface deposition, ρq is the density of the 
quartz crystal (2.684g cm-3) and µq is the shear modulus (2.947ⅹ1011g cm-1 s-2 for AT-cut 
quartz crystals). 
When the SPR biosensor was compared with QCM biosensor for protein adsorption and 
antigen-antibody recognition, they were comparable with respect to sensitivity and the 
detection limit for monoclonal antibody (mAb) and sera was nearly the same for both 
methods (Koesslinger et al., 1995) (see Table 4-2). 
 
Table 4-2 Overview of quantities that can be used for a comparison of the QCM and 
SPR 
Quantity QCM SPR 
Thickness sensitivity 184 Hz/nm 26.3 millio/nm 
Detection limit of mAb 20 nM 23 nM 
Detection limit of sera 1:1000 1:1000 
Immunological sensitivity for mAb 0.5 nM/Hz 3 nM/ millio 
Penetration depth 126 nm 150 nm 
Sensitive area 5 mm2 5ⅹ10-3 mm2 
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Even if the QCM machine is less expensive and easier to handle, the SPR sensor has several 
advantages compared with QCM. SPR responses occur at a faster time than the QCM 
responses and the SPR technique was also cost effective (Laricchia-Robbio and Revoltella, 
2004). Moreover, because the sensitive area of SPR is smaller than QCM sensor, fewer 
molecules are necessary for the same surface density and smaller flow-through cells with 
smaller sample volumes could be possible compared to the QCM (Koesslinger et al., 1995). 
Accordingly, SPR transducer can be more easily integrated with microfluidics to make total 
analysis system, so-called “lab on a chip”, which includes sample preparation and handling, 
chemical analysis and signal acquisition capabilities.  
 
There are two leading SPR systems on the market (Luppa et al., 2001); the BIAcoreTM 
systems and the IAsysTM. Other systems (with small market positions) are the IBISTM, the 
BIOS-1TM, the SPR-20TM, the DPXTM and SpreetaTM. However, the BIAcoreTM has the 
largest market share. Although first two commercial SPR systems are widespread in 
research laboratories due to the sophisticated apparatus and user friendly control software, 
they are composed of a disposable biochip and big SPR detection system and it is difficult 
to be remodeled as a point-of-care (field investigation) system. In the case of SpreetaTM 
system, which was used in this experiment, it is small enough to be used as a point-of-care 
system. However, even with the temperature control system of this experiment, there was a 
problem of unstable signal in this experiment and this problem makes a relatively big 
baseline drift (>0.5 millio) for the detection limit to be increased (see section 2.2.2(3)). If 
this background noise can be reduced by using several methods such as the incorporation 
the SpreetaTM transducer into a well-designed sensor system, the detection limit will be 
decreased for the SpreetaTM system to be sufficient for medical application even in the field 
investigation (Chinowsky et al., 2003).  
 
4.1.4 Future perspectives for clinical applications 
 
The disposable enzyme electrode intended for home monitoring of blood glucose is the most 
representative world market for biosensor (Newman et al., 2001). However, the medical 
application of biosensors with “real” clinical samples is still rare. As shown in the 
application of the detection for hHBV antibody (see section 3.3.1), all immunosensors are 
still one magnitude less sensitive than commercial immunoassays for determining analytes 
in human serum, particularly those with low molecular weight (Kubitschko et al., 1997). 
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The improvement of sensitivity can be accomplished by the detection chemistry, such as the 
high molecular mass label or nanoparticle, or increasing the sensitivity of the transducer. 
And reducing background noise is also important and it can be done with well-established 
system. However, the analytical potential of immunosensor technique such as ease of use or 
short analysis time is evident and in particular, the applications of optical immunosensor 
systems will most likely be of clinical interest (Luppa et al., 2001).   
 
4.2 Discussion on the limitations of biosensor for real application 
 
For the real medical application, the techniques in this work have been developed and the 
feasibility was demonstrated. Here, the limitations of each technique as well as the 
alternative solutions will be discussed.  
 
4.2.1 The number of repeated measurement by using in the additive assay  
 
The applicability of the additive assay was demonstrated by using CA 19-9 in 10 mM PBS 
as a model biomarker (see section 3.1.4). The detection limit of CA 19-9 was determined to 
cover the general detection range (400 – 192,000 U/ml) of most patient samples with 
pancreatic cancer (Del Villano et al., 1983). In this experiment, the feasibility was tested by 
four concentrations such as 1.3, 2.5, 5.0 and 6.7 kU/ml. Although those concentrations were 
relatively low part of the detection range, the uncertainty of measurement increased steeply 
only after the measurement of several analytes and the number of use seemed to be very 
limited. 
As the measured signal is saturated by repeated measurement, the uncertainty of 
concentration measurement increases steeply according to the increased accumulated 
concentration, even if the signal deviation (baseline uncertainty, ± 0.6 millio) is uniform (see 
Figure 3.7). In the saturated region of the correlation curve (the high accumulation 
concentration), only a small deviation in signal (baseline uncertainty) could result in the 
higher deviation of measured concentration in comparison to the low region of 
accumulation concentration. To maintain the accuracy of additive assay, the uncertainty of 
accumulated concentration by baseline uncertainty should be less than the detection limit 
(8.3 nM) (see section 3.1.3). In this case, the valid range of accumulated concentration 
should be within a limited range and it means that the applicable number of binding sites in 
the IA layer is strictly limited. When the number of additively attached analytes increases 
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the accumulated concentration, free binding sites of IA layer are also decreased. 
If the signal of same size can be obtained by the less number of binding between analytes 
and IA layer, the number of use can be increased in the additive assay. If several methods 
such as the orientation control of IA layer (see section 3.3.2) can be used to improve the 
sensitivity, the less number of binding sites is required for the same sensitivity and number 
of use can be increased because there is a constant number of binding sites in the IA layer. 
For the decrease of attachment by the same concentration of analyte, the reaction time 
should be decreased and the valid range of reaction time is until the sensitivity is still 
enough for the diagnosis. According to the above methods, the number of use can be 
increased in the additive assay of CA 19-9. 
 
4.2.2 Integration of simultaneous detection with additive assay 
 
Because simultaneous detection in this experiment should use a label with the sandwich 
assay format, there was a problem to integrate simultaneous detection with the additive 
assay. As the labels made sandwich complex with a part of the analyte on the IA layer, the 
rest of the analytes remained on the IA layer. These rest analytes on the IA layer made a 
significant influence on the next measurement by participating as analytes in the next 
measurement. Even if no more target analyte was treated to the IA layer, the rest analytes on 
the IA layer without label made a false positive signal. And, it resulted in a difficulty to get a 
uniform correlation curve for additive assay, and the additive assay was not possible for the 
simultaneous detection. The simultaneous detection has been disposable method until now. 
If label treatment can saturate the all binding sites corresponding to the analytes on the IA 
layer, additive assay can be used for the simultaneous detection. It can be possible by the 
treatment of a large amount of labels or several treatments of labels until the signal by next 
treatment of labels is disappeared.  
 
4.2.3 Signal amplification 
 
For the detection of analytes in serum, label-free assays with SPR biosensor has been with 
one order of magnitude lower sensitivity than commercial enzyme immunoassays 
(Lundstroem, 1994; Mullett et al., 2000; Goh et al., 2003; Kubitschko et al., 1997). Even 
with the signal amplification of this experiment such as usage of mass label or control of IA 
layer, the sensitivity of SPR biosensor should be improved for the medical application.  
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4.2.3.1 The improvement of label effect for the signal amplification  
 
In the detection of hHBV antibody (see section 3.3.1), several mass labels such as second 
antibody, avidin-biotin labeled antibody and PAP complex were compared and PAP complex 
was selected as efficient mass label. However, the detection limit of SPR detection with PAP 
complex label (0.64 nM) was still higher than the commercial ELISA kit (0.24 nM). 
Moreover, this experiment was done by 20-fold diluted serum sample (5 % serum) and the 
real detection limit by undiluted sample should be changed 20-times higher than 20-fold 
diluted sample from 0.64 nM to 12.8 nM. Accordingly, more effective label should be 
investigated. There are several factors such as mass, density and characteristic to influence 
the signal size of SPR biosensor as follows:  
 
(1) Mass label 
A large label with heavy mass such as liposome or latex particle could naturally make a 
higher signal than small label. By using liposome (100 ~ 1000 nm) as a label for the 
detection of interferon-γ, a liposome-enhanced sandwich SPR immunoassay improved the 
assay sensitivity 4 ⅹ 104 times and detection limit to a low picomolar level (Wink et al., 
1998). The sensor signal for hCG was also enhanced by using big latex particles (with a 
diameter of 238 nm) as a label (Severs and Schasfoort, 1993). Latex particles seemed to 
cause effect of signal amplification, compared to antibodies: at least twice at high 
concentration and 30 times at lower concentration of analyte. 
 
(2) Density label 
Label with a high density would be more efficient. High density means that mass is included 
in the smaller size. Because evanescent field for the SPR signal is inversely proportional to 
the distance from sensor surface (see Figure 4-1) (Ivarsson and Malmqvist, 2002), mass at 
the short distance can make high signal than mass at the long distance. Even if two different 
particles have same masses, label with high density will improve the effect of signal 
amplification. 
Even if label with heavy mass was used, the effect of signal enhancement was lower than 
the expected value (Severs and Schasfoort, 1993). Though a mass of hCG-coated latex was 
about as much as 2 ⅹ 104 antibodies, the signal by hCG-coated latex was far less than 2 
ⅹ 104-fold than antibodies because the size of hCG-coated latex was also as much as 400 
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antibodies. Evanescent field at a distance of 117 nM (the radius of the latex particle) should 
be less sensitive for refractive index changes than at a distance of about 10 nM (the 
dimension of an antibody). Considering the size and a mass between latex particle and 
antibody, theoretically expected signal of latex particle should be 50 times higher than 
antibodies. However, real efficiency for signal amplification was calculated to be less than 
50 times. The fact that latex bound less efficiently than free anti-antibody might be the main 
reason for the lower signal increase.  
 
 
Figure 4-1: Relative evanescent electric field amplitude (E) versus distance from 
solid/solution interface into sample (BIACORE instrument). Continuous line for SPR-
evanescent wave (gold film) and dashed line for non-absorbing TIR (no gold film). 
 
(3) Characterisitic label for SPR signal 
If label has good characteristic to make SPR signal, it would be better for signal 
amplification. Linkage with optically active particles has been proposed to enhance the 
sensitivity of SPR biosensor and among those particles, some particles such as colloidal 
gold with high optical refractive index lead to greater signal enhancement, while other 
particles such as polystyrene bead with smaller refractive index have less certain effect of 
the signal enhancement (Leung et al., 1994). When the colloidal gold was incorporated in 
analyte or label in the SPR boisensor, the sensitivities of ligand-protein and DNA-DNA 
interactions were increased and the change in SPR angle magnitude was particle-size 
dependent up to 45 nm in diameter (Lyon et al., 1998; He et al., 2000). 
 
In the future, the SPR signal amplification will be improved by developing efficient label, 
which simultaneously has several factors such as a heavy mass, high density and good 
characteristic to make SPR signal.  
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4.2.3.2 The optimal use of the NeutrAvidin-protein A complex 
 
In the detection of CEA tumor marker in the 10 mM PBS, NeutrAvidin-protein A complex 
layer was used as efficient layer to control IA layer (see section 3.3.2). Although the 
sensitivity with NeutrAvidin-protein A layer was improved 1.5-fold higher compared with 
the bare gold surface, the detection limit (30 ng/ml) was still higher than the cut-off value 
for medical diagnosis (5~10 ng/ml). In the real medical application, the detection limit will 
be increased by the nonspecific binding of serum. Accordingly, more efficient method to use 
the NeutrAvidin-protein A complex should be investigated to improve the detection limit. 
When NeutrAvidin-protein A complex was used in molecular recognition part, the 
orientation of receptor antibody in IA layer was controlled by protein A, which is a molecule 
for fixing receptor antibody. The degree of binding affinity between antibody and protein A 
is influenced by the species which makes antibody (Fulton, 1989). For the detection of CEA, 
anti-CEA antibody was used as receptor antibody of IA layer in this experiment and it was 
mouse IgG1. Because immunoglobulin binding property of protein A is known to be weak 
for mouse IgG1, the special ordering for the antibody from proper species such as rabbit, pig 
and human can improve the binding property between the receptor antibody and protein A to 
be strong (see Table 4-3). The improved binding property seems to have a potential to 
increase the amount of receptor antibody on the NeutrAvidin-protein A complex layer. In 
this case, more analytes can be also attached to the IA layer to increase the signal 
amplification. 
If change of animal species is difficult, the change of protein A can be an alternative method. 
Protein G also has a binding property for the Fc binding domains of antibody similar to the 
protein A and biotin-labelled protein can be used instead of protein A to make NeutrAvidin-
protein G layer. Although protein G has strong binding property for mouse IgG1, binding 
ability was not distinctly improved in comparison with the NeutrAvidin-protein A and signal 
ratio of protein G to protein A was just 1.1-fold in our experiment. This phenomenon 
seemed to be due to the difference of number of binding sites between protein A (four Fc 
binding domains) and protein G (one Fc binding domains) (Dubrovsky et al., 1996; 
Akerstrom et al., 1985): Though the protein G has better binding property for mouse IgG1 
than protein A, protein A has more binding sites than protein G. From this result, most 
proper situation is when the protein A has good binding property. 
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Table 4-3: Immunoglobulin binding properties of protein A and protein G.  
Antibody Protein A Protein G 
Rabbit ++ ++ 
Rat － + 
Goat + ++ 
Horse － ++ 
Pig ++ ++ 
Sheep － ++ 
Cow + ++ 
Dog ++ + 
Cat ++ － 
Guinea pig + ++ 
Chicken － － 
Mouse   
IgG1 － ++ 
 Others ++ ++ 
Human   
IgG1 ++ ++ 
IgG2 ++ ++ 
IgG3 － ++ 
IgG4 ++ ++ 
IgM ++ － 
IgA ++ － 
IgE ++ － 
IgD － － 
(Fulton, 1989) 
 
Molecular biology can also play an important role for the control of IA layer. If orientation 
control part such as avidin is attached to the molecular recognition part of antibody in the 
construction of recombinant antibody, this recombinant antibody can be well-oriented 
immobilized on the biotin-labeled SAM surface. 
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4.3. The problems for the application to blood samples 
 
The real samples of medical diagnosis include blood, hair, milk, saliva, semen, sweat and 
urine. These samples include not only target analytes, but also other components which can 
interrupt effective detection of the target analyte. Serum is prepared by separating blood 
cells from the whole blood and it has a high concentration of protein which includes 
albumin and other globulins and so on. As proteins in serum can bind to the IA layer on the 
sensor surface (Matson, 2000; Wilde, 2001), the proteins influence to make a false positive 
or negative signal as follows; (1) The binding substances in the serum may cause 
interference in some immunoassay systems by decreasing analyte binding and by 
suppressing the antigen-antibody reaction (Hedenborg et al., 1979; Vladutiu et al., 1982; 
Schmidt, 1984). (2) The protein in serum may increase an assay response in sandwich assay 
(Boscato and Stuart, 1988). For example, the presence of rheumatoid factors or 
autoantibodies is known to be a common source of non-specific binding in serum and it 
bridges between the first and the second antibody in the immunoassay. The presence of 
these substances in serum that are capable of binding antibodies multivalently can lead to 
erroneous analyte quantification in sandwich assay. As these substances can attach to the 
immobilized antibodies and they also bind with label antibodies, the substances can link 
two kinds of antibodies to make false positive signal. In the real application of assay, these 
interferences were caused from 15 % of serum samples (Boscato and Stuart, 1986). 
Usually, the non-specific binding is one of the most serious problems for mass- or refractive 
index-sensitive detection systems such as SPR biosensor, especially when low-molecular-
weight or low-concentration analytes are examined (Vikinge, et al., 1998). As the biosensor 
such as QCM or SPR biosensor generate a signal by the binding of analytes, the non-
specific binding of other molecules can directly make a false positive signal. Various 
attempts to minimize the non-specific binding have been reported to detect target analytes 
in serum with SPR biosensors, and those methods were tried in our experiments. Several 
solutions to decrease the non-specific binding have been investigated, such as blocking of 
IA layer, dilution of blood sample and application of detergents.  
 
(1) Blocking of IA layer 
In solid-phase immunoassay, BSA and gelatin are commonly used as blocking agents after 
immobilization of antibody or antigen (Matson, 2000). For the polystyrene microtitre plates, 
many other proteins such as nonfat dry milk, casein, lipoprotein and BSA at high 
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concentration (120-3750 µg/ml) have been used (Vogt et al., 1987; Pratt and Roser, 1997). 
SAM was also used to block non-specific binding (Silin et al., 1997) and water-soluble-
hydrophilic organic macromolecule such as dextran was used as a coating to prevent non-
specific protein adsorption (Frazier et al., 2000). A number of polymers have been also used 
as blocking reagents such as polyvinyl alcohols, polyethylene glycols and polyvinyl 
pyrrolidone (Bangs laboratories, 1998). 
In this work, the NeutrAvidin-protein A complex layer had three layers such as NeutrAvidin 
layer, protein A layer and receptor antibody layer on the gold surface, sequentially and these 
three layers seems to block the gold surface more well than the one receptor layer. With the 
treatment of BSA (10 mg/ml) similar to the concentration of 20 % serum, non-specific 
binding at the IA layer on the NeutrAvidin-protein A complex layer (< 0 millio) was far less 
than the IA layer on the bare gold surface (44 millio) (see Figure 4-2).  
 
A          B 
 
Figure 4-2: The comparison of non-specific binding between the IA layer on the 
NeutrAvidin-protein A layer and on the bare gold surface.  
After the immobilization of the receptor antibody (anti-CEA) layer on (A) the bare gold surface and 
(B) the NeutrAvidin-protein A complex layer, non-specific bindings for each IA layer were measured 
by the treatment of BSA (10 mg/ml). Non-specific binding at the IA layer on the NeutrAvidin- 
protein A complex layer (< 0 millio) was far less than the IA layer on the bare gold surface (44 millio). 
The IA layer on the NeutrAvidin-protein A complex layer seemed to prevent the non-specific 
binding and real medical sample with high concentration of serum seems to be used with this layer. 
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(2) Dilution of serum sample 
The non-specific binding with serum sample is proportional to the serum concentration and 
the dilution of serum sample has been used as a general solution against non-specific 
binding in the immunoassay. For example, serum samples for monitoring of tumor antigen 
were reported to be diluted as much as 15- folds (Campagnolo et al., 2004). In the detection 
of serum antibodies against Salmonella enteritidis and Salmonella typhimurium, the serum 
sample was diluted to be 40- folds (Jongerius-Gortemaker et al., 2002). If the signal by the 
non-specific binding in the diluted sample is similar with the signal of detection limit (2.1 
millio), the interrupting effect by non-specific binding can be ignored. However, there is a 
limitation of dilution to minimize the non-specific binding. Even if serum samples were 
diluted upto 100- folds, the non-specific bindings by serum samples were still observed 
(Vikinge et al., 1998). Moreover, the diluted serum sample reduces the concentration of 
target analyte and it can be too low to obtain the required sensitivity. If high sensitivity is 
needed instead of accuracy and signal of target analyte can be distinguishable in the serum 
sample, low degree of dilution should be used. For the measurement of ferritin, the serum 
sample was only at a dilution of 1/2 (Cui et al., 2003). Generally, the serum is diluted to 
decrease erroneous signal in immunoassays and the dilution ratio should be around 1/500 ~ 
1/2000 in the ELISA application (Crowther, 2001). However, if the sample is diluted too 
much, the sensitivity is also decreased under the required detection range. In the general 
ELISA, serum is diluted to be 10 % ~ 50 % according to the required sensitivity of the 
assay (http://www.m.ehime-u.ac.jp/~yasuhito/ElisaS.html). Therefore, an appropriate 
dilution factor should be selected for each application.  
 
(3) Application of detergents 
The application of detergent components in wash and assay buffers is also generally used to 
minimize nonspecific binding in immunoassay (Matson, 2000). Detergents can remove 
nonspecifically bound biomolecules from the surface by disruption of hydrophobic bonds 
formed between the biomolecule and surface groups. Generally, these are used at relatively 
low concentration (0.01 ~ 0.1 %) in order to avoid potential interference with the assay, such 
as the displacement of antibody or antigen coatings from the surface. There are nonionic 
detergents such as Tween 20, or ionic detergents such as SDS or DTAB. Though nonionic 
detergent of 0.5% Tween 20 had been used for our experiments, however, it seems to be 
valuable to try other strong detergents. 
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(4) Others 
There were also other attempts to minimize nonspecific binding. For example, the proper 
selection of species which produces antibodies for IA layer can influence against the 
nonspecific binding (Vikinge et al., 1998). When chicken IgY and mouse IgG were 
immobilized to a sensor chip CM5 dextran matrix and compared their background signals 
with serum (negative signal by nonspecific binding), chicken antibodies and mouse 
antibodies bound low quantities and large quantities of human serum, respectively. Chicken 
IgY is known to have a much lower reactivity to human serum proteins than any known 
murine antibody (Weber et al., 1990; Larsson et al., 1991; Larsson et al., 1993). The 
immobilized chicken antibodies can improve the detection of serum antigens with surface 
plasmon resonance.  
 
Moreover, addition of EDTA to serum can also reduce the background signal modestly for 
both IgG and IgY (Vikinge et al., 1998). When diluted normal human serum samples (1% in 
HBS) were flown over IgG or IgY immobilized to the dextran matrices, serum protein 
binding was quantified. After addition of 3.4 nM EDTA, responses by non-specific binding 
were reduced from 924 to 347 RU (1 kRU = 1 ng/mm2) for the IgG matrices and from 606 
to 114 RU for the IgY matrices, respectively.  
 
In the making of IA layer, the use of Fab fragments instead of whole antibodies may also 
help to minimize non-specific binding (Matson, 2000). Moreover, since rheumatoid 
autoantibodies react mainly with the Fc region, the use of Fab fragments can also reduce this 
problem. In our experiments, antibodies for IA layer were not Fab fragments but whole 
antibodies. Accordingly, blocking property seems to be improved by using Fab fragments. 
 
The pH at which the assay operated was also evaluated to minimize interference by sera 
(Jongerius-Gortemaker et al., 2002). A pH-dependent non-specific and specific response 
was found in the tested pH range from 5.0 to 7.6. A pH of 7.4 was selected as the working 
pH for minimal interference stemming from the serum matrix. Our experiment was already 
done with a condition of pH 7.4.  
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